<SEC-DOCUMENT>0001104659-24-085889.txt : 20240805
<SEC-HEADER>0001104659-24-085889.hdr.sgml : 20240805
<ACCEPTANCE-DATETIME>20240805170055
ACCESSION NUMBER:		0001104659-24-085889
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20240805
DATE AS OF CHANGE:		20240805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rezolute, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281257
		FILM NUMBER:		241175811

	BUSINESS ADDRESS:	
		STREET 1:		275 SHORELINE DRIVE, SUITE 500
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		650-206-4507

	MAIL ADDRESS:	
		STREET 1:		275 SHORELINE DRIVE, SUITE 500
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AntriaBio, Inc.
		DATE OF NAME CHANGE:	20130114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm2420753-1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html>
  <head>
    <title>tm2420753-1_s3 - none - 3.5312718s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">As filed with the Securities and Exchange Commission on August&#160;5, 2024</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:0.9pt; text-align:right; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:1.4pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.4pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.9pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.9pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.9pt; text-align:center; width:541.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">UNITED STATES</font>
          <br >
          <font style="letter-spacing:-0.32pt;">SECURITIES AND EXCHANGE COMMISSION</font>
        </div>
        <div style="margin-top:0.9pt; text-align:center; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">FORM S-3</font>
        </div>
        <div style="margin-top:0.89pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">REGISTRATION STATEMENT</font>
          <br >
          <font style="letter-spacing:-0.18pt;">UNDER</font>
          <br >
          <font style="letter-spacing:-0.18pt;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:9pt; text-align:center; width:541.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">REZOLUTE, INC.</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:-1.11pt; text-align:center; width:541.31pt; line-height:9pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Exact Name of Registrant as Specified in Its Charter)</font><font style="font-size:9pt;">&#8203;<font style="letter-spacing:0.18pt;"> </font></font>
        </div>
        <table style="width:541.31pt;margin-top:6pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center;font-weight:bold;font-size:10pt;">
                <font style="letter-spacing:-0.2pt;">Nevada</font>
              </div>
              <div style="margin-top:2pt; text-align:center; line-height:10pt;">
                <font style="letter-spacing:0.16pt;">(State or Other Jurisdiction of </font>
                <br >
                <font style="letter-spacing:0.16pt;">Incorporation or Organization)</font><font style="font-size:10pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center;font-weight:bold;font-size:10pt;">
                <font style="letter-spacing:-0.2pt;">27-3440894</font>
              </div>
              <div style="margin-top:2pt; text-align:center; line-height:10pt;">
                <font style="letter-spacing:0.16pt;">(I.R.S. Employer </font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification No.)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.9pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">275 Shoreline Drive, Suite 500</font>
          <br >
          <font style="letter-spacing:-0.18pt;">Redwood City, CA 94065</font>
          <br >
          <font style="letter-spacing:-0.18pt;">(650) 206-4507</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:0.8pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</font><font style="font-size:9pt;">&#8203;<font style="letter-spacing:0.18pt;"> </font></font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Nevan Elam</font>
          <br >
          <font style="letter-spacing:-0.18pt;">Chief Executive Officer</font>
          <br >
          <font style="letter-spacing:-0.18pt;">275 Shoreline Drive, Suite 500</font>
          <br >
          <font style="letter-spacing:-0.18pt;">Redwood City, CA 94065</font>
          <br >
          <font style="letter-spacing:-0.18pt;">Telephone: (650) 206-4507</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:0.8pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</font><font style="font-size:9pt;">&#8203;<font style="letter-spacing:0.18pt;"> </font></font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Copies to</font><font style="font-style:normal;letter-spacing:-0.18pt;">: </font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Anthony W. Epps</font>
          <br >
          <font style="letter-spacing:-0.18pt;">Dorsey &amp; Whitney LLP</font>
          <br >
          <font style="letter-spacing:-0.18pt;">1400 Wewatta St #400</font>
          <br >
          <font style="letter-spacing:-0.18pt;">Denver, CO 80202</font>
          <br >
          <font style="letter-spacing:-0.18pt;">(303) 629-3400</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Approximate date of commencement of proposed sale to the public</font><font style="font-weight:normal;letter-spacing:0.18pt;">: From time to time after the effective date of this registration statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, please check the following box. &#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.18pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act: </font>
        </div>
        <table style="width:501.31pt;height:33.5599999999999pt;margin-left:20pt;margin-top:6pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
          <tr style="line-height:8.97000000000003pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:132pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:132pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.78pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Accelerated Filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.78pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:132pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:132pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.78pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.18pt;">&#9746;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section&#160;8(a), may determine.</font>
        </div>
        <div style="margin-top:3.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 3.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:48.66pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where such offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;color:#FC0014;">
          <font style="letter-spacing:-0.2pt;">SUBJECT TO COMPLETION, DATED AUGUST&#160;5, 2024</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_rezolute-4clr.jpg" alt="[MISSING IMAGE: lg_rezolute-4clr.jpg]" height="60" width="324" >
        </div>
        <div style="margin-top:15.31pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to 4,500,000 Shares of Common Stock and</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to the resale of 4,500,000 shares of Common Stock, par value $0.001 per share (&#8220;Common Stock&#8221;) of Rezolute, Inc. by certain selling stockholders named herein (the &#8220;Selling Stockholders&#8221;) consisting of, (i)&#160;1,500,000 shares of Common Stock, (ii) 610,404 shares of Common Stock and (iii)&#160;2,389,596 shares of Common Stock issuable upon the exercise of pre-funded warrants (the &#8220;Warrants&#8221;) of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Warrants were issued pursuant to the securities exchange agreement dated March&#160;8, 2024 between the Company and certain Selling Stockholders. The Warrants have an exercise price of $0.001 per share. We may receive proceeds from the exercise of the Warrants if the Warrants are exercised on a cash basis. 610,404 shares of Common Stock covered by this prospectus were issued a certain Selling Stockholder upon the partial exercise of the Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain shares of the Common Stock was issued pursuant to the securities purchase agreement dated June&#160;25, 2024 and July&#160;5, 2024, respectively, between the Company and certain Selling Stockholders. We will not receive any proceeds from the sale of any shares of Common Stock by the Selling Stockholders pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our registration of the securities covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the shares of Common Stock. The Selling Stockholders may sell the shares of Common Stock offered by this prospectus from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means described in this prospectus under the caption &#8220;Plan of Distribution.&#8221; The shares of Common Stock may be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;RZLT&#8221;. On July&#160;26, 2024, the last reported sale price for our Common Stock was $4.68 per share. Each prospectus supplement to this prospectus will indicate if the securities offered thereby will be listed on any securities exchange. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves risks. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">11</a> of this prospectus, any applicable prospectus supplement or any related free writing prospectus, and in any documents incorporated by reference herein or therein before investing in our securities.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE&#160;SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION&#160;PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:152.31pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus is &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2024</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:230.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">2</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">3</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHOF">10</a></font> <a href="#tTHOF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">11</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">12</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tDOTW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF TRANSACTION WITH THE SELLING STOCKHOLDERS AND WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOTW">13</a></font> <a href="#tDOTW"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">14</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSSF"><font style="letter-spacing:0.2pt;">SELLING STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSSF">15</a></font> <a href="#tSSF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">17</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">19</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">19</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">19</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:0.2pt;">INCORPORATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIBR">20</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:276pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in this prospectus or in any related free writing prospectus filed by us with the Securities and Exchange Commission (&#8220;SEC&#8221;). We and the Selling Stockholders have not authorized anyone to provide you with any information or to make any representation not contained in this prospectus. We and the Selling Stockholders do not take any responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you. This prospectus is not an offer to sell or an offer to buy securities in any jurisdiction where offers and sales are not permitted. The information in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of securities. You should also read and consider the information in the documents to which we have referred you under the caption &#8220;Where You Can Find More Information&#8221; in the prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the Selling Stockholders have done anything that would permit a public offering of the securities or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside of the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section titled &#8220;Where You Can Find Additional Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We urge you to read carefully this prospectus, as supplemented and amended, before deciding whether to invest in any of the Common Stock being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the context indicates otherwise, as used in this prospectus, the terms &#8220;Rezolute,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;our business&#8221; refer to Rezolute, Inc. and its subsidiaries.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:320pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, and the documents incorporated by reference herein, contain certain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act, Section&#160;21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995, and are based on management&#8217;s current expectations. These forward-looking statements can be identified by the use of forward-looking terminology, including, but not limited to, &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;see,&#8221; &#8220;confidence,&#8221; &#8220;trends,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;on track,&#8221; &#8220;are positioned to,&#8221; &#8220;on course,&#8221; &#8220;opportunity,&#8221; &#8220;continue,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;anticipated,&#8221; &#8220;plan,&#8221; &#8220;potential&#8221; and the negative of these terms or comparable terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Various factors could adversely affect our operations, business or financial results in the future and cause our actual results to differ materially from those contained in the forward-looking statements, including those factors discussed under &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; or otherwise discussed in our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023, our Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2024, and in our other filings made from time to time with the SEC after the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please see the documents that we have filed with the SEC, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form&#160;8-K and other documents and reports filed from time to time with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We are not under any obligation to, and expressly disclaim any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">We are developing transformative therapies for devastating rare and chronic metabolic diseases. Our lead compound, RZ358, is a fully human monoclonal antibody for the treatment of hypoglycemia resulting from excessive secretion of insulin or insulin-like substances such as IGF-2 (&#8220;hyperinsulinism&#8221; or &#8220;HI&#8221;). The antibody counteracts excess insulin receptor activation thereby improving hypoglycemia. We have commenced a global Phase&#160;3 study (&#8220;sunRIZE&#8221;) for congenital HI, an ultra-rare pediatric and genetic form of HI. In addition, through our expanded access program (&#8220;EAP&#8221;), U.S. physician-investigators have been administering RZ358 on a compassionate use basis for the management of hypoglycemia resulting from hyperinsulinism associated with tumors (&#8220;tumor HI&#8221;). We are also developing RZ402, a small molecule selective and potent plasma kallikrein inhibitor (&#8220;PKI&#8221;), as a potential oral therapy for the chronic treatment of diabetic macular edema (&#8220;DME&#8221;). </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Our primary objectives for the first half of 2024 are to complete the Phase&#160;2 study for RZ402 to enable announcement of topline results in May&#160;2024, as well as to continue site activation and increase patient enrollment for sunRIZE to enable completion of enrollment by the end of this calendar year. Primary objectives for the second half of 2024 are to continue site activation and increase patient enrollment for sunRIZE to enable completion of enrollment by the end of this calendar year. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">RZ358 for congenital hyperinsulinism (&#8220;cHI&#8221;)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">cHI</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">cHI is the most common cause of recurrent and persistent hypoglycemia in children. Individuals with cHI typically present with signs or symptoms of hypoglycemia shortly after birth. Hypoglycemia can result in significant brain injury and death if not recognized and managed appropriately. Additionally, recurrent, or cumulative, hypoglycemia can lead to progressive and irreversible damage over time, including serious and devastating brain injury, seizures, neuro-developmental problems, feeding difficulties, and significant impact on patient and family quality of life. Treatment options for individuals include treatment with diazoxide or glucagon, carbohydrate supplements or off label administration of somatostatin analogues. In cases that are unresponsive to medical management, surgical removal of the pancreas may be required. In those with diffuse disease where the whole pancreas is affected, a near-total pancreatectomy can be undertaken, although ongoing medical treatment of hypoglycemia is generally required for several&#160;years after surgery, and patients will eventually develop insulin-dependent diabetes. cHI occurs in one in 28,000 live births in the U.S., and we estimate that in the U.S. alone the addressable market for cHI is more than 1,500 individuals. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">sunRIZE Phase&#160;2b Study</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">In our Phase&#160;2 RIZE study of RZ358 in patients with cHI ages two and older, nearly all participants achieved significant improvement in hypoglycemia across multiple endpoints, including the primary and key secondary endpoints planned for the sunRIZE study. At doses and exposures planned for sunRIZE, RZ358 was generally safe and well-tolerated, and resulted in median improvements in hypoglycemia of up to ~90% at top doses. Furthermore, a clinically-relevant threshold of &ge;25% hypoglycemia correction was observed. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:18pt;margin-left:12pt;width:456pt;">
          <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
            <img src="bc_exemplary-4clr.jpg" alt="[MISSING IMAGE: bc_exemplary-4clr.jpg]" height="272" width="607" >
          </div>
          <div style="text-indent:20pt; margin-top:12.4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">sunRIZE is currently not being studied in the U.S. because of partial clinical holds (&#8220;PCHs&#8221;) imposed by the FDA&#8217;s Office of Cardiology, Hematology, Endocrinology and Nephrology-Division of Diabetes, Lipid Disorders, and Obesity (&#8220;Division&#8221;). As part of the preclinical program for RZ358, Sprague Dawley rats (&#8220;SD rats&#8221;) demonstrated a microvascular injury in liver sinusoidal endothelial cells (&#8220;LSECs&#8221;) at potentially clinically relevant doses and exposures (&#8220;rat findings&#8221;). Consequently, the Division mandated PCHs that prevent us from dosing participants under the age of 12 and restrict us from dosing participants above the lowest dose studied to date, 3mg/kg. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">sunRIZE Phase&#160;3 Study</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In December&#160;2023, we initiated sunRIZE, a randomized, double-blind, placebo-controlled, parallel arm evaluation of RZ358 in participants with cHI who are not adequately responding to standard-of-care medical therapies. We plan to enroll approximately 56 participants ages three&#160;months and above from up to approximately 20 clinical trial sites in more than 15 countries in Europe, the Middle East, Asia and North America, and to complete enrollment by the end of calendar year 2024, to enable announcement of topline results in mid-2025. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">RZ358 Ongoing Studies and Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We do not believe that the rat findings are relevant to humans particularly since no adverse liver findings were observed in monkey toxicology studies at significantly higher RZ358 dose levels (up to&#160;90&#160;mg/kg tested), with drug levels that were more than 8 times higher than those that showed toxicity in SD rats and more than 5 times higher than the top human doses. Moreover, in our clinical studies conducted to date there have been no liver findings, including at the highest human doses that have been administered. While the precise mechanism of liver microvascular injury in SD rats remains unknown, we believe that the SD rat may be hypersensitive to exaggerated pharmacology and severely impaired insulin signaling with RZ358, due to its baseline predisposition to obesity, metabolic syndrome, insulin resistance, and over-dependence on the liver for insulin signaling and glucose handling. Notably, individuals who suffer with cHI are the opposite of insulin resistant as they have excessive insulin activity. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As part of our effort to investigate the mechanism of toxicity in SD rats, we have retained advisement from a former senior FDA pharmacology-toxicology official and we have partnered with a research group with LSEC expertise. In the second half of 2023, we conducted additional </font><font style="font-style:italic;letter-spacing:0.2pt;">in-vivo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in-vitro</font><font style="letter-spacing:0.2pt;"> non-clinical studies to enhance our understanding of the mechanism of toxicity in SD rats and its potential relevance to humans, including experiments in SD rat LSECs and another toxicology study in an additional rodent species. We have been unable to reproduce or characterize the toxicity observed in SD rat toxicology studies in our LSEC experiments and we therefore believe that the mechanism of toxicity cannot be characterized </font><font style="font-style:italic;letter-spacing:0.2pt;">in-vitro</font><font style="letter-spacing:0.2pt;">. Importantly, we conducted a CD-1 mice toxicology study to determine if we could reproduce rat findings in a different rodent species. CD-1 mice were administered significantly higher dose levels of </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">RZ358 (up to 120 mg/kg tested) with drug levels that were more than 20 times higher than those that caused the SD rat findings and substantially higher than human doses. No adverse liver findings were observed in this study at any dose level. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">To continue along these lines of evaluating and demonstrating the likelihood that liver findings are specific to SD rats and irrelevant to human patients, we then undertook another toxicology study in a different strain of rat. In the first half of 2024, we conducted and recently completed an </font><font style="font-style:italic;letter-spacing:0.2pt;">in-vivo</font><font style="letter-spacing:0.2pt;"> toxicology study in brown Norway rats, using SD rats as a positive control. Early results show that at the highest tested dose of 40 mg/kg, there were no observed liver abnormalities in the brown Norway rat strain. Notably, the 40 mg/kg dose is more than four times the dose that causes liver injury in SD rats. We expect to have final data tabulations and a report for this study completed in the third quarter of 2024 and believe that the Norway rat study further suggests that liver toxicity is specific to the SD rat and not relevant otherwise, based on the absence of findings in other rat strains, other rodent species (&#8220;CD-1 mice&#8221;), primates, or our clinical trials in humans to date. We are conducting additional in-vitro studies and plan to incorporate those studies along with the Norway rat toxicity study into a complete response to the PCHs to be submitted to the Division in the third quarter of 2024. Nonetheless, there can be no assurance that the Division will agree to modify or remove the PCHs. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Regardless of U.S. trial sites in our current Phase&#160;3 study, we believe data from sunRIZE will be sufficient for a potential submission to FDA for approval for RZ358 for cHI if the study meets its efficacy objectives, with an acceptable safety profile. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">RZ358 has received Orphan Drug Designation in the U.S. and European Union for the treatment of cHI, as well as Pediatric Rare Disease Designation in the U.S., a prerequisite for a request for a Rare Pediatric Disease Priority Review Voucher upon Biologics License Application submission. Based on the RIZE clinical trial outcomes and the substantial unmet medical need, RZ358 was subsequently granted a priority medicines designation by the European Medicines Agency and an Innovation Passport designation by the UK Innovative Licensing and Access Pathway Steering Group for the treatment of cHI in October&#160;2023. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">RZ358 for tumor hyperinsulinism (&#8220;HI&#8221;)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Tumor HI</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Tumor HI may be caused by two distinct types of tumors: islet cell tumors (&#8220;ICTs&#8221;) and non-islet cell tumors (&#8220;NICTs&#8221;), both of which lead to hypoglycemia due to excessive activation of the insulin receptor. Insulinomas are the most common type of functional ICT and mediate hypoglycemia through excessive insulin production. NICTs are generally associated with relatively large, solid tumors such as hepatocellular carcinoma, fibrosarcoma and mesothelioma, and can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances such as IGF-2 or related variants that bind to and activate the insulin receptor. This form of hypoglycemia can occur in more than 15 different tumor types, 60% of which are malignant, including hepatocellular carcinoma. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Current therapies for insulinomas and NICTs can be grouped into two main categories: (a)&#160;tumor directed de-bulking therapies (e.g. surgery, chemotherapy, radiotherapy), which may indirectly and/or eventually lead to decreased levels of circulating insulin and/or insulin-like substances, and therefore control HI and related hypoglycemia; and/or (b)&#160;medical therapies that directly treat HI and the associated hypoglycemia. Tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or NICTs. In many cases, tumor-directed therapies are administered concurrently with medical therapies for hypoglycemia and in other cases successful treatment of hypoglycemia often enables the initiation and/or continuation of tumor-directed therapies, as indicated. During the period from diagnosis to surgical treatment, or if surgery is contraindicated or refused, medical treatments are often necessary to directly manage the HI and hypoglycemia induced by the tumor. Additionally, chronic medical management of refractory hypoglycemia is often necessary for patients who cannot be cured by surgery, such as those with extensive disease of the pancreas, multi-focal insulinomas, inoperable or unresectable benign or malignant insulinomas, metastatic insulinomas, non-pancreatic insulinomas, or NICT hypoglycemia resulting from a variety of other tumors. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">A significant unmet need exists for treatment options with improved efficacy and tolerability as normalization of glucose levels is crucial to ensure patients are fit to receive cancer treatment and to reduce mortality. Unfortunately, some patients are unresponsive to the current standard of care medical therapies for tumor HI and experience debilitating hypoglycemia that is otherwise untreatable. Currently available medical therapies are directed at reducing or eliminating insulin production and/or secretion from tumors, which may be challenging when the tumor is differentiated or dysregulated, and therefore not responding to usual control mechanisms for suppressing insulin production. In some cases, commonly utilized somatostatin analog therapies may even worsen hypoglycemia due to suppression of glucagon. Therefore, currently available medical therapies directed at suppressing insulin production may have limited effectiveness in tumor HI. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The total addressable market for the combined indications causing tumor HI is estimated to be approximately 4,500 patients in the U.S. alone, including approximately 1,500 with ICT hypoglycemia and approximately 3,000 with NICT hypoglycemia. We believe this addressable market represents a greater than $1&#160;billion market opportunity. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Expanded Access Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">RZ358 has been shown to counteract excessive insulin action downstream, at the insulin-receptor on target organs. The unique mechanism of action of RZ358 makes the therapy a potential universal treatment for any form of hyperinsulinism, including tumor HI. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We maintain the EAP for a variety of HI indications for the purpose of making RZ358 available on a compassionate use basis when available therapeutic options have failed, and an individual&#8217;s hypoglycemia is unmanageable. In the fourth quarter of 2022, we received and approved an EAP request from Dr.&#160;Mary Elizabeth Patti, Director of the Hypoglycemia Clinic at the Harvard Medical School and Beth Israel Medical Center-affiliated Joslin Diabetes Center, for a patient with intractable hypoglycemia caused by a metastatic insulinoma. Dr.&#160;Patti received a single patient investigational new drug (&#8220;IND&#8221;) approval from the Division to treat the patient with RZ358. Dr.&#160;Patti reported that the patient safely achieved correction of hypoglycemia with RZ358, enabling the patient to wean off continuous intravenous dextrose and several other medications for hypoglycemia, leave the hospital after a prolonged stay, and resume receiving concurrent treatment for cancer with tumor-directed therapies. The patient remained on RZ358 for more than a year until he eventually passed away due to progression of his underlying malignant/metastatic insulinoma. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have received and approved requests to date for single patient use of RZ358 in patients with tumor HI caused by metastatic insulinomas and other insulin secreting metastatic cancer (cervical). In the U.S., these requests have all been approved by the Division. These patients have been refractory to usual standard of care therapies for chronic management of hypoglycemia and required continuous high&#160;volume/</font>&#8203;<font style="letter-spacing:0.2pt;">concentration intravenous dextrose or nutritional infusion and were hospitalized and in life-threatening or hospice-bound condition because of uncontrollable hypoglycemia. Further treatment with tumor-directed therapies (e.g., embolization, radiotherapy, chemotherapy) was often deferred as a result of the debilitating hypoglycemia. </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Generally, dosing for tumor HI patients has been either 6 mg/kg or 9 mg/kg every 1&#8201;&#8211;&#8201;2 weeks. In all cases to date, RZ358 has led to substantial improvement in hypoglycemia and has been well tolerated. Within a relatively short period of time after administration of RZ358, continuous intravenous dextrose was discontinued and hospitalized patients were able to be discharged and receive maintenance RZ358 doses on an outpatient basis, with durable benefit. In most cases, other background medical therapies for hypoglycemia were able to be weaned or stopped, and patients were able to resume tumor-directed therapies for treatment of their underlying cancer. Patients with metastatic tumor HI often have underlying hepatic injury (abnormal enzymes) at baseline due to hepatic metastases or previous tumor-directed treatments (e.g., partial liver resection or embolization). The patients with hepatic injury that have been treated under the EAP have not exhibited any indication of hepatic toxicity with the use of RZ358. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Evaluation of a Clinical and Regulatory Development Path</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In January&#160;2024, we had a Type B pre-IND meeting with the Division to discuss a potential IND application and a clinical and regulatory development strategy for tumor HI. The Division acknowledged </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">the unmet need as well as the potential therapeutic benefit of RZ358 as demonstrated by the cases under the EAP as well as the efficacy demonstrated in previous clinical experience in cHI. The Division is aligned with us that it would be warranted to study RZ358 in an IND-opening late-stage (registrational) clinical trial, which we are currently evaluating as a development program and second rare disease indication for RZ358. This study could simultaneously include both ICT and NICT patients with tumor HI. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">To further validate the utility of RZ358 in treating hyperinsulinism and hypoglycemia resulting from NICT, we also conducted </font><font style="font-style:italic;letter-spacing:0.2pt;">in-vitro</font><font style="letter-spacing:0.2pt;"> experiments which demonstrated that RZ358 can blunt signaling of IGF-2 at the insulin receptor. We believe that this is additional proof of mechanism and concept for RZ358 as a potential universal treatment for hyperinsulinism, due to its novel mechanism of action at the insulin receptor. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In addition to other factors that impact a decision and timing of initiation of a new development program, we are not resourced to support an additional late stage registrational study. While we are optimistic about the positive impact RZ358 is already having on the lives of tumor HI patients, there can be no assurance that we will expand its pipeline to include tumor HI as a new indication for RZ358 nor can there be any assurance that such a program will be successful in a registrational study to support commercial approval for use of RZ358 in tumor HI by FDA or other regulatory authorities worldwide. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">RZ402 for DME</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">DME</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Diabetic retinopathy (&#8220;DR&#8221;) affects approximately one third of adults with diabetes and is the leading cause of vision loss in the working age population. DME is a severe, systemic, vision-threatening complication of DR characterized by swelling of the retina and thickening of the macula, the part of the eye that is responsible for high-resolution vision. There are an estimated 22&#160;million DME patients worldwide and over&#160;1&#160;million in the U.S. alone, representing a potential addressable market of over $1.5&#160;billion. Anti-vascular growth factor (&#8220;anti-VEGF&#8221;) injections into the eye are the current standard of care for DME, requiring continued administration over long periods of time to preserve vision. Due to their invasive route of administration and occasional serious side effects, there is a tendency to delay treatment until later in the disease course, and long-term compliance with eye injection regimens can be difficult for patients. In addition, only 40&#8201;&#8211;&#8201;50% of DME patients are responsive to the anti-VEGF treatment, which results in overall undertreatment and suboptimal vision outcomes in DME patients. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The contact-activation kallikrein-kinin system promotes increased vascular permeability and inflammation via key downstream mediators, including bradykinin, and activation of the intrinsic pathway of coagulation. Pathophysiologic upregulation of this system has been linked to a variety of diseases which are characterized by vascular dysfunction, including DME. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe that an oral PKI therapy is the ideal approach for targeting a systemic vascular disease such as DME. An oral PKI would be a non-invasive approach that allows for earlier disease intervention, directly impacts the site of disease and therapeutic target, and could be used alone or in tandem with anti-VEGF injections, which could potentially lead to better clinical outcomes overall. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Phase&#160;2 Study</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In December&#160;2022, we initiated a Phase&#160;2 U.S. multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are na&#239;ve to, or have received limited anti-VEGF injections. The study population is comprised of DME patients with mild to moderate non-proliferative DR, experiencing compromised vision. Eligible participants were randomized equally, to one of three RZ402 active treatment arms at doses of 50, 200, and 400 mg, or a placebo control arm, to receive study drug once daily for 12-weeks, before completing a four-week follow-up. Topline results were announced on May&#160;21, 2024. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">RZ402 met both primary endpoints of change in macular edema (&#8220;CST&#8221;) and a good safety profile. </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">CST improved significantly at all RZ402 dose levels compared to placebo (up to approximately 50&#160;microns; p=0.02) </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Continued downward trajectory in CST over course of study and at end of treatment </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">No significant difference between RZ402 dose levels, though response was largest at the 200 mg dose </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Sub-analysis by DME severity (CST &ge;400 microns) indicates an improvement of approximately 75&#160;microns at the 200 mg dose </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">CST declined in most patients who received the 200 mg dose of RZ402, including clinically significant improvements from baseline in more than 20% of participants, compared to none in placebo, with high rates of worsening </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">RZ402 was safe and well-tolerated </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Adverse events (&#8220;AEs&#8221;) were generally mild and rates were comparable to placebo </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Three participants experienced serious AEs which were all judged by the Investigator as unrelated to study drug </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">No ocular adverse effects that are typically seen with intravitreal injections </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Electrocardiograms, vitals, and safety labs were unremarkable </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Target concentrations were exceeded at all three dose levels and continue to support once daily oral dosing </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
            <img src="tb_treatment-4clr.jpg" alt="[MISSING IMAGE: tb_treatment-4clr.jpg]" height="361" width="521" >
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:18pt;margin-bottom:32pt; margin-left:12pt;width:456pt;">
          <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
            <img src="lc_primary-4clr.jpg" alt="[MISSING IMAGE: lc_primary-4clr.jpg]" height="387" width="608" >
          </div>
          <div style="position:relative;margin-top:13pt; text-align:center; width:456pt;">
            <img src="bc_partcst-4clr.jpg" alt="[MISSING IMAGE: bc_partcst-4clr.jpg]" height="288" width="607" >
          </div>
          <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Secondary and Additional Observations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">No significant improvements in Best Corrected Visual Acuity compared to placebo </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">In-line with expectations for a study of this duration </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Observed improvements in CST would predict visual improvements in a longer duration study </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Five RZ402 treated participants at 200 mg (20%) experienced a 1-step improvement in Diabetic Retinopathy Severity Score (&#8220;DRSS&#8221;) compared to one participant in placebo</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Securities Offered by the Selling Stockholders:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">4,500,000 shares of Common Stock, consisting of, (i) 1,500,000 shares of Common Stock, (ii) 610,404 shares of Common Stock and (iii) 2,389,596 shares of Common Stock issuable upon the exercise of the Warrants </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Use of Proceeds:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will not receive any proceeds from the sale of Common Stock in this offering. However, we may receive proceeds from the exercise of the Warrants by the selling stockholder to the extent they are exercised for cash. In the event we receive proceeds from the cash exercise of the Warrant, we intend to use the aggregate net proceeds from such exercise for general corporate purposes, including working capital. See the sections titled &#8220;Use of Proceeds&#8221; for additional information. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Risk Factors:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page [&#8226;] of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in our securities. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Nasdaq trading symbol:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our common shares are listed on Nasdaq under the symbol &#8220;RZLT&#8221;. There is no established public trading market for the Warrants, and we do not expect a market to develop. We do not intend to list the Warrants on Nasdaq or any other national securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a risk of loss. Before investing in our securities, you should carefully consider the risk factors described under &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the SEC for the most recent year, in any applicable prospectus supplement and in our filings with the SEC, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, together with all of the other information included in this prospectus and any prospectus supplement and the other information incorporated by reference herein and therein. These risks are not the only ones facing us. Additional risks not currently known to us or that we currently deem immaterial also may impair or harm our business and financial results. Statements in or portions of a future document incorporated by reference in this prospectus, including, without limitation, those relating to risk factors, may update and supersede statements in and portions of this prospectus or such incorporated documents. Please also refer to the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:528pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">All of the shares of Common Stock offered by the Selling Stockholders pursuant to this prospectus will be sold by the Selling Stockholders for its own account. We will not receive any of the proceeds from these sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We will receive up to an aggregate of approximately $3,000 from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for general corporate purposes. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOTW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:348pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF TRANSACTION WITH THE SELLING STOCKHOLDERS AND WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;8, 2024, we entered into a securities exchange agreement (the &#8220;Exchange Agreement&#8221;) with certain Selling Stockholders to which we exchanged an aggregate of 3,000,000 shares of Common Stock owned by the Selling Stockholder, for pre-funded warrants to purchase an aggregate of 3,000,000 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.001 per share. The Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of Common Stock are entitled. Pursuant to the Exchange Agreement, we are required to file this resale registration statement with the SEC to register for resale of the Common Stock within 120&#160;days from the closing date of the transaction contemplated by the Exchange Agreement. We will receive up to an aggregate of approximately $3,000 from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. On July 24, 2024, the Warrants were partially exercised on a cashless basis for 610,273 shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;25, 2024, we entered into a securities purchase agreement with certain Selling Stockholders (the &#8220;Purchasers&#8221;), relating to a private placement, pursuant to which we agreed to sell to the Purchasers 1,500,000 shares of Common Stock at a purchase price of $4.00 per share (the &#8220;Private Placement&#8221;). In connection with the Private Placement, we entered into a registration rights agreement with the Purchasers, pursuant to which we are required to file this resale registration statement with the SEC to register for resale of the Common Stock within 30&#160;days of receipt of funds. We will be obligated to pay certain liquidated damages to the Purchasers if we fail to file this registration statement when required, fails to cause this registration statement to be declared effective by the SEC when required, of if we fail to maintain the effectiveness of this registration statement. The Private Placement closed on July&#160;5, 2024. The gross proceeds of the Private Placement to the Company were approximately $6.0&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:144pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus describes the general terms of our capital stock. For a more detailed description of our capital stock, you should read the applicable provisions of the Nevada Revised Statutes (the &#8220;NRS&#8221;), our amended and restated articles of incorporation (our &#8220;Articles of Incorporation&#8221;) and our amended and restated bylaws (our &#8220;Bylaws&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Articles of Incorporation provides authority for us to issue up to 100,000,000 shares of common stock, par value $0.001 per share. As of July&#160;26, 2024 there were 55,356,931 shares of our common stock outstanding. Under the NRS, stockholders generally are not personally liable for our debts or obligations solely as a result of their status as stockholders. Our outstanding shares of common stock are, and any shares offered by this prospectus will be, when issued and paid for, fully paid and nonassessable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of our common stock are entitled to one vote per share on all matters submitted to our stockholders for a vote. There are no cumulative voting rights in the election of directors. Our shares of common stock are entitled to receive such dividends as may be declared and paid by our Board of Directors out of funds legally available therefor and to share ratably in the net assets, if any, of Rezolute upon liquidation. Our stockholders have no preemptive rights to purchase any shares of our capital stock. Our Articles of Incorporation provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the NRS Chapters 78 or 92A, our Articles of Incorporation or our Bylaws or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine. Notwithstanding this exclusive forum provision, the exclusive forum provision shall not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the Exchange Act or the Securities Act, or the respective rules and regulations promulgated thereunder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Funded Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to Common Stock, we have issued pre-funded warrants to purchase common stock. As of July&#160;26, 2024, the number of pre-funded warrants outstanding were exercisable into 14,409,967 shares of our Common Stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent of our Common Stock is Issuer Direct Corporation. Its address is One Glenwood Avenue, Suite 1001, Raleigh, NC 27306.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSSF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELLING STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus covers the resale by the selling stockholders identified below of 4,500,000 shares of common stock, including 3,000,000 issuable upon the exercise of the Warrants. The 3,000,000 shares issuable upon the exercise of the Warrants were issued on March&#160;8, 2024. For additional information regarding the Warrants, see &#8220;Description of Transaction and Selling Stockholders and Warrants&#8221; above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 1,500,000 remaining shares were issued on July&#160;5, 2024 in connection with the Private Placement. For additional information regarding the Private Placement, see &#8220;Description of Transaction and Selling Stockholders and Warrants&#8221; above. The following table sets forth the number of shares of our common stock beneficially owned by the selling stockholders on July&#160;25, 2024 and after giving effect to this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the Selling Stockholders. The second column lists the number of shares of common stock beneficially owned by each Selling Stockholder, based on its ownership of the shares of common stock and warrants, as of July&#160;26, 2024 assuming exercise of the warrants held by the Selling Stockholders on that date, without regard to any limitations on exercises. The third column lists the shares of common stock being offered by this prospectus by Selling Stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus generally covers the resale of the maximum number of shares of Common Stock and common stock issuable upon exercise of the Warrants, determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment, without regard to any limitations on the exercise of the warrants. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Warrants, a Selling Stockholder may not exercise the warrants to the extent such exercise would cause such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 19.99% (or 9.99%) of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of the warrants which have not been exercised. The number of shares in the second and third columns, and the&#160;percentage ownership in the fourth column, do not reflect this limitation. The Selling Stockholders may sell all, some or none of their shares in this offering. See &#8220;Plan of Distribution.&#8221; </font>
        </div>
        <table style="width:456pt;height:146.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:184.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Selling Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior</font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Maximum Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares of Common</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock to be Sold</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pursuant to this</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prospectus </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After the</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:184.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Handok, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">7,192,617 </td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,250,000</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5,942,617 </td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">10.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:184.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Genexine Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2,076,019 </td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">250,000</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,826,019 </td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">3.30<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:184.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Nantahala Capital Partners Limited Partnership</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,221,417</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">610,404</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">611,013</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:184.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">NCP RFM LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">999,359</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">533,689</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">465,670</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:184.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Blackwell Partners LLC&#8201;&#8211;&#8201;Series A</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3,537,282</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,855,907</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,681,375</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">3.04<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:184.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:6.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents ownership of less than 1%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Applicable&#160;percentage ownership is based on 55,356,931, shares of our common stock outstanding as of July&#160;26, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Assumes the sale of all shares of common stock offered in this prospectus.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Voting and investment authority over shares of Common Stock owned by Handok, Inc. is held by the board of directors of Handok, Inc. The address of the stockholder is 132, Teheran-Ro, Gangman Gu, Seoul, Republic of Korea.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Voting and investment authority over shares of Common Stock owned by Genexine Inc. is held by the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:124pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">board of directors of Genexine Inc. The address of the stockholder is 700 Daewangpangyo-ro Korea Bio-Park, Building B, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea.</font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of the selling stockholder as a General Partner, Investment Manager, or Sub-Advisor and would be considered the beneficial&#160;owner of such securities. The above shall not be deemed to be an admission by the record owners or the&#160;selling stockholder that they are themselves beneficial owners of these securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or any other purpose. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by the selling stockholder. The warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of the stockholder is 130 Main St. 2nd Floor New Canaan, CT 06840.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of the selling stockholder as a General Partner, Investment Manager, or Sub-Advisor and would be considered the beneficial&#160;owner of such securities. The above shall not be deemed to be an admission by the record owners or the selling stockholder that they are themselves beneficial owners of these securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or any other purpose. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by the selling stockholder. The warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of the stockholder is 130 Main St. 2nd Floor New Canaan, CT 06840.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of the selling stockholder as a General Partner, Investment Manager, or Sub-Advisor and would be considered the beneficial&#160;owner of such securities. The above shall not be deemed to be an admission by the record owners or the selling stockholder that they are themselves beneficial owners of these securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or any other purpose. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by the selling stockholder. The warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of the stockholder is 280 South Mangum Street, Suite&#160;210 Durham, NC 27701. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each Selling Stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an exchange distribution in accordance with the rules of the applicable exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">privately negotiated transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">settlement of short sales; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a combination of any such methods of sale; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other method permitted pursuant to applicable law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Selling Stockholders may also sell securities under Rule&#160;144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of our common stock, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with Financial Industry Regulatory Authority, or FINRA, Rule&#160;5110; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&#160;2121. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:312pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We agreed to keep this prospectus effective until the date that all shares of Common Stock covered by this propsectus (i)&#160;have been sold, thereunder or pursuant to Rule&#160;144, or (ii)&#160;may be sold without volume or manner-of-sale restrictions pursuant to Rule&#160;144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule&#160;144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected holders The Company shall telephonically request effectiveness of a Registration Statement as of 5:00&#160;p.m. (New York City time) on a Trading Day. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation&#160;M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation&#160;M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule&#160;172 under the Securities Act). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:284pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain legal matters in connection with the offered securities will be passed upon for us by Dorsey &amp; Whitney LLP, Denver, Colorado. Any underwriters or agents will be represented by their own legal counsel, who will be identified in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Plante &amp; Moran, PLLC has audited our consolidated financial statements included in our Annual Report on Form 10-K for the&#160;years ended <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023015755/rzlt-20230630x10k.htm">June&#160;30, 2023</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837022014432/rzlt-20220630x10k.htm">2022</a>, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Plante &amp; Moran, PLLC&#8217;s report, given their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our reports on Forms&#160;10-K, 10-Q and 8-K, and amendments to those reports, are also available for download, free of charge, as soon as reasonably practicable after these reports are filed with, or furnished to, the SEC, at our website at www.rezolutebio.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As permitted by SEC rules, this prospectus does not contain all of the information we have included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may refer to the registration statement, exhibits and schedules for more information about us and the securities. The registration statement, exhibits and schedules are available through the SEC&#8217;s website or at its public reference room. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:62pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this prospectus, we &#8220;incorporate by reference&#8221; certain information that we file with the SEC, which means that we can disclose important information to you by referring you to that information. The information we incorporate by reference is an important part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. The following documents or information have been filed by us with the SEC and are incorporated by reference into this prospectus&#160;(other than, in each case, documents or information that are or are deemed to have been furnished rather than filed in accordance with SEC rules, including disclosure furnished under Items&#160;2.02 or 7.01 of Form&#160;8-K): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023015755/rzlt-20230630x10k.htm">the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2023, filed on September&#160;14, 2023;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Company&#8217;s Quarterly Reports on Form 10-Q for the quarter ended September&#160;30, 2023, filed on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837023018839/rzlt-20230930x10q.htm">November&#160;13, 2023</a>, for the quarter ended December&#160;31, 2023 filed on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837024001069/rzlt-20231231x10q.htm">February&#160;13, 2024</a>, and for the quarter ended March&#160;31, 2024 filed on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000155837024008294/rzlt-20240331x10q.htm">May&#160;15, 2024</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Company&#8217;s Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924071813/tm2416818d3_8k.htm">June&#160;13, 2024</a>, and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924075387/tm2418270d1_8k.htm">June&#160;2</a><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924075387/tm2418270d1_8k.htm">7</a><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1509261/000110465924075387/tm2418270d1_8k.htm">, 2024</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of the Company&#8217;s common stock, par value $0.001 per share, as contained in Item&#160;1 of Amendment No. 1 to the Registration Statement on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1509261/000110465921082937/tm2120011d10_8a12ba.htm">Form 8-A/A filed on June&#160;21, 2021</a>, under the Exchange Act, including any amendment or report filed under the Exchange Act for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All documents and reports that we file with the SEC (other than, in each case, documents or information that are or are deemed to have been furnished rather than filed in accordance with SEC rules) under Sections&#160;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to in this prospectus as the &#8220;Exchange Act,&#8221; from the date of this prospectus until the completion of the offering under this prospectus shall be deemed to be incorporated by reference into this prospectus. Unless specifically stated to the contrary, none of the information we disclose under Items&#160;2.02 or 7.01 of any Current Report on Form 8-K that we may from time to time furnish to the SEC will be incorporated by reference into, or otherwise included in, this prospectus. The information contained on or accessible through any websites, including our website, is not and shall not be deemed to be incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may request a copy of these filings, other than an exhibit to these filings unless we have specifically included or incorporated that exhibit by reference into the filing, at no cost, by writing or telephoning us at the following address: </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rezolute, Inc. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">275 Shoreline Drive, Suite 500</font>
          <br >
          <font style="letter-spacing:-0.2pt;">Redwood City, CA 94065</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(650) 206-4507</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement, or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 14.&nbsp;&nbsp;&nbsp;OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth expenses payable by us in connection with the issuance and distribution of the securities being registered pursuant to this registration statement. </font>
        </div>
        <table style="width:416pt;height:70.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,979 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,979</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.7pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 15.&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our officers and directors are indemnified under Nevada law, our amended and restated Articles of Incorporation, as amended, and our amended and restated bylaws, as amended, against certain liabilities. Our amended and restated Articles of Incorporation, as amended, require us to indemnify our directors and officers to the fullest extent permitted by the laws of the State of Nevada in effect from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to our amended and restated Articles of Incorporation, as amended, and our amended and restated bylaws, as amended, each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, by reason of the fact that he is or was a director or an officer of the Company or is or was serving at the request of the Company as a director, officer, or trustee of another enterprise, (hereinafter an &#8220;lndemnitee&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by the Company to the fullest extent permitted by the Nevada Revised Statutes, as the same exists or may hereafter be amended, against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith; provided, however, that, except as otherwise provided in our amended and restated Articles of Incorporation, we shall not be required to indemnify or advance expenses to any such Indemnitee in connection with a proceeding initiated by such Indemnitee unless such proceeding was authorized by the Board of Directors of the Company. However, Nevada Revised Statutes 78.138 currently provides that, except as otherwise provided in the Nevada Revised Statutes, a director or officer shall not be individually liable to us or our stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that (i)&#160;the presumption established by Nevada Revised Statutes 78.138(3) has been rebutted, (ii)&#160;the director&#8217;s or officer&#8217;s acts or omissions constituted a breach of his or her fiduciary duties as a director or officer, and (iii)&#160;such breach involved intentional misconduct, fraud or a knowing violation of the law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, an lndemnitee shall also have the right to be paid by the Company the expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if Nevada Revised Statutes requires, an advancement of expenses incurred by an Indemnitee in his capacity as a director or officer shall be made only upon delivery to the Company of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such lndemnitee is not entitled to be indemnified for such expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No director shall be personally liable to us or our stockholders for any monetary damages for breaches of fiduciary duty as a director; provided that this provision shall not eliminate or limit the liability of a director, to the extent that such liability is imposed by applicable law, (i)&#160;for any breach of the director&#8217;s duty of loyalty to the Company or our stockholders; (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii)&#160;under Section&#160;174 or successor provisions of the Nevada Revised Statutes; or (iv)&#160;for any transaction from which the director derived a personal benefit. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director for or with respect to any acts or omissions of such director occurring prior to such amendment or repeal. If the Nevada Revised Statutes is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated or limited to the fullest extent permitted by Nevada Revised Statues, as so amended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;78.7502 of the Nevada Revised Statutes permits a corporation to indemnify, pursuant to that statutory provision, a present or former director, officer, employee or agent of the corporation, or of another entity or enterprise for which such person is or was serving in such capacity at the request of the corporation, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, except an action by or in the right of the corporation, against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection therewith, arising by reason of such person&#8217;s service in such capacity if such person (i)&#160;is not liable pursuant to Section&#160;78.138 of the Nevada Revised Statutes, or (ii)&#160;acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to a criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. In the case of actions brought by or in the right of the corporation, however, no indemnification pursuant to Section&#160;78.7502 of the Nevada Revised Statutes may be made for any claim, issue or matter as to which such person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Any discretionary indemnification pursuant to Section&#160;78.7502 of the Nevada Revised Statutes, unless ordered by a court or advanced to a director or officer by the corporation in accordance with the Nevada Revised Statutes, may be made by a corporation only as authorized in each specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances. Such determination must be made (1)&#160;by the stockholders, (2)&#160;by the board of directors by majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding, (3)&#160;if a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or (4)&#160;if a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;78.751 of the Nevada Revised Statutes further provides that indemnification pursuant to Section&#160;78.7502 of the Nevada Revised Statutes does not exclude any other rights to which a person seeking indemnification or advancement of expenses may be entitled under our amended and restated Articles of Incorporation, as amended, or any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, for either an action in the person&#8217;s official capacity or an action in another capacity while holding office, except that indemnification, unless ordered by a court pursuant to Section&#160;78.7502 of the Nevada Revised Statutes or for the advancement of expenses, may not be made to or on behalf of any director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable for intentional misconduct, fraud or a knowing violation of law, and such misconduct, fraud or violation was material to the cause of action. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As permitted by the Nevada Revised Statutes, we have entered into indemnity agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director and officer to the fullest extent permitted by law and advance expenses to each indemnitee in connection with any proceeding in which indemnification is available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, or otherwise. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See also the undertakings set out in response to Item&#160;17 herein. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 16.&nbsp;&nbsp;&nbsp;EXHIBITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXHIBITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:200.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:29pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit </font>
                <br >
                <font style="letter-spacing:-0.16pt;">No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:240pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Registrant&#8217;s</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Form </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Filed </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Filed</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Herewith </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:29pt;text-align:left;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">2.1 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:240pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2420753d2_ex2-1.htm">Form of Securities Purchase Agreement dated June&#160;25, 2024 by and between the Company and the Purchasers thereto</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">X </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29pt;text-align:left;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">4.1 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1509261/000110465921082912/tm2120169d1_ex3-3.htm">Amended and Restated Articles of Incorporation</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6/21/21 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29pt;text-align:left;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">4.2 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1509261/000110465921115980/tm2126910d1_ex3-4.htm">Amended and Restated Bylaws</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">9/15/21 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.4 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29pt;text-align:left;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">4.3 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1509261/000110465924034564/tm248506d2_ex4-1.htm">Form of Exchange Warrant</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8-K </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3/14/24 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29pt;text-align:left;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">5.1 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:240pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:0.2pt;">Opinion of Dorsey &amp; Whitney LLP (to be supplied by amendment) </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">23.1 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:240pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:0.2pt;">Consent of Dorsey &amp; Whitney LLP (to be included in Exhibit&#160;5.1 and supplied by amendment). </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">23.2 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2420753d2_ex23-2.htm">Consent of Plante &amp; Moran, PLLC</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">X </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">24 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a href="#tSIG">Power of Attorney (included in the signature page)</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">X </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">107 </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2420753d2_ex-filingfees.htm">Filing Fee Table filed herewith as EX-FILING FEES</a>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:39.25pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:39.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">X</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 17.&nbsp;&nbsp;&nbsp;UNDERTAKINGS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee Tables&#8221; or &#8220;Calculation of Registration Fee&#8221; table, as applicable, in the effective registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii)&#160;or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof. </font><font style="font-style:italic;letter-spacing:0.2pt;">Provided, however</font><font style="letter-spacing:0.2pt;">, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities of the undersigned registrant pursuant to the registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:556pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Redwood City, State of California, on August&#160;5, 2024. </font>
        </div>
        <div style="margin-left:240pt; margin-top:12pt; width:216pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">REZOLUTE, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:240pt; line-height:12pt; margin-top:17pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:17pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:260pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">/s/ Nevan Charles Elam </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="white-space:nowrap; margin-left:260pt; margin-top:2.5pt; width:196pt;">
          <div style="margin-left: 0pt; width: 196pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:260pt; margin-top:2pt; width:196pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nevan Charles Elam</font>
          <br >
          <font style="font-style:italic;letter-spacing:0.2pt;">Chief Executive Officer</font>
          <br >
          <font style="letter-spacing:0.2pt;">(Principal Executive and Financial Officer)</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each person whose signature appears below constitutes and appoints each of Nevan Elam his attorney-in-fact and agent, with the full power of substitution and resubstitution and full power to act without the other, for them in any and all capacities, to sign any and all amendments, including post-effective amendments, and any registration statement relating to the same offering as this registration that is to be effective upon filing pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended, to this registration statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:330.5pt;margin-top:19pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:132pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:236.93pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:46.25pt; white-space:normal;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.917pt 0pt 0.5pt 0pt; width:132pt;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Nevan Elam </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Nevan Elam </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.917pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Chief Executive Officer and Acting Chair of the Board (Principal Executive) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.917pt 0pt 0.5pt 0pt; width:63.07pt;white-space:nowrap;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:46pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Daron Evans</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Daron Evans </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer (Principal Financial Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:46pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Young-Jin Kim</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Young-Jin Kim </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:46pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Nerissa Kreher</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Nerissa Kreher </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:46pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Gil Labrucherie</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Gil Labrucherie </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:46pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Philippe Fauchet</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Philippe Fauchet </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Wladimir Hogenhuis</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Wladimir Hogenhuis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:236.93pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 0.5pt 0pt; width:63.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">August&#160;5, 2024</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2420753d2_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SECURITIES PURCHASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SECURITIES PURCHASE AGREEMENT
(this &ldquo;<U>Agreement</U>&rdquo;) is made as of June&nbsp;27, 2024, by and among Rezolute,&nbsp;Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each of those persons and entities, severally and not jointly, identified as a Purchaser on the Schedule of Purchasers attached as
<U>Exhibit&nbsp;A</U> hereto (the &ldquo;<U>Schedule of Purchasers</U>&rdquo;). Such persons and entities together with their permitted
successors and assigns, are referred to collectively as the &ldquo;<U>Purchasers</U>&rdquo; and each individually as a &ldquo;<U>Purchaser</U>&rdquo;.
The Company and the Purchasers may each be referred to herein individually as a &ldquo;<U>Party</U>&rdquo; and collectively as the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Parties are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section&nbsp;4(a)(2)&nbsp;of
the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) and the provisions of Regulation D (&ldquo;<U>Regulation
D</U>&rdquo;) or other applicable exemptions from registration, as promulgated by the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;)
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 5pt">&#8239;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Purchasers wish to purchase, severally but not jointly, from the Company, and the Company wishes to sell and issue to the Purchasers,
upon the terms and conditions stated in this Agreement, [&#9679;] shares of the Company&rsquo;s common stock, par value $0.001 per share
(the &ldquo;<U>Common Stock</U>&rdquo;) for an aggregate purchase price of $[&#9679;] (the &ldquo;<U>Shares</U>&rdquo;), with Jefferies
LLC and Cantor Fitzgerald&nbsp;&amp; Co. acting as placement agents (the &ldquo;<U>Placement Agents</U>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 5pt">&#8239;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Contemporaneously
with the execution and delivery of this Agreement, the Parties will execute and deliver a Registration Rights Agreement, in the form
attached hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;), pursuant to which the Company agrees
to provide certain registration rights with respect to the Shares under the Securities Act and applicable state securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of the mutual
promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to those terms defined elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the
meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 5pt">&#8239;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to any Person, any other Person directly or indirectly controlled by, controlling or under common control with, the
Person, but only for so long as such control shall continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>&ldquo;Business
Day</U></FONT>&rdquo; means any day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Closing Date</U>&rdquo;
means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all
of the conditions set forth in <U>Section&nbsp;6.1</U> and <U>Section&nbsp;6.2</U> hereof are satisfied or waived by the Required Purchasers,
as the case may be, or such other date as the Company and the Required Purchasers may agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Company Counsel</U>&rdquo;
means Dorsey&nbsp;&amp; Whitney LLP, with offices located at 1400 Wewatta Street, Suite&nbsp;400, Denver, CO 80202-5549.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Company Intellectual
Property Counsel</U>&rdquo; means Marshall, Gerstein&nbsp;&amp; Borun LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>&ldquo;Company&rsquo;s
Knowledge&rdquo;</U></FONT> means with respect to any statement made to the knowledge of the Company, that the statement is based upon
the actual knowledge of the officers of the Company who, as of the date hereof, have responsibility for the matter or matters that are
the subject of the statement, and the knowledge that each such person would have reasonably obtained in the performance of each such person&rsquo;s
duties as an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Contract</U>&rdquo;
means any written agreement, contract, subcontract, lease, understanding, arrangement, instrument, note, option, warranty, purchase order,
license, sublicense, insurance policy, benefit plan or legally binding commitment or undertaking of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Control</U>&rdquo;
(including the terms &ldquo;controlling,&rdquo; &ldquo;controlled by&rdquo; or &ldquo;under common control with&rdquo;) means the possession,
direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of a Person (whether through ownership
of securities or partnership or other ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities
(whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Insider</U>&rdquo;
means each director, executive officer, other officer of the Company participating in the offering, any beneficial owner of twenty percent
(20%) or more of the Company&rsquo;s outstanding voting equity securities, calculated on the basis of voting power, and any promoter connected
with the Company in any capacity on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Law</U>&rdquo; or
 &ldquo;<U>Laws</U>&rdquo; means any federal, state, local, municipal, foreign or other law, statute, constitution, principle of common
law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Order</U>&rdquo; means
any order, writ, injunction, judgment or decree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Registration Statement</U>&rdquo;
has the meaning set forth in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Required Purchasers</U>&rdquo;
means the Purchasers beneficially owning (calculated in accordance with Rule&nbsp;13d-3 under the Exchange Act) a majority of the aggregate
outstanding Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, or any successor statute, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Share Purchase Price</U>&rdquo;
means $4.00 per Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Subscription Amount</U>&rdquo;
means, with respect to each Purchaser, the aggregate amount to be paid for the Shares purchased by such Purchaser hereunder as indicated
on such Purchaser&rsquo;s signature page&nbsp;hereto next to the heading &ldquo;Aggregate Purchase Price (Subscription Amount)&rdquo;
in United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB
or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transaction Documents</U>&rdquo;
means this Agreement and the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchase
and Sale of the Shares</U>. Subject to the terms and conditions of this Agreement, at the Closing, each Purchaser shall severally, and
not jointly, purchase, and the Company shall sell and issue to such Purchaser, such number of Shares described in the Schedule of Purchasers
attached as <U>Exhibit&nbsp;C</U> hereto, equal to the quotient resulting from dividing (i)&nbsp;the Subscription Amount for such Purchaser
by (ii)&nbsp;the Purchase Price, rounded down to the nearest whole Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
The closing of the issuance and sale of the Shares (the &ldquo;<U>Closing</U>&rdquo;) shall occur remotely via the exchange of documents
and signatures on the Closing Date. At the Closing, each Purchaser shall deliver or cause to be delivered to the Company the Subscription
Amount for such Purchaser, via wire transfer of immediately available funds pursuant to the wire instructions delivered to such Purchaser
by the Company prior to the Closing. Promptly after the Closing, the Company shall deliver to each Purchaser the uncertificated Shares
registered in the name of such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. The Company hereby represents and warrants to the Purchasers that, except as disclosed to the Purchasers
or in the SEC Filings (as defined below), as of the date hereof and as of the Closing Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Incorporation
and Good Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a corporation in good standing
under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties
and to conduct its business as disclosed to the Purchasers and/or described in the SEC filings and to enter into and perform its obligations
under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State
of Nevada and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property
or the conduct of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
Each of the Company&rsquo;s &ldquo;subsidiaries&rdquo; (for purposes of this Agreement, as defined in Rule&nbsp;405 under the Securities
Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability
company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and
authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the SEC Filings. Each
of the Company&rsquo;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable,
to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership
or leasing of property or the conduct of business. All of the issued and outstanding capital stock or other equity or ownership interests
of each of the Company&rsquo;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned
by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse
claim. <FONT STYLE="background-color: white">None of the outstanding capital stock or equity interest in any subsidiary was issued in
violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each
of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization
and are in full force and effect. </FONT>The Company does not own or control, directly or indirectly, any corporation, association or
other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Company&rsquo;s Annual Report on Form&nbsp;10-K for the fiscal
year ended June&nbsp;30, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required</U>. Neither the Company nor any of its subsidiaries is in violation
of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default
(or, with the giving of notice or lapse of time, would be in default) (&ldquo;<U>Default</U>&rdquo;) under any indenture, loan, credit
agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement,
security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which
the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties
or assets are subject (each, an &ldquo;<U>Existing Instrument</U>&rdquo;), except for such Defaults as could not be expected, individually
or in the aggregate, to result in a Material Adverse Change (as defined below). The Company&rsquo;s execution, delivery and performance
of this Agreement and the Shares, consummation of the transactions contemplated hereby and the issuance and sale of the Shares (i)&nbsp;have
been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws,
partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary (ii)&nbsp;will
not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the
creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant
to, or require the consent of any other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law,
administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No consent, approval,
authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is
required for the Company&rsquo;s execution, delivery and performance of this Agreement, and consummation of the transactions contemplated
hereby. As used herein, a &ldquo;<U>Debt Repayment Triggering Event</U>&rdquo; means any event or condition which gives, or with the giving
of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such
holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company
or any of its subsidiaries</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization
and Other Capital Stock Matters</U>. The authorized, issued and outstanding capital stock of the Company is as disclosed to the Purchasers
and/or set forth in the SEC Filings (other than for subsequent issuances, if any, pursuant to employee benefit plans, upon the exercise
of outstanding options or warrants, or as otherwise disclosed to the Purchasers and/or described in the SEC Filings). All of the issued
and outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued
in compliance with all federal and state securities laws. None of the outstanding shares of Common Stock was issued in violation of any
preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no
authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt
securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than
those disclosed to the Purchasers and/or described in the SEC Filings. The descriptions of the Company&rsquo;s stock option, stock bonus
and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the SEC Filings and/or disclosed
to the Purchasers, accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options
and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization
of the Shares</U>. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered
by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance
and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase
the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Applicable Registration or Other Similar Rights</U>. There are no persons with registration or other similar rights to have any equity
or debt securities registered for sale included in the offering contemplated by this Agreement, except for such rights as have been duly
waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>SEC
Filings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under the Exchange Act for
the three (3)-year period preceding the date hereof (or such shorter period as the Company was required by Law to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred
to herein as the &ldquo;<U>SEC Filings</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the time of filing thereof, or to the extent corrected by a subsequent filing, the SEC Filings complied as to form in all material respects
with all applicable requirements of the Exchange Act and did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
registration statement and any amendment thereto filed by the Company during the three (3)&nbsp;year period preceding the date hereof
pursuant to the Securities Act, as of the date such statement or amendment became effective, complied as to form in all material respects
with the Securities Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements made therein not misleading; and each prospectus filed during the three (3)&nbsp;year
period preceding the date hereof pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act, as of its issue date and as of the closing
of any sale of securities pursuant thereto, did not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Material Adverse Change</U>. Except as otherwise disclosed to the Purchasers, (i)&nbsp;there has been no material adverse change, or any
development that could be expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the
earnings, business, properties, operations, operating results, assets, liabilities or prospects<B>,</B> whether or not arising from transactions
in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company
to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to
herein as a &ldquo;<U>Material Adverse Change</U>&rdquo;); (ii)&nbsp;the Company and its subsidiaries, considered as one entity, have
not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference
with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from
any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the
Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business;
and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness
of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or,
except for dividends paid to the Company or other subsidiaries, by any of the Company&rsquo;s subsidiaries on any class of capital stock,
or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Law Compliance</U>. The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns
or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any
related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate
proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;4.13
below in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company
or any of its subsidiaries has not been finally determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Taxes</U>. There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political subdivision
thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the Company or sale by
the Company of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such
amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including,
but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage,
destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and
clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to
renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions
as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material
Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which
it has applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Material Actions or Proceedings</U>. There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or
governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries,
which could be expected, individually or in the aggregate, to result in a Material Adverse Change or materially and adversely affect the
consummation of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder. No material
labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer,
customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Financial
Statements</U>. The financial statements filed with the SEC present fairly the consolidated financial position of the Company and its
subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&rsquo; equity and cash flows for the
periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on
a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data
in eXtensible Business Reporting Language included or incorporated by reference in the SEC Filings fairly presents the information called
for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.
No other financial statements or supporting schedules are required to be included in the SEC Filings. The financial data set forth in
the SEC Filings fairly present the information set forth therein on a basis consistent with that of the audited financial statements contained
in the SEC Filings. Any disclosures contained in the SEC Filings that constitute non-GAAP financial measures (as defined by the rules&nbsp;and
regulations under the Securities Act and the Exchange Act) comply with Regulation G under the Exchange Act and Item 10 of Regulation S-K
under the Securities Act, as applicable. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being associated
with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule&nbsp;5300 promulgated by the
Public Company Accounting Oversight Board (&ldquo;<U>PCAOB</U>&rdquo;), has participated in or otherwise aided the preparation of, or
audited, the financial statements, supporting schedules or other financial data filed with the SEC as a part of the SEC Filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Accountants</U>. Plante&nbsp;&amp; Moran, PLLC, which has expressed its opinion with respect to the financial statements (which term
as used in this Agreement includes the related notes thereto) and Grant Thornton have each filed with the Commission as a part of the
SEC Filings, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the
rules&nbsp;of the PCAOB, (ii)&nbsp;in compliance with the applicable requirements relating to the qualification of accountants under
Rule&nbsp;2-01 of Regulation S-X under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB
whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company&rsquo;s
Accounting System</U>. The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal
accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s
general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only
in accordance with management&rsquo;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared
with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Filings fairly presents the information
called for in all material respects and is prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. The Company has established and
maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15 and 15d-15 under the Exchange Act), which (i)&nbsp;are designed
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&rsquo;s
principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which
the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for
effectiveness as of the end of the Company&rsquo;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to
perform the functions for which they were established. Since the end of the Company&rsquo;s most recent audited fiscal year, there have
been no significant deficiencies or material weakness in the Company&rsquo;s internal control over financial reporting (whether or not
remediated) and no change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company&rsquo;s internal control over financial reporting. The Company is not aware of any change in
its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or
is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property Rights</U>. The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent
applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in
the SEC Filings as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently
conducted or as currently proposed to be conducted (collectively, &ldquo;<U>Intellectual Property</U>&rdquo;) and the conduct of their
respective businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights
of others. The Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole
or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company&rsquo;s
knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights
of third-party licensors with respect to Intellectual Property that is disclosed in the SEC Filings as licensed to the Company or one
or more of its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. There is no pending
or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&rsquo;s
rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action,
suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is
unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the
Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described
in the SEC Filings as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret
or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action,
suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual
Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect. To the Company&rsquo;s
knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company
and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution
of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees,
and no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention
assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or
with a former employer where the basis of such violation relates to such employee&rsquo;s employment with the Company. The duty of candor
and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent
applications included in the Intellectual Property have been complied with; and in all foreign offices having similar requirements, all
such requirements have been complied with. None of the Intellectual Property or technology (including information technology and outsourced
arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation
of any contractual obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or
otherwise in violation of the rights of any persons. The product candidates described in the SEC Filings as under development by the Company
or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any
subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure</U>.
The Company understands and confirms that the Purchasers will rely on the foregoing representations in effecting transactions in securities
of the Company. To the Knowledge of the Company, all due diligence materials regarding the Company, its subsidiaries, their businesses
and the transactions contemplated hereby, furnished by or on behalf of the Company or its subsidiaries to the Purchasers upon their request
are, when taken together with the SEC Filings, true and correct in all material respects and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Contracts</U>.
Each franchise, contract or other document of a character required to be described in the SEC Filings or to be filed as an exhibit to
the SEC Filings under the Securities Act and the rules&nbsp;and regulations promulgated thereunder (collectively, the &ldquo;<U>Material
Contracts</U>&rdquo;) is so described or filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. The Company and its subsidiaries have been and are in compliance with all applicable laws, rules&nbsp;and regulations,
except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Health Care Laws</U>. The Company and its subsidiaries are, and at all times have been, in compliance with all Health Care Laws.
For purposes of this Agreement, &ldquo;Health Care Laws&rdquo; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301
et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all
applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute
(42 U.S.C. Section&nbsp;1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements
law (42 U.S.C. Section&nbsp;1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health
Act (collectively, &ldquo;<U>HIPAA</U><B>&rdquo;</B>), (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn),
the civil monetary penalties law (42 U.S.C. Section&nbsp;1320a-7a), the exclusion law (42 U.S.C. Section&nbsp;1320a-7), the Physician
Payments Sunshine Act (42 U.S.C. Section&nbsp;1320-7h), and applicable laws governing government funded or sponsored healthcare programs;
(iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et
seq.); (iv)&nbsp;the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act
of 2010; (v)&nbsp;licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or
regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation
of the Company or its subsidiaries, and (vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state
or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&rsquo;s
knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The
Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material
respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to
any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by
any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees,
officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or
human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other
similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Clinical
Data and Regulatory Compliance</U>. The preclinical tests and clinical trials, and other studies (collectively, &ldquo;studies&rdquo;)
that are described in, or the results of which are referred to in, the SEC Filings and/or disclosed to the Purchasers were and, if still
pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved
for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate
and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have
no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or
referred to in the SEC Filings and/or disclosed to the Purchasers; the Company and its subsidiaries have made all such filings and obtained
all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee
thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional
Review Board (collectively, the &ldquo;<U>Regulatory Agencies</U>&rdquo;); neither the Company nor any of its subsidiaries has received
any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials
that are described or referred to in the SEC Filings and/or disclosed to the Purchasers; and the Company and its subsidiaries have each
operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory
Agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cybersecurity</U>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted,
free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including &ldquo;Personal Data,&rdquo; used in connection with their businesses. &ldquo;<U>Personal Data</U>&rdquo;
means (i)&nbsp;a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or
tax identification number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account
number; (ii)&nbsp;any information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission
Act, as amended; (iii)&nbsp;&ldquo;personal data&rdquo; as defined by the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;)
 &ldquo;) (EU 2016/679); (iv)&nbsp;any information which would qualify as &ldquo;protected health information&rdquo; under HIPAA; and (v)&nbsp;any
other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis
of any data related to an identified person&rsquo;s health or sexual orientation. There have been no breaches, violations, outages or
unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify
any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are
presently in material compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court
or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation
or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable
state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries
have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in compliance
with, GDPR (collectively, the &ldquo;<U>Privacy Laws</U>&rdquo;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries
have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies
and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal
Data (the &ldquo;<U>Policies</U>&rdquo;). The Company and its subsidiaries have at all times made all disclosures to users or customers
required by applicable laws and regulatory rules&nbsp;or requirements, and none of such disclosures made or contained in any Policy have,
to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules&nbsp;or requirements in any
material respect. The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential
liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition
that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree,
or agreement that imposes any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Not an &ldquo;Investment Company&rdquo;</U>. The Company is not, and will not be, either after receipt of payment for the Shares or after
the application of the proceeds therefrom, required to register as an &ldquo;investment company&rdquo; under the Investment Company Act
of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>All
Necessary Permits,&nbsp;etc</U>. The Company and its subsidiaries possess such valid and current certificates, authorizations or permits
required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and
as described in the SEC Filings (&ldquo;<U>Permits</U>&rdquo;). Neither the Company nor any of its subsidiaries is in violation of, or
in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or non-compliance
with, any such certificate, authorization or permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Title
to Properties</U>. The Company and its subsidiaries have good and marketable title to all of the real and personal property and other
assets reflected as owned in the financial statements referred to in Section&nbsp;4.13 above (or elsewhere in the SEC Filings), in each
case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects. The real property,
improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable
leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real
property, improvements, equipment or personal property by the Company or such subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>ERISA
Compliance</U>. The Company and its subsidiaries and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<U>ERISA</U>&rdquo;))
established or maintained by the Company, its subsidiaries or their &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance
in all material respects with ERISA. &ldquo;<U>ERISA Affiliate</U>&rdquo; means, with respect to the Company or any of its subsidiaries,
any member of any group of organizations described in Sections 414(b), (c), (m)&nbsp;or (o)&nbsp;of the Internal Revenue Code of 1986,
as amended, and the regulations and published interpretations thereunder (the &ldquo;<U>Code</U>&rdquo;) of which the Company or such
subsidiary is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with
respect to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates.
No &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if
such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined
under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any
liability under (i)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo;
or (ii)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries
or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and nothing
has occurred, whether by action or failure to act, which would cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Environmental Laws</U>. Except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change:
(i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation,
ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative interpretation thereof, including any judicial or
administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws
and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous
substances, petroleum or petroleum products (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;);
(ii)&nbsp;the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental
Laws and are each in compliance with their requirements; (iii)&nbsp;there are no pending or threatened administrative, regulatory or judicial
actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to
any Environmental Law against the Company or any of its subsidiaries; and (iv)&nbsp;there are no events or circumstances that might reasonably
be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental
body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Anti-Corruption
and Anti-Bribery Laws</U>. Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or any
of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any
of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made
or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign
or domestic government official or employee, including of any government-owned or controlled entity or public international organization,
or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of
the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<U>FCPA</U>&rdquo;), the UK Bribery Act 2010, or any other applicable
anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful
bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit . The Company and its subsidiaries and, to the
knowledge of the Company, the Company&rsquo;s affiliates have conducted their respective businesses in compliance with the FCPA and have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Money
Laundering Laws</U>. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with
applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the money laundering statutes of all applicable jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar applicable
rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the
Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.32.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sanctions</U>.
Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, after due inquiry,
any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target
of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<U>OFAC</U>&rdquo;)
or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury of the United Kingdom,
or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;); nor is the Company or any of its subsidiaries located,
organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Crimea,
Cuba,&nbsp;Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of
financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject
or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in
the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past ten years, the Company and
its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that
at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.33.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Exchange Listing</U>. The shares of Common Stock are registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act
and are listed on The Nasdaq Capital Market (&ldquo;<U>NASDAQ</U>&rdquo;). The Company shall cause the Shares to be listed on NASDAQ prior
to the effectiveness of the Registration Statement and shall use its best efforts to maintain the continued listing of such Shares. The
Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange
Act or delisting the Shares from NASDAQ, nor has the Company received any notification that the Commission or NASDAQ is contemplating
terminating such registration or listing. To the Company&rsquo;s knowledge, it is in compliance with all applicable listing requirements
of NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.34.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Unlawful Contributions or Other Payments</U>. Neither the Company nor any of its subsidiaries nor, to the best of the Company&rsquo;s
knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate
for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the SEC Filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.35.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Outstanding Loans or Other Extensions of Credit</U>. The Company does not have any outstanding extension of credit, in the form of a personal
loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly
permitted by Section&nbsp;13(k)&nbsp;of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.36.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Contract Terminations</U>. Neither the Company nor any of its subsidiaries has sent or received any communication regarding termination
of, or intent not to renew, any of the contracts or agreements referred to or described in or filed as an exhibit to the SEC Filings,
and no such termination or non-renewal has been threatened by the Company or any of its subsidiaries or, to the Company&rsquo;s knowledge,
any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.37.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Dividend
Restrictions</U>. No subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company,
or from making any other distribution with respect to such subsidiary&rsquo;s equity securities or from repaying to the Company or any
other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from
the Company or from transferring any property or assets to the Company or to any other subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Assuming the accuracy of the representations and warranties of the Purchasers set forth in <U>Section&nbsp;5</U>,
the Company has not, directly or indirectly through any agent, made any offers or sales of, or solicited any offers to buy, any Company
 &ldquo;security&rdquo; (as defined in the Securities Act) under circumstances that would adversely affect reliance by the Company on Section&nbsp;4(a)(2)&nbsp;for
the exemption from registration for the transactions contemplated hereby or would require registration of any of the Securities under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.39.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Price Stabilization or Manipulation; Compliance with Regulation M</U>. Neither the Company nor any of its subsidiaries has taken, directly
or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or of
any &ldquo;reference security&rdquo; (as defined in Rule&nbsp;100 of Regulation M under the Exchange Act (&ldquo;<U>Regulation M</U>&rdquo;))
with respect to the Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would
directly or indirectly violate Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.40.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Brokers</U>.
Except pursuant to the Transaction Documents, there is no broker, finder or other party that is entitled to receive from the Company any
brokerage or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.41.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Private
Placement</U>. Assuming the accuracy of the representations and warranties of the Purchasers set forth in <U>Section&nbsp;5</U>, and in
reliance thereon, the offer and sale of the Shares to the Purchasers as contemplated hereby is exempt from the registration requirements
of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.42.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shell
Company</U>. The Company is not, and was not within the past three (3)&nbsp;years, an &ldquo;ineligible issuer&rdquo; (as defined in Rule&nbsp;405
promulgated under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.43.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Use
of Form&nbsp;S-3</U>. The Company meets the registration and transaction requirements for use of Form&nbsp;S-3 for the registration of
the resale of the Shares by the Purchasers, subject to the SEC&rsquo;s guidance and interpretations regarding secondary offerings being
considered primary offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.44.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Stop Order</U>. No stop order or suspension of trading has been imposed as of the date hereof by the OTC Markets Group, the Financial
Industry Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;), the SEC or any other governmental authority or regulatory body with respect
to public trading in the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.45.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley
Act</U>. There is, and has been, no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities
as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules&nbsp;and regulations promulgated
in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser hereby severally, and not jointly, represents and warrants to the Company that, as
of the date hereof and as of the Closing Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Existence</U>. Such Purchaser is a duly organized, validly existing corporation, limited partnership or limited liability company
and in good standing under the Laws of the jurisdiction of its organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization</U>.
Such Purchaser has the requisite corporate (or similar) power and authority and has taken all requisite action on the part of such Purchaser,
its officers, directors, members and stockholders necessary for (i)&nbsp;the authorization, execution and delivery of the Transaction
Documents to which such Purchaser is a party and (ii)&nbsp;the authorization of the performance of all obligations of the Purchaser hereunder
or thereunder. The Transaction Documents to which such Purchaser is a party constitute the legal, valid and binding obligations of the
Purchaser, enforceable against such Purchaser in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar Laws of general applicability, relating to or affecting creditors&rsquo; rights generally and to
general equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflict, Breach, Violation or Default</U>. The execution, delivery and performance of the Transaction Documents by such Purchaser will
not (i)&nbsp;conflict with or result in a material breach or material violation of (a)&nbsp;any of the terms and provisions of, or constitute
a material default under, its organizational documents, as in effect as of immediately prior to the Closing, or (b)&nbsp;any Law or Order
of any governmental agency or body or any court, domestic or foreign, in each case having jurisdiction over such Purchaser or any of its
assets or properties, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would
become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of
such Purchaser or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of
time or both) of, any material agreement, indenture or instrument to which such Purchaser is a party; except in the case of clauses (i)(b)&nbsp;and
(ii)&nbsp;such as would not have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchase
Entirely for Own Account</U>. The Shares to be received by such Purchaser hereunder, will be acquired for such Purchaser&rsquo;s own account,
not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and
such Purchaser has no present agreement, understanding or intention of selling, granting any participation in, or otherwise distributing
the same in violation of the Securities Act without prejudice, subject, however, to such Purchaser&rsquo;s right at all times to sell
or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Experience</U>. Such Purchaser acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and
has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment
contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
of Information</U>. Such Purchaser has had an opportunity to review all information related to the Company requested by it and to ask
questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of
the Shares. Such Purchaser acknowledges that copies of the SEC Filings have been made available to it. Such Purchaser has sought such
accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to its acquisition of the Shares.
Based on the information such Purchaser has deemed appropriate, and without reliance upon the Placement Agent, it has independently made
its own analysis and decision to enter into the Transaction Documents. Such Purchaser is relying exclusively on its own investment analysis
and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance of the
Transaction Documents and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company,
including but not limited to all business, legal, regulatory, accounting, credit and tax matters. Such Purchaser has not relied on any
advice furnished by or on behalf of the Placement Agent in connection with the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restricted
Securities</U>. Such Purchaser understands that the Shares are characterized as &ldquo;restricted securities&rdquo; under the U.S. federal
securities Laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such
Laws the Securities may be resold without registration under the Securities Act only in certain limited circumstances. Such Purchaser
understands that except as provided in the Registration Rights Agreement: (i)&nbsp;the Shares have not been and are not being registered
under the Securities Act or any state securities Laws, and may not be offered for sale, sold, assigned or transferred unless (a)&nbsp;subsequently
registered thereunder, (b)&nbsp;such Purchaser shall have delivered to the Company an opinion of counsel, in a form reasonably acceptable
to the Company, to the effect that such Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an
exemption from such registration, or (c)&nbsp;such Purchaser provides the Company with reasonable assurance that such Shares can be sold,
assigned or transferred pursuant to Rule&nbsp;144 or Rule&nbsp;144A promulgated under the Securities Act, as amended, (or a successor
rule&nbsp;thereto) (collectively, &ldquo;<U>Rule&nbsp;144</U>&rdquo;); (ii)&nbsp;any sale of the Shares made in reliance on Rule&nbsp;144
may be made only in accordance with the terms of Rule&nbsp;144 and further, if Rule&nbsp;144 is not applicable, any resale of the Shares
under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term
is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules&nbsp;and regulations
of the SEC thereunder; and (iii)&nbsp;neither the Company nor any other Person is under any obligation to register the Shares under the
Securities Act or any state securities Laws or to comply with the terms and conditions of any exemption thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. Such Purchaser is an institutional &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3)&nbsp;or
(a)(7)&nbsp;under the Securities Act or a &ldquo;qualified institutional buyer&rdquo; within the meaning of Rule&nbsp;144A under the Securities
Act. Such Purchaser is a sophisticated &ldquo;institutional account&rdquo; as defined in FINRA Rule&nbsp;4512(c), with sufficient knowledge
and experience in investing in private placement transactions to properly evaluate the risks and merits of its purchase of the Shares.
Such Purchaser is not a registered broker-dealer registered under Section&nbsp;15(a)&nbsp;of the Exchange Act, or a member of FINRA or
an entity engaged in the business of being a broker-dealer. Such Purchaser is not affiliated with any broker-dealer registered under Section&nbsp;15(a)&nbsp;of
the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reliance
on Exemptions</U>. Such Purchaser understands that the Shares are being offered and sold to it in reliance on specific exemptions from
the registration requirements of federal and state securities Laws and that the Company is relying in part upon the truth and accuracy
of, and such Purchaser&rsquo;s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such
Purchaser set forth in the Transaction Documents in order to determine the availability of such exemptions and the eligibility of such
Purchaser to acquire the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
General Solicitation</U>. Such Purchaser did not learn of the investment in the Shares as a result of any general solicitation or general
advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Brokers
and Finders</U>. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest
or claim against or upon the Company, any subsidiary thereof or any Purchaser for any commission, fee or other compensation pursuant
to any agreement, arrangement or understanding entered into by or on behalf of such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Prohibited
Transactions</U>. Since the earlier of (i)&nbsp;such time as such Purchaser was first contacted by the Company or any other Person acting
on behalf of the Company regarding the transactions contemplated hereby or (ii)&nbsp;thirty (30) days prior to the date hereof, neither
such Purchaser nor any Affiliate of such Purchaser which (a)&nbsp;had knowledge of the transactions contemplated hereby, (b)&nbsp;has
or shares discretion relating to such Purchaser&rsquo;s investments or trading or information concerning such Purchaser&rsquo;s investments,
including in respect of the Securities, or (c)&nbsp;is subject to such Purchaser&rsquo;s review or input concerning such Affiliate&rsquo;s
investments or trading has, directly or indirectly, effected or agreed to effect any short sale, whether or not against the box, established
any &ldquo;put equivalent position&rdquo; (as defined in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act) with respect to the Common Stock,
granted any other right (including, without limitation, any put or call option) with respect to the Common Stock or with respect to any
security that includes, relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its
position in the Shares. Such Purchaser acknowledges that the representations, warranties and covenants contained in this <U>Section&nbsp;5.12</U>
are being made for the benefit of the Purchasers as well as the Company and that each of the other Purchasers shall have an independent
right to assert any claims against such Purchaser arising out of any breach or violation of the provisions of this <U>Section&nbsp;5.12</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;506(d)&nbsp;Representation</U>.
Such Purchaser represents that it is not a person of the type described in Section&nbsp;506(d)&nbsp;of Regulation D under the Securities
Act that would disqualify the Company from engaging in a transaction pursuant to Section&nbsp;506 of Regulation D under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Residency</U>.
Such Purchaser is a resident of that jurisdiction specified on such Purchaser&rsquo;s signature page&nbsp;hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Placement
Agent</U>. Such Purchaser hereby acknowledges and agrees that (a)&nbsp;the Placement Agent is acting solely as a placement agent in connection
with the execution, delivery and performance of the Transaction Documents and are not acting as an underwriter, initial purchaser, dealer
or in any other such capacity and are not and shall not be construed as a fiduciary for such Purchaser, the Company or any other person
or entity in connection with the execution, delivery and performance of the Transaction Documents, (b)&nbsp;it is not relying upon, and
has not relied upon, any statement, representation or warranty made by the Placement Agent, any of their respective affiliates or any
of their respective control persons, officers, directors and employees, in making its investment or decision to invest in the Company,
(c)&nbsp;the Placement Agent has not made and will not make any representation or warranty, whether express or implied, of any kind or
character, and have not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction
Documents, (d)&nbsp;the Placement Agent will not have any responsibility with respect to (i)&nbsp;any representations, warranties or agreements
made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Documents, or the
execution, legality, validity or enforceability (with respect to any person) thereof, or (ii)&nbsp;the business, affairs, financial condition,
operations, properties or prospects of, or any other matter concerning the Company, and (e)&nbsp;the Placement Agent will not have any
liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments,
awards, liabilities, costs, expenses or disbursements incurred by such Purchaser, the Company or any other person or entity), whether
in contract, tort or otherwise, to such Investor, or to any person claiming through it, in respect of any action heretofore or hereafter
taken or omitted to be taken by any of them in connection with any Purchasers purchase of the Shares or the execution, delivery and performance
of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to the Purchasers&rsquo; Obligations</U>. The obligation of each Purchaser to purchase the Shares at the Closing is subject to the fulfillment
to satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Purchaser (as to itself
only):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
representations and warranties made by the Company in <U>Section&nbsp;4</U> hereof shall be true and correct in all material respects
(except for those representations and warranties that are qualified by materiality or Material Adverse Change, which shall be true and
correct in all respects) as of the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier
date, in which case such representation or warranty shall be true and correct in all material respects (except for those representations
and warranties that are qualified by materiality or Material Adverse Change, which shall be true and correct in all respects) as of such
earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed
by it on or prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by
the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">a
Certificate of the Secretary of the Company, dated as of the Closing Date, shall be delivered (i)&nbsp;certifying the resolutions adopted
by the Board of Directors of the Company and any duly authorized committee thereof relating to the transactions contemplated by this Agreement
and the other Transaction Documents and the issuance of the Shares, (ii)&nbsp;certifying the current versions of the certificate of incorporation,
as amended, and bylaws of the Company and (iii)&nbsp;certifying as to the signatures and authority of persons signing the Transaction
Documents and related documents on behalf of the Company, in form and substance reasonably acceptable to the Purchasers (the &ldquo;<U>Secretary&rsquo;s
Certificate</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, in each case having authority over the Company or its subsidiaries, or any order of or by any applicable governmental authority,
shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing
the consummation of the transactions contemplated hereby or in the other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer,
dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a)&nbsp;and (b), of this Section&nbsp;6.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Purchasers shall have received an opinion of (i)&nbsp;Company Counsel dated as of the Closing Date and (ii)&nbsp;Company Intellectual
Property Counsel, each in a form and substance reasonably acceptable to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have executed and delivered the Transaction Documents to each Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
stop order or suspension of trading shall have been imposed or threatened in writing by the Trading Market, FINRA, the SEC or any other
governmental or regulatory body with respect to public trading in the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to the Company&rsquo;s Obligations</U>. The Company&rsquo;s obligation to sell and issue the Shares at the Closing to each Purchaser is
subject to the fulfillment on or prior to the Closing Date of the following conditions, any of which may be waived by the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
representations and warranties made by such Purchaser in Section&nbsp;5 hereof shall be true and correct in all material respects (except
for those representations and warranties that are qualified by materiality, which shall be true and correct in all respects) as of the
date hereof as of the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in
which case such representation or warranty shall be true and correct in all material respects (except for those representations and warranties
that are qualified by materiality, which shall be true and correct in all respects) as of such earlier date. Each Purchaser shall have
performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser shall have delivered its applicable portion of the Purchase Price to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser shall have executed and delivered the Transaction Documents to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Termination
of Obligations to Effect Closing; Effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
obligations of the Company, on the one hand, and the Purchasers, on the other hand, to effect the Closing shall terminate as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;<FONT STYLE="font-size: 5pt">&#8239;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the mutual written consent of the Company and the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;<FONT STYLE="font-size: 5pt">&#8239;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
the Company if any of the conditions set forth in <U>Section&nbsp;6.2</U> shall have become incapable of fulfillment, and shall not have
been waived by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 5pt">&#8239;</FONT>&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
a Purchaser (with respect to itself only) if any of the conditions set forth in <U>Section&nbsp;6.1</U> shall have become incapable of
fulfillment, and shall not have been waived by such Purchaser; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
either the Company or any Purchaser (with respect to itself only) if the Closing has not occurred prior to 11:59 PM (New York time) on
July&nbsp;30, 2024; provided, however, that, except in the case of clause (i)&nbsp;above, the party seeking to terminate its obligation
to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this
Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party&rsquo;s seeking
to terminate its obligation to effect the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event of termination by the Company or any Purchaser of its obligations to effect the Closing pursuant to this <U>Section&nbsp;6.3</U>,
written notice thereof shall forthwith be given to the other Purchasers by the Company and the other Purchasers shall have the right to
terminate their obligations to effect the Closing upon written notice to the Company and the other Purchasers. Nothing in this <U>Section&nbsp;6.3</U>
shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or
the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations
under this Agreement or the other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Other
Covenants and Agreements of the Parties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>[Reserved]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legends</U>.
The Shares shall bear the following legends:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&rdquo;THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY&nbsp;NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS. THIS SECURITY MAY&nbsp;BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a)&nbsp;UNDER THE SECURITIES ACT
OR OTHER LOAN SECURED BY SUCH SECURITIES.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
connection with any sale, assignment, transfer or other disposition of the Shares by a Purchaser pursuant to Rule&nbsp;144 or pursuant
to any other exemption under the Securities Act such that the purchaser acquires freely tradable securities and upon compliance by such
Purchaser with the requirements of this Agreement, if requested by such Purchaser, the Company shall cause the Transfer Agent to timely
remove any restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry
Shares sold or disposed of without restrictive legends, provided that the Company has received from the Purchaser customary representations
and other documentation reasonably acceptable to the Company in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to receipt from the Purchaser by the Company and the Transfer Agent of customary representations and other customary documentation reasonably
acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of (i)&nbsp;the Shares being subject to an
effective registration statement covering the resale of the Shares, (ii)&nbsp;such time as the Shares have been sold pursuant to Rule&nbsp;144,
or (iii)&nbsp;such time as the Shares are eligible for resale under Rule&nbsp;144(b)(1)&nbsp;or any successor provision, the Company shall
(A)&nbsp;deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book
entry Shares, together with either (1)&nbsp;a customary representation by the Purchaser that Rule&nbsp;144 applies to the Shares represented
thereby or (2)&nbsp;a statement by the Purchaser that such Purchaser has sold the Shares represented thereby in accordance with the plan
of distribution contained in the Registration Statement, and (B)&nbsp;cause its counsel to deliver to the Transfer Agent one or more opinions
to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer
Agent to effect the removal of the legend in accordance with the provisions of this Agreement. The Company agrees that following such
time as such legend is no longer required under this <U>Section&nbsp;7.3</U>, it will, upon a Purchaser&rsquo;s written request and compliance
with the immediately preceding sentence, deliver or cause to be delivered to such Purchaser, a certificate representing that such Shares
are free from all restrictive and other legends. Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent
to the Purchaser by crediting the account of the Purchaser&rsquo;s custodian as directed by such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Furnishing
of Information</U>. In order to enable the Purchasers to sell the Shares under Rule&nbsp;144, until the date that the Shares cease to
be Registrable Securities (as defined in the Registration Rights Agreement), the Company shall use its commercially reasonable efforts
to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed
by the Company after the date hereof pursuant to the Exchange Act. During such period, if the Company is not required to file reports
pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make publicly available in accordance with Rule&nbsp;144(c)&nbsp;such
information as is required for the Purchasers to sell the Shares under Rule&nbsp;144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Purchasers</U>. Subject to the provisions of this <U>Section&nbsp;7.5</U>, the Company will indemnify and hold each Purchaser harmless
from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts
paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation, that any such Purchaser may suffer
or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement; <U>provided</U>, <U>however</U>, that the aggregate liability of the Company to each Purchaser under this <U>Section&nbsp;7.5
</U>shall not exceed the amount paid by such Purchaser to the Company pursuant to <U>Section&nbsp;3</U>. Promptly after receipt by any
Purchaser (the &ldquo;<U>Indemnified Person</U>&rdquo;) of notice of any demand or claim from any Person that would or might give rise
to a claim or the commencement of any action, proceeding or investigation in respect of which indemnification may be sought pursuant
to this <U>Section&nbsp;7.5</U> (a &ldquo;<U>Third Party Claim</U>&rdquo;), such Indemnified Person shall promptly notify the Company
in writing, and in reasonable detail, of such Third Party Claim. Thereafter, the Indemnified Person will deliver to the Company, within
five (5)&nbsp;Business Days after the Indemnified Person&rsquo;s receipt thereof, copies of all notices and documents (including court
papers) received by the Indemnified Person relating to the Third Party Claim. If a Third Party Claim is made against the Company, the
Company will be entitled to participate in the defense thereof and, if it so chooses, to assume the defense thereof (subject to a reservation
of rights) with counsel selected by the Company by giving the Indemnified Person notice within twenty (20) days of the Company&rsquo;s
receipt of notice of the Third Party Claim pursuant to this <U>Section&nbsp;7.5</U>. If the Company does not give such notice to the
Indemnified Person of the Company&rsquo;s intent to assume the defense of the Third Party Claim, the Indemnified Person shall be entitled
to assume the defense thereof. Should the Company so elect to assume the defense of a Third Party Claim, the Company will not be liable
to the Indemnified Person for legal expenses subsequently incurred by the Indemnified Person in connection with the defense thereof.
If the Company assumes such defense, the Indemnified Person will have the right to participate in the defense thereof and to employ counsel,
at its own expense, separate from the counsel employed by the Company, it being understood, however, that the Company will control such
defense. If the Company chooses to defend any Third Party Claim, then all the Parties will cooperate in the defense or prosecution of
such Third Party Claim. The Indemnified Person will not admit any liability with respect to, or settle, compromise or discharge, any
Third Party Claim without the prior written consent of the Company. Notwithstanding any other provision of this Agreement, the Company
shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Person (which consent shall
not be unreasonably withheld), unless such settlement requires only the payment of money that the Company is obligated to pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Equal
Treatment of Purchasers</U>. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of
any provision of any of the Transaction Documents unless the same consideration is also offered to all of the Parties to the Transaction
Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated
separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed
as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U><I>. </I>Notwithstanding any other provision of this Agreement, each Purchaser covenants that the Shares may be disposed
of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Shares Act, or pursuant
to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance
with any applicable state and federal securities Laws. In connection with any transfer of the Shares other than (i)&nbsp;pursuant to an
effective registration statement, (ii)&nbsp;to the Company, (iii)&nbsp;pursuant to Rule&nbsp;144 (provided that the Purchaser provides
the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the Shares may be
sold pursuant to such rule), or (iv)&nbsp;to its Affiliates, the Company may require the transferor thereof to provide to the Company
an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall
be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares under
the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement
and shall have the rights of a Purchaser under this Agreement with respect to such transferred Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
of Material Non-Public Information</U>. The Company shall not disclose material non-public information to the Purchasers, or to advisors
to or representatives of the Purchasers, unless prior to disclosure of such information the Company identifies such information as being
material non-public information and provides the Purchasers, such advisors and representatives with the opportunity to accept or refuse
to accept such material non-public information for review and any Purchaser wishing to obtain such information enters into an appropriate
confidentiality agreement with the Company with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination
of Certain Obligations</U>. The provisions of <U>Section&nbsp;7.8</U> shall terminate and be of no further force and effect on the date
on which the Company&rsquo;s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration
covering the Registrable Securities (as defined in the Registration Rights Agreement) shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations, warranties, covenants and agreements contained in this Agreement shall survive for a period of one (1)&nbsp;year
following the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assignment</U>.
This Agreement may not be assigned by a party hereto without the prior written consent of the Company or the Purchasers, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors</U>.
This Agreement shall be binding solely on, and inure solely to the benefit of, each of the undersigned and their respective successors
and permitted assigns, and nothing set forth in this Agreement shall be construed to confer upon or give to any Person other than each
of the undersigned and their respective successors and permitted assigns any benefits, rights or remedies under or by reason of, or any
rights to enforce or cause the Company to enforce, the equity commitment or any provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts;
Faxes; Electronic Mail</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or electronic mail,
each of which shall be deemed an original.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively
given as hereinafter described: (i)&nbsp;if given by personal delivery, then such notice shall be deemed given upon such delivery; (ii)&nbsp;if
given by facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal; (iii)&nbsp;if given
by mail, then such notice shall be deemed given upon the earlier of (A)&nbsp;receipt of such notice by the recipient or (B)&nbsp;three
(3)&nbsp;days after such notice is deposited in first class mail, postage prepaid; and (iv)&nbsp;if given by an internationally recognized
overnight air courier, then such notice shall be deemed given one (1)&nbsp;Business Day after delivery to such carrier. All notices shall
be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten (10)&nbsp;days&rsquo;
advance written notice to the other party:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Rezolute,&nbsp;Inc.<BR>
275 Shoreline Drive, Suite&nbsp;500<BR>
Redwood City, CA 94065<BR>
Attn: Nevan Elam, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Dorsey&nbsp;&amp; Whitney LLP,<BR>
1400 Wewatta Street, Suite&nbsp;400<BR>
Denver, CO 80202-5549<BR>
Attn: Anthony W. Epps,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">If to the Purchasers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">to the addresses set forth on the signature pages&nbsp;hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments
and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Required Purchasers.
Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Shares purchased under this
Agreement at the time outstanding, each future holder of all such Shares, and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Publicity</U>.
Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall be issued by the Company
or the Purchasers without the prior written consent of the Company (in the case of a release or announcement by the Purchasers), the Placement
Agent or the Required Purchasers (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld),
except (i)&nbsp;as such release or announcement may be required by Law or the applicable rules&nbsp;or regulations of the SEC, any securities
exchange or securities market, in which case the Company or the Purchasers, as the case may be, shall allow the Purchasers or the Company,
as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in
advance of such issuance or (ii)&nbsp;a public release or announcement in connection with discussions to investors not including the Required
Purchasers, in which case such consent shall not be required. Notwithstanding the foregoing, no Purchaser may be named in a public release
or announcement concerning the transactions contemplated hereby without such Purchasers prior written consent. The Purchasers hereby acknowledge
and agree that no later than the fourth (4<SUP>th</SUP>) Business Day after the date hereof, the Company shall (x)&nbsp;issue a press
release reasonably acceptable to the Required Purchasers and (y)&nbsp;file a Current Report on Form&nbsp;8-K describing the terms of the
transactions contemplated by the Transaction Documents in the form required by the Exchange Act and attaching the material Transaction
Documents (including, without limitation, this Agreement (and all schedules and exhibits to this Agreement) and the Registration Rights
Agreement, as exhibits to such filing (including all attachments)). In addition, the Company will make such other filings and notices
in the manner and time required by the SEC or NASDAQ and the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as
if it were written so as to be enforceable to the maximum extent permitted by applicable Law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by
applicable Law, the Parties hereby waive any provision of Law which renders any provision hereof prohibited or unenforceable in any respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. This Agreement, including the Exhibits and the Registration Rights Agreement constitute the entire agreement among the
Parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written,
among the Parties with respect to the subject matter hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Further
Assurances</U>. The Parties shall execute and deliver all such further instruments and documents and take all such other actions as may
reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial</U>. This Agreement shall be governed by, and construed in accordance with, the internal
Laws of the State of Nevada without regard to the choice of law principles thereof. Each of the Parties irrevocably submits to the exclusive
jurisdiction of the courts of the State of Nevada and any state appellate court therefrom within the State of Nevada and any state appellate
court therefrom within the State of Nevada for the purpose of any suit, action, proceeding or judgment relating to or arising out of this
Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served
on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of
the Parties irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue
in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought
in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in
an inconvenient forum. EACH OF THE PARTIES WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT
AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.12.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclaimer</U>.
Except as expressly set forth in this Agreement, no Party makes any representation or warranty to any other Party of any nature, express
or implied. Each Purchaser acknowledges and agrees that in evaluating its investment in the Shares, it is not relying on any representations,
warranties or information (including the accuracy or completeness thereof) other than the representations and warranties contained herein
and the information contained in the SEC Filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.13.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations
of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Shares pursuant to the Transaction Documents
has been made by such Purchaser independently of any other Purchaser. Nothing contained in any Transaction Document, and no action taken
by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any
other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such
obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted
as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser
in connection with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents. Each Purchaser shall
be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of the Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
The Company acknowledges that each of the Purchasers has been provided with the same Transaction Documents for the purpose of closing
a transaction with multiple Purchasers and not because it was required or requested to do so by any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person except as provided in the next
paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reliance
by the Placement Agent</U>. The parties agree and acknowledge that the Placement Agent may rely on the representations, warranties, agreements
and covenants of the Company contained in this Agreement and may rely on the representations and warranties of the respective Purchasers
contained in this Agreement as if such representations, warranties, agreements, and covenants, as applicable, were made directly to the
Placement Agent. The parties further agreement that the Placement Agent may rely on or, if the Placement Agent so request, be specifically
named as an addressee of, the legal opinions to be delivered pursuant to <U>Section&nbsp;6(f)</U>&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Placement Agent, and its affiliates and its respective representatives shall be entitled to (1)&nbsp;rely on, and shall be protected in
acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of it by or on behalf
of the Company, and (2)&nbsp;be indemnified by the Company for acting as Closing Agent in connection with the transactions contemplated
by the Transaction Documents pursuant the indemnification provisions set forth in the Engagement Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature pages&nbsp;follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have executed this Agreement as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company:</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REZOLUTE,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Nevan Elam</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to PIPE &ndash; Securities
Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have executed this Agreement as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Purchase Price (Subscription Amount): </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares to be Acquired:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice/Residency of Purchaser:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.: _______________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.:________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail Address: ________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: _______________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery Instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(if different than above)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o _______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Street: ____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">City/State/Zip: ______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: __________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Telephone No.: ____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to PIPE &ndash; Securities
Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>tm2420753d2_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420753d1_ex23-2img003.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference
in this Registration Statement on Form S-3 of Rezolute, Inc. of our report dated September 14, 2023 relating to the financial statements
of Rezolute, Inc., which report appears in the Form 10-K dated September 14, 2023. We also consent to the reference to us under the heading
&ldquo;Experts&rdquo; in the Prospectus, which is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Plante &amp; Moran, PLLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cleveland, Ohio</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2420753d1_ex23-2img004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>tm2420753d2_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 107 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rezolute, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered and Carry Forward
Securities </U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid; width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Security</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Type</P></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Security</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Class</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Title</P></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fee</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Calculation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or Carry</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Forward</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rule</P></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amount</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registered&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposed</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Maximum</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Offering</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Price Per</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Unit<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT>&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposed Maximum</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Aggregate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Offering</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Price&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-left: black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fee</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rate</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: bottom; border-top: Black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amount of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registration</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fee</P></TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fees to Be</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Paid</P></TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Common Stock, $0.001 par value per share, to be sold by the Selling Stockholders </TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">457(c)</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;2,110,273</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;$4.485</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;9,464,574.40</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;0.0001476</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">$1396.97</TD></TR>
  <TR>
    <TD ROWSPAN="6" STYLE="border-top: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Common Stock, $0.001 par value issuable upon the exercise of the Warrants</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">457(c) and 457(g)</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;2,389,727</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">$4.485</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">10,717,925.60</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;0.0001476</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">$1581.97</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Total Offering Amounts </TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">$2,978.94</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Total Fees Previously Paid </TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">N/A</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Total Fee Offsets </TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">N/A</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fees</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Previously</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Paid</P></TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">Net Fee Due </TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carry</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Forward</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities</P></TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(1)</TD>
    <TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(g) under the Securities Act, as amended., based on the average of the high and low sales price of the Common Stock as reported on Nasdaq on July 31, 2024. </TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>bc_exemplary-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_exemplary-4clr.jpg
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M_\0 X@ !  $% 0$!              $"! 4&!P,("0$! 0$! 0$! 0
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@(5R^Z/V: _.(XGIYE_:_P!WP>J"8?V-7.RBY1R#IC1_&2T"U=Q*D$*U
M<AJKZC<E:64\K:=S$^L.E&PO9LQVX7<]TABXA6XX3*FGY6.F.RW66)' W2MU
M8 5:U[5X)N;^T=XY=PQVR_:53G.L62Z,;HVTO;6>C+?:QTER2F0U*=CI\4)
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M6 JZ;\C7=V8M5BSEUK3HU0^K4$DD*M<>BO&>@^+_ /[A;:#MO8X4 H"7D_6
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M&KU#P[W.G6O+EW"N*K4W;>&S<%OO;D_:FZ(:9V$R2/#D,J-E"QNE:%#BE:2
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M*#52TP&V\#M: ,5MS&Q<3C$J+@AP641V0M7-6E  N;<36I2<G5A)+892LE%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MU9G&S*/WG4^1J=9:U&OMN>56X.*JME$\76E7ZS1,]T:W3E,5/AN8QV0K#X7
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MJ?4XI$&7BD>(ZLW!<8$H'5?@GERH#ZJ1JT]Z@*J 4 H!0"@% * 4 H!0"@%
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M?CS4*6S\8$Z=*M)&J]K\* R^/W'C\AG,CM]AU?UIB0RN<TIM2$Z9*2I!0M0
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MZH- 9?K%F,/+R?3S'Q,C%?R$?>N*2_$;?;6^@H#H5J;"BH6OQX<* [&.WWZ
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M#ERWYEU#.K3Q41K(O;MH##ES$=0-HNJ83XV&S<=QMOQD<TW* I23S 4-0]-
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M TWN%U\04L+;=#7G5"_EB_H\+QN/[GKO?ASKBH/:='-'-_\ O+8G=&!ZC?9
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MA 6#4S($ ]_[E:J"5FR3?T5&Z%H>;4AETJ0VL*+9T. ?@JM>QJ*29$>O:*T
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M""4\P#>U6I0#=2ON502>1H #PJ5 J@I6H $?_A4J";W%_O50<7ZDF2>HFV3
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M##,],=CL/8Y].%CN/X=1<QCS^M]QA1(4 E3BE$I20"A)N$GBFU :MUI*T/\
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M>C-K?0&P CO$<=( ";\NRE6*(K5T[V(K='VU5MV K=G#^>%,(,JZ18*UD7U
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M++K#!0@#PVUJXJ2FUKGG0&;H!0'*.M=_,]-O_C3$_L.T!U8<S0$T!\K^T/\
M\?1S_P#TYK_6+KX>M^V?T/\ U[_JR],O<<GX5XV?H!RXT %N= .-[6O4!U?V
M>?\ CN5PL?JYW_6)KWZ+]0_._P"Q?]5?O?0?4Z?AK[1_/V54(* 4 H!0"@%
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MU?A/:7NA'YB1.ZO#A]6X#Z5*^:IFU&]#VCJ_">TO="/S$&9U;<2$N8W $7N
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M\->* 6W LDA?X'"@/H44 5R-5$9\K>T+_P >1N?]&M<O[]5?"UOVS^B_Z_\
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M>JKZ$EY+NGR;7=;#7AEN_H*N_?TT!">F?6)"4I5U6?41Y,$^3;N?+J)>^6!
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M[%QLXS(Z8Z6TYMILITKU$DELWO7IT^F5IL^3XGXJ]8DFMATH;PZ]CETRQ_\
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MB@'AH)!MQ'*@(\- Y"WN]M 3X:/10#0GT4!'AI'_ .- "V@BQ'"@)#:4FX%
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M0C4HD"@-@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * I-K^[4H4JJD% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * @_L4!9(&2$BZTLF-8^IK#M[]WG
MPM;G0%Z!0$T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MH?T^R/3MO>F-G8Z+#C97=&1S.*DPG=:9$&:H+:UH(NVML=PI)/*A#K5 * 4
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M\["5E=VR&9F:B93)XQR9':$9#R($MQA"RTDD)44IX@4!T\-H2;@6]R@*J 4
MH!0"@% * 4 O0"@% * 7H!0"@(O4!-4"@*2H V'%7HH"-7$6'/\ M4!8RG5G
M(PHZ5D,O)>\1/I* DC[U*@N2PLIT!7</98<[\":H]Q3Y>004E\VX:2$@<!S!
M]-Z#=*E,+4DIUD!0(MV7-0C52GRRKZDN$.6MJ(O[]6HH:QNKIOM7>ZXCVYH1
MFKA!2&;//,@MN$%2%AI:0M)MQ"KBN-RVI[3W:76W=,ZVW3V_LS8XT(1&&X<<
M)9BLA*&6FDA"$M(&E*$@<@ +"NJHMAXY2E)U;JVZGJ(IT%(5Q/;8?L54VC+2
M9"&'K?&/%9Y%5M/#T&U,*EW"5,J#B5)61?F+7O86XTJ#"QMGXB%G<CN:)'"<
M]ED--3YZRI;BVF!9#:=1(0@<RE-@3Q-8C%)U/1/47)6XVV_ABZT,TF.!Q!M>
M^KASOPK=3SOW@,%*0T5?%D$:;<*S3:'CM"HZB$)"[)2 --@0;55PD:5,"D1$
M*67"HE1X&YX6'*JVRJE:DKC:BE16;\C?M'HI4$KCJ*@MM90X/PR+\/N^Y2IF
MA99G"0]P8B=A,D%.XW(-KCRV$*4R5-."RDZT$*%QPX&LM55#T6;TK-Q3AMCC
MZS'(V/MUM>WUHQS;?V62M& 0T2A$8.-^$K2D&Q[@MWKUCJXU3IL.JU=W+.+E
M7K*9N&CJ; AI:%%17=2N=_?KH>1U-2S?3#9NY<\SN3-XP3,O'#:4+<==\!7@
MG4V7&0L-K*#Q3J37.5N,G5K</=8UUZU!PC*B]OJ>U%_G=GXC<K<./GH_GHL&
M2U,C,.J44>.P#H4X 0%@7OI7<5N45))-;#A8OSLU<'1M.->!_MM,X(Z[DJ<)
MO?AV<>P^FJ<'B0F.I.FRR2DWU$ \:U4E""WX5R73WU<+G@+\>%8>)<-TE-TG
M@LZ/5'OFKNU%'4@1U>(I8<(2KUTD7!JU")5%&K5?F--OP;7ORI4E%M)+"S>S
MB@3S(X4J*(H3%4 =+G?!X*(O8T9?2>J&5)'?65*[3RN*#<Q/30D'AP'HK-,:
MD!3?MINE 1Z#RY505 <^- 04GG?[M1[08S-;@P>V8:9^X,E'Q<);B6$2);J6
M6RZY?2@%1 N;&PK4(2DZ1Q!D4%+B$N-KNE8"DJ'$$'T5-A&5:38\>)[:B*0
MJW/[O;58)";=O*@(L=1()]ZJ0!-CSX>BH4DCW>-2FZ"JJ!0"] * BXH#QE26
MXK1D.J"&4#4XL\ E(YFHY)*K-1BVZ(A,C6A+C8"DKL4J'(@BX(^Y6824E4C5
M'0]^ K9""JU_0*  @\N(H0JH44 N.5 #;MH#![DVEMG=\1./W3AX6;QZ%!QN
M/D&&Y"$K_&2' ;'WJJ;0HCUA;=PV.;ALX_&1(36.0IF F.PVV([3GK)9T@:
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M% 4K[#:]C>@.;]$-E9O8&SY6!SY85.>S&5R"#%67&_+SICC[5R0.]I4-0]-
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M'^4?M4[WXAV"Z<1DL<Y\1"I.?N+XYB]_X?\ :IWKQ!_V%TXCJ[/.9)E;@/\
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M+IQ)U=CG,PV<D9QPKC.L-L,N19&MI+UTD #O<N8KY.OU'B4L%:44XR^\L<.
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M@[-V%[16Q8VSL*QAVY>#S*I8CZOC @M:=6I2N1H0^B: I5R/O4*MI\E]>/\
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M9>,C&9*DNITQ_"2WXR_#5>[A2@W5I'"O>:,=*WO"W=T]S6;V[CI&2:++T9J
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M10 / 7X*T%QI6D%25W!/$T4Y+8R94S>V6&XR$-LI2VPTD(;;0-*4H2+ ) X
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MVI,Y7/%U<44[-ND518%T.FN1[=][DMV?G37S5;ZI\YGG\QA2G4V^+ZR/U:Y
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M[D^E-?-4ZG\3)YE'L;?%]8_5GD[_ /'FY/I37S5.I_$QYE'L;?%]8_5GD_\
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MV51EW$L;A7A([:3I)9FQ VL2/#4+H4GL Y5N-U94<W;J6G53HEUJW;D]PP&
M<E@G<M"R.W7#F!#QK&.C*;'EUXW19R2D)-Y#BC>WIKK;NQ6T.#-JW5T:W[F<
MYUBP,=J,-J=4(D9Z)N)<H!<*9!CZ$,.Q=.M:'%#25)5P3V'E7",TJ<!K*ZOA
M,'C.@&Z,_@<WB=QX21A-PO[7>VUC]QR]QN9QL:_#/@L1O#1X$9:D$E.HZ!P
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M0_HG@/\ TU^\SFM>)GW4_P!OI^@6J$K^W[;^T4-2> L*"3Q_;;SO0=#Z'?\
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MC=&?);<BN@&8=-X2"V@$6Y*!NL?A'C0'G_W9]N!A3'VJW#I7'\J5"<=6@/\
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MX_C5^T]*TG\55NIX>H^HT]5>F)(6O>>$U=MLA&MP_P#'K[1_.MP]/UL]+_\
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M2K!XKVCM9R7#GN8#'+G8]*&H$I41@O1VV^"$M+*+H2G\$)/#LJU!G$WMQX5
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M7=1'.A38!TWZ>VM]D,*!VCZNB?-T(3^K;IU_RAA?_9L3YN@'ZMNG7_*.%_\
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M"@% * 4 H!0"@% * @4!- * 4 O0"@% * 4 H!0"@% * 4 H!0"@% 1SH":
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MS@^K&%W#N>+D)F,A8S-X6#D'YYDEAKZT6_"\PDKNL+C'2A1!.JU^5 ?1] *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * H<404@&US:A3YFR?M.;MQ>0W/D5
M[6@2MF;6W&K:\GP<CIS3[GBH:2\Q%4BRQ=8.E)O:_H-O0K-5ZCCUGO.Q9[JY
MTZVMG8>VMQ;FA8W.SM'@07U$+27?4#I *6BKL\12;]E<5%LVVD>V0ZH[$Q6[
M(FP\EN&*QO"<4IBXDE2GE+<%T))2"A*E#U4J4">RF5O$N9%,7JOT]E[N7L1G
M<T%S=K1+;F*2OXSQ0+EL+MH4X.UM*M0]%'!T"DJG*]C=<MZ;CC8!R<C"M+RV
M\,GMN0F0Z[&=,&#8MF*BY\1^Q-P>%=;EJE>"@3.D8[K7TLR^8@;>Q>[X$G-9
M-3B($-"R%.K966UMW4  O4D@(40H]@KDX21,R+N3U:Z=P]V-[$D[F@M[M=4&
MV\8I??\ $4.#2EVT)</8A2M1]%,CI4N9%AU7ZJ1^F&$@2C =S.X,Y.:Q&WL'
M'4&G9<U\V2"M7!"$\UJ[*MN&9F922-<R_6#>/3[:D[.]4MJ-Q,GYB-"V] P<
MU,[ZUFSBI+<9L+2E3:TD=]2QIMQ%ZL89I43*V9C ;LZQ^<4YO79,#&8-<=^2
M9D'*HE.1%,M*<2U(;4A.LK(T:F;@'CRJ46X*O=-1Z)^T@GJ7C-PS=UXM&V9&
M#@ISB4MO&0V_AE>)^<I)2""@M*2H>FMSM.)F,TS)=".N&7ZPO;I9R>!3@',
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M;D]M5LE"]H44 H!0"@% * 4 H!0"@*5IU"U[4!YADV OP% 26B04J42/_"U
M TKM4;>BYM:@'A*MZQN. /N&@(\%0M95K<J@*@VH?A<^?,7^]5!!:/"RN5
MT;FZN"N8XU 1X*@20NU^=5 D-*!)U=XBQ-0$>"H<E$>BW"J &"!;43QU<>/&
M@'@DBQ43?G>Y%ONT!/A*_')'P4!'@DWUJ*AZ#RH"0TH<2JY[#VT +9)XG[E
M26R>!5<'F.R@(#2AZJK?^'.@(\$\!JX#L-Z >"J]]9N>?.@,-N?9FW-Z8A6"
MW3 ;R6)6ZS(,=PK19Z,L.-N)6VI*DJ2H7!2:)T&TS0:4+66> L*@(#'$F_.E
M / 5>^LDVM<WY502EHI%DJ-J >&H<E>_[M "TKA99%O[= /#6.2S]WC0&(VK
ML_;NRL>YBML0&\=CWI#TUYELK67)4E6MUU:G"I14H\[FJW4B5#.5"B@% * 4
E H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>bc_partcst-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_partcst-4clr.jpg
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M_\0 U  !   ' 0$               $" P0%!@<("0$! 0 # 0$!
M      $" P0%!@<0  $# P," P0#" D,#0D'!0$" P0 $04A$@8Q!T$3"%%A
M(A1Q,A6!D4(CTQ87&+'14M*4=94W5Z'!DC-38Y,DM#555F)R@K)#<Z.S5'0E
M-@GPX?'"@\1EM2:B-$1DA*1&)T6%*#@1 0 " 0($ @8'" (# 0     ! A$2
M R$Q401!$V&1,E(4!7&!H;$B,P;PP=%R(S05%D*"8I(DLO_:  P# 0 "$0,1
M #\ ]_4"@\4^J'N7W7Q/>WC_  +@O)W<%#R<**AIMK:ALRIDA30<=44J) L.
ME=_;[5=$VGP<V[-LXB6O\OYYZJO3ADL1D^>YZ)ROCV2=6CRM'V'5-64MK>I#
M;K2RGXD$?#]-B*NW3:W(GP86MN4F'LO&<ZXQ(XGB^9S,E'QF"R\5F;'D3WFV
M$@/H"]A4X4@J%[&N":SG$.S*&![E]O.42Q X[RG%Y.<;@18LMEQXVZV0%;C]
MP4G;MXIJAG,EF\-AV$R<QD(V.C*6&TO3'D1VRM71(4X4@D^RIC*\F/<YAQ-&
M<1Q8YR GD;C1D(Q*I+7S99 W[_*W;K;?BZ=-:NF<&8<('J?_ /\ 8%7:I<?$
M_F3MLGE/SH!\P1?/)*RKRK;AY=K]:W^1.C4T^;&K#:?4$SS/D7;!$CM5RV%@
MYCDMAY66,]N$Q(A_$E3;4NY0"56/76W6L-K$3Q9WS,-Y[61N18WM_P <B<PR
MS><Y.F&@9#*QU^<W(<))"@X-%V20-WC:]8WY\&58X+A[NAVXCY8X%_EN(;S(
M5M5"7.82Z%7MM(*]%7\.M31/0B8<E]3^([I97#\:_1AS&+Q0-2W_ +3,G((Q
M9D[TI+!2ZO1:6R%%2!J;ULV<<<L-R,P['C<HQQWC.*<Y?F8C<I$6*Q-RLAYM
MB/(F!I(6M"W"D'S% J3[:U<Y9\H0S?</@?&I3$'D')<9BYLH!4>/+ELLN+2K
M4*"5*!VGP/2K%9GP29B&=3+CN-(>:<#C+B0XVXDA2%((N%!0T*2/&]8X9-3F
M=V^UV.E_(3>9X5B9>Q97/CA0/L/QZ5EY=^B3:(;7&G0YL=J7"?1)B/I#C,AE
M27&EH/125I)!'O!K&>$JQJ^9<21 EY16>QWV9 5Y<Z8);)987^Y<6%V2H^ .
MM73.4S"7 \OXMRZ(N9Q?,0\Q$0H(<=@OHD)2HZ@*V$[2;>-2:S!G+A/<#U-K
MXEWLXWVWQL7%9#C.5\A&4SAEW7%6\ZIM8)02VCRPFZ@NM\;,S7+7.[$3AZ&Q
MN6Q67BIEXB<QD(94I DQ'4/M%2>HWMDBX\16G#8Q'/.68G@G$\KS'.*(QF%C
M.2GDIL%+*1\#:;_A+59"?>:D1JM$%K:8R\7\2S'J<]3V0R7(./<L_,;AL-[R
M&?EBMEE+A&\,(#:?,><2D@N+6JU^G@*]+<C:V9CQESQ-KSPY.V]F\?W^X-G,
M]Q_N_E&^3\)BXQ61Q7)6R%N_,-K&]@E82X26]RK+2;6T-<>YHF(PVTS'-POB
MO*>_WJBY;R)_B7-CP?C6%*%,PHZUM;&W5K#";-#>XHA!*UJT_J"NJ?+VXCAG
M+1FVY/#@[9P[AWJ:B=ON<\2Y-RN-(Y6HQT\%Y5Y@6-BCN?*U!'F#0;1YB+B^
MFE<TVI-HG#=%;17$R\]=WLOZI^RC6'7R[N.98SJWT0AC'"LI,8(4KS/-:1^[
M%K5T[,;=L\'/N^97&)=M[2\!]4K'*N/\EYIW B9;@[B/FI^-2XZMU]A]@EM(
M264@$%0).[PKGO:F,1#HK6WC+U&$FP&FA\?97+P;G@OFG/._'+/4?R#M9P/F
MCF&!E.M8N.Z0W#::BQ_-()0A2KFQ\*]&E-N-K,PX]<S>8RFG=W?47Z>N=X?#
M=U<DSRGCV5*'5H&QT.QUN!IQ3#X0A:'&R;[5Z>ZKIVKU_#PE9W)I.)>Z/GX4
M>&N=)DH:@H0'UR7E!MM+1&[<I2K "QZFO/PZ<L'ANYG;SD60^R<%RG%9')W*
M1$C3&77E$=0E*5$G[E9:9,PV*3-AP8SLR:^W&B,)*WI#RPVVA(ZE2E$ #Z:Q
M5KV$[E=ON23E8OC_ "C%Y+)))'RD68RZ\2.MD)42?N5=,PF8EFG\YAHV09Q,
MG(Q6<K)%XT%QYM$AT"^J&U*"E=#T%,&6&C]R.W\K.'C4;D^+>SX5L^SD3&5/
ME?[D)"KE7^Q&M-,F8;)YS>MS:VIOI8"L5:BONUVN;R)Q*^989.1"@@QS/CA6
MXZ6^O:LO+GHFJ&U_-1RGS/,'E;0X';C9LM>^[I:VMZBL1)YMPZ'B'>02>08Y
MO!LK+3N2,MGY9+HU*"X%[=W^QO>KB4S"O@N4<<Y1 ^U..96)EL=?:94)Y$AL
M*&MB6R;'W&I,3"QQ6O(N=\+XB&SRC/P,/YPNTF=);84L7M=*5J!(OX@58K-D
MFT0O\3G\'GX:,E@LC&R>/6=J94-U$AHD>&YLD7]U.2L9R#N'P/BLA,/DO)<;
MB9:[;8\R6RP[970E"U @'VD58K,IF&9@97&96(UD,9+9FP'AN9E1G$O,K'M2
MM!(/WZQG,+'%A,]W&X#Q>4B#R3DN-Q4YRVV+,ELLO?%T)0I04 ;]2*RTRF89
MR!D\=E(S4W&2FIL)].]B3'<2\TM/M2M!((^@UCC KO/-,)4X\L-MI25K<40E
M*4I%R23H !16GN]WNUC,T8YSFF%3-4=H9.0CWO[/KVK+1/1C-H9O-9_%XG#/
MYJ5,C-06V2ZU(?>0TPX2DE #BB$_'X:UC$3,X69QQ<*]/OJ7_2NOD#'+V<3Q
MI_&2&&L8@2]AE(?WV 2^H%2AM'U?;6_<VIJU[>[J>C-X(TKGGTMKSQWSQ?J1
MY3RN#QOM%/:X]Q$0OF,CG5N)94J6IQ0\OS %.Z)L;-I^FNG:G;B/Q-=LYX/-
M;?=;O_V![I1.,<]Y"_R*,'8WVA E/F9%DPIBP Y'<6 I"A?0^T6(KJ\NM]O,
M-'F36<2]*^JCO9D>T'$<?&XF4?G;R)Q36/D.(#GRT=M(+CH0="LE24H!TZ^R
MN3M]JMIX\H;=W=TX]+@W,<7ZK.T'%,;W9RG<-_)-R'(ZI^&6XM],;YE.Y"'D
M.)V+23\*]OU3TKHKY=[36(:;ZJQJR[_G?4/&Q_IVB]YV(:!E<BPW'AXTF[(R
MKBE-*2HWOY:%(4NW7:+5HC9S?2VVW?P9>?VL1ZK<_P!MG^^H[B26&$M.Y-G
M,N*;6J$TH[UH:2GR@+ J2@]4UOM.WG3AKMJQJR])>F'N[.[P=OQE<YY?YS8F
M08&66T-B'CL"VGP@:)\Q)U'M!M7/O[=:VX-^W?5#MCS[+"%./+#;:05+6HV2
ME*1<DDZ  5H;&#F<ZX5C\.>03>18UG!A9:^TERV?EBX.J YNVE7^Q!O5TRF8
M5H?,.*Y#"*Y)"S4&1QY"2IS*MR&E14@6ON="MHZ^)IB3*GQ[FO$.7,NR.+YR
M#F66" ^J!(;D>63TWALDIO;QJS68YD3$J^=Y3QKBT(9#DF6B8B"20E^<^B.A
M1&I"2X1<^X5(B9,Q#&P>Y/;S),LOP.68A]J00&%(GQB5E1L !OO<^RK,29;,
M5!:3MZCJ*PX>(\:>KSN=W*XCW&XKQGA'(W\%$R<%!6AC:$+DORE,A;A*2; 6
MKN[;;I-9F8<O<;DQ,1$M9Y[E_5WV"B1.7<DY?$Y!@W)"8SR1:5'#JKE#3J'6
MVUI"PD@*1]^LZ1L[D8\65[6I&7H#,9+N%WG[(8#DG:/*M<2Y3F%1ICKLA2@E
M#*-Z)# 6E"S;>+I-M0*YHB*7F+<6S5-JQ,/./=3]:CLY@&N0\P[JQBS)?1%A
M08;RURY#A!*BVE;"1M0!=9)TTKIVHV[SR:+^96.;TGZ7<MS_ #_:;'Y[N'+?
MGY3)2I$C'2)0 ?5CB0&BNP'4A13?PKDWJUU<'1M3.GBX5ZE_4%SQ/-LCQ'M/
ME'<?B.&1@_RK)0DI),EQ:6RE3B@=J&RI*+#JLFNK8V(M&9:-W=F+8AW3T]<\
MRV>[$PN;<ZR*ITN*B<_D,@X$I6J/$6I1)L +A*;5R[VW$6TNBE\UR\]<6SOJ
M(]4F<Y#F^&\R/">)XAU+4*&RMQE%W+J9;)9!4M92-SBU:"]A75>-O;B(F,RY
MMN]MR9F.3?/2UWIYUF>89[LYW2DJG<@PP>7#R#Q!D^9$<\N0PXI.C@'UT+ZV
MT/A6O?VZ8BU6S:W,SB5KS3AWK&[A<ES\K$<A;XAQ:)+>9P,!N5\FY(C-FR%
ML)6H[Q;XG3XTV[;58XP6K>9]# >ECOEW*F]S'>U'<'(/YA#R):&GIUERXDR
MDK6DN@76A24D?%XZUL[C;I%<PU[.[,SB7N#0 7_\U<#L>8O5-ZA<QVTDX_@G
M $!SGF8;2ZN8I"7S$8=7Y;:6FC<*>=5HG=HE.NMQ;IV=F+1-I:-W<M'"&FL=
MF?65'Q2>5,=SRKDH;^9'''Y#CB-WUO)4I2"R5>%OJ>^L_,V^6&%:;G.9>IN
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M3'*6S;W-7-S?_P 0.P9[>?\ '9.W]@Q6SM>4M?<>#U_PT?\ TC@#_P##8?\
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M!<I58]:SW*4M;,7A:S,<,.PY57/N=>G;.GD'%_L3FV6Q4Q XQ#!6M"BI0:0
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M9/-9-K*2IFY<B"J!+6TQ%CJ)"HZ&D(04I01U^BL[SB>!7BI<J[==OW?4%P.
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MK#S2DLI?()6$ZZVT3I2UHGQ2M<*V([7\@PDV-/A=O([DF#'DP,>)?*I<EN+
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M4_*>>\/X6PS(Y3F&,8U)44L!TJ4M>S512A 4HA/X2K6'C4B)GDDSAJW(.]G
ML!R;CG'9F12[^<T=V9"R$:[T5#"0/*4I384%!TDI1MOTUK+1,FJ%YW0YGFN%
MXS#+X_ CY'.9[,Q,%"9F.J9CH<F;OQCBD JLD(Z"K2L3S)G"PX?W/=E(Y9#Y
M]%B<<R7#)#368EM2@_C7&I:/-9<:<4 H$CX5-J^)*O>;5)K'@F6PX_N5P#*8
M&;RB!R"(Y@<:2C(3%+\L1UC\%Q*PE25&_P *2FZO"]8Z)75""NYO 4\91R]>
M?C(XXZY\NU.65)"W[V\I+:DA:E_[$)OXTT3E=4-=Y%W+!R/;U7$)L/)8'EN5
M7!ERT?C06$,J60@@C8L*%E!0N.EKUG%.$IJA=XCNE@HO'F,OS;.87'O2I,]F
M*N!*4_%=1 =*5!"U@%3J$V\Q 'UM!4T3X&J&?'<+A!XLGFHST3\U5@;,IY@\
MHJOMV ?6WWTV6W7TM4TSR,PI_I+X%^;'YY?G!$_-KS/(^?W_  ^?>WE;+;_-
MO_P>W=[JN)3,-LK%D4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4$CB2I!2/&K"3QAKK'#,!'Y,YRMM@_;;R2E3I42@$C:5!/0$CQKSMOY
M?M4W9W<?BEWW[_=MM1LS/X8;(!:O0<*5?A8V-Z+#SWF\#R'/]R,1F>-\%G<1
MY;"RK2\YRU,EE&.F89E?XQ+P94/FBZC1*%(W)/X6E;>&.;7CBYY,Q',>+YSB
MF+QD-$'F#O)>79K%1'OEGUG'R2V$/;)#C;1"DG]V%CPK;$Q.?J83')MO!>.8
MWD<KM:]QW&/Y'!\*RO(H_)7<FW'2J+E'F@LK2A"EME/G+/E%HD)%M;UA,XSZ
M5B.2_C]O.5,3V"SABW%9[IR.1I0E3:4(PZV@!)2 ?JE7AUK&M^?T,M/WJ,WM
M[S%_@_,,8G#*5D,CW%<SL*.2WN<Q?SS#J7QK:VU*C8ZU(MQ^I=+.\?Q7(^)\
MNY/A9W _MYKDG(W<_!Y2%QS#1$?V[#(6X"XAV+8I;0D7(^K;QLSF(XL8B8EJ
MO'>-=U,GSC@^3Y1BIS3_ !O*SUYE0;@Q<)&9D-.(;..2Q^,<0L%/F+5X_6%]
M:RU1%9@Q.87/%>V'(,9VQ[;8MWCJ8O(\1S-C-9M" TEYN,)TE;DA:P?BNVI%
M];D6'A6$VXLHAO\ VLA<AX_F^:\>S&$?BQ).=GYW&YP%M4*5&R"TJ;0C:=P<
M2 =R2-*7MG"5C#1.XG;?EV=<[M(AX8S(W)<CQ=W&-E393+CXX-"5=*CT1M-P
MKK5BW"/K)KEF.<]M\]E^5<\5Q_%M,8_-\+:Q&.D)\MEEV>T^LH9-K6(18)41
MH+6J18FO-!G 9WE?(^S>;RO%'X4/B[>48S$7))968CP@ML,NV!4"'%I/EJ3K
MXZ4U<UPU?N1QCNIRC*9K$##37(J,_!R.$:Q[<!C"KQD=]I?S$AT_CW)=DJW)
MT(TL;:5LK:(AA:N6SP.V>?F1>]T=4)O&9?F,Z2,%E%[0I]A<0--DK3=01>Z?
M=<UA%^,,IKS8K@W!,E-R>-<S6,Y)!S?'L'+P\=_+J@(P[)E1A'4TR8R0M]HD
M!2#T%K]:RFR151QO%>;Y'B_9[$2^,2<=/X+R6(,WYZFE(^6B1G4+EM+2H[FE
M%0 /6L9GC*Q'"#$=K^11>W$3'+X^EKD*>>)STD(#0D?)IR1<^9*_$AHZ:WVZ
M5EKS/U,9KP^MC^8<6[L<ES[^/FXB:I,+ET7+XY,!$*/@1AV7PI$DNBTAV:1?
MS+V4/HI$PDQ+L/:W"9;!2.<KRT941.4Y5D,ECRH@^;#?2T$.BQZ*VGK6JTY;
M(X.72NWG-7>"<YQ;>&7]H93N1(SV.82I +V+7.CNID"YL 4H4;'6LXMQ^I,2
MM>=<3[AC$]U^!XCB3^7;YO..8P^:8?93"##@8\UM[>0I+R%-D)18[^HM668X
M3T2<\60YWVVYEF9G/I..Q"9K4J3Q+(P(#SB&VLJU@T7EQ25: WZ!8VE0%*VB
M,,;5F?L;7P.!G\EW7S7/YG$7>*X+)8&-!CB46$S'Y#,A2E%]IHJV*"3M%U'X
M1>L;8TQ#.(XY:7WHXYW1Y1-YOQR#B9LO"YB%%1QH8EN"W"EEM"?F/M60^/-\
MQ"Q^)3[/JVK*EHB$M$RV!/;_ "\GD/<W)S<(A]>;XK Q.'DNI;6M]]N ZV\P
MDJNH#S"D*W&UZQB_(T\98;"<7Y=Q"=A<C.X2OE+.2X5B>,+B;V"<?/A-;78\
MCSC9,=TF[C@N--0:N8GQ\3#<>"<+Y'']/4?@.00</R=S#S\:I"U B.^^IX(&
M]%QLLI.J?P=:PFT:LLL<&%PO&9O,>W4GMKR#@?YIB#@!B7<](5&\I,V.$J:5
M%+7Q.-!U D%9*1?KKK5U<<L8CAAJ'"L1D>X7;?)]R^88:?F,UR";CF8Z,&^V
MC(QXO&B8[4Z&ITV6M;Z7']G16ZLYG3/!(S,<6<.+[L%CMYS7DF$<S61XSF\F
M]+QT9,9G*KQ.285'C/OM(/E?,)N%/H;5_5O4M,9X+7..+,P,3S'$]UEKXEA9
M^*X]DLH]D>8HR2H\C"2&W&0@3(+MRZW*<4 %MIT]NE)Q,,F5[JM\[5R'!KX_
M!F.\95&DQ\A)P;,-S,IF.E/DM*<E@^5%4!^,6B_^RTJ4Q"6RT7B'#N=\*Q/9
M[)RN,/SGN-)S>/Y!C(BV%R8WVH\HQW-2E*T)ZJV_5JS;,RE:XB&^=_./SN0\
M;X\U"PLCD47'<BQ^1RN*@D"0[!8#@=V74@W^(=%"L:3A;M Q_$^X&)PW.\AV
M[XN[@,!DW,<_A>+Y?R)DLR6G;Y":TQ(6XA#JFTI\IMQ9W*2%::"L\QXL>/@M
M\=P'D$Y?<G+\IXWR#)X7D*^.2,:'GH;'(EJQ3;B5R4)9LVEUE6W:VK50\:9C
M@8YKC+\5[K9B#P[EN=C9%]WC>4RSA9QZ83'(E8N<PAJ)*7'4%1U2T$*#B4G=
M8W!O<TU1&8-,SC+)X;M]EH[W"LCA\1EVXWYWS.0YX9U49$QOYF-Y9D*;CV0A
M*U"_EIN=US4FT<5BK'\%[8<FARNV/V]QY/D8#.<IGY,/^4XF,B>I9B.V-P2L
MV*2-12;\\)%?WJ&<[6\T#+N4QV/DLL8?N%D^2-XS'*CHF/XR2PAIJ3$2Z"UY
MC:KJ0A0N=;6-6+1]BS7[U?\ 1XQ]F?G?]D\U^V?MW[7V_P#9WVK\SY'D_-_)
M6\JUM+WW[OBO35]":.+T[6AM*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!:]!"PZU)C(B!:J)5)"M#4F%B4/*1[/ZM5&#Y)PGB?,(K<+
ME&(C96.RK>R)+84IM70E"]%)O;6QUJQ.$F,K_%8+#X* SB\+!9Q^-CIV,Q8R
M TTD>Y*;"Y\3U-,JO/);Z6J!Y+?L]WC0 RV!:VGLH(AI \/OT M(-].OC<T$
M/);)O;PM]R@CY+>NG7WF@>4CI;W^- +39TMI[*!Y+?LH(>0U8#;H-11<HEIL
MFY&M3"'E(TTZ=*H>4V;Z==#J:F #38\/ZIJ@6FSU3>@@&&AX>SQ/A0/);%S;
M4^\T$?*;-KB]NE!#R6_ 6OUH 9;'0?U301#2 +6TJ"53+9L"-+U8)3>4@CII
M]VI@4WH<:2P]%D-AR.^A33S:M4J0L%*DGW$&JBECL5C<1 C8O%Q6X>.AMI8B
MQF$AMMMM L$I2- !2>*KCR&[WMK^W4P(^4CV?<^FJ'DM^S^J: 6FSU30/*;M
M:VGTF@%ILZE.IH :0/#W]30/*;]G]4U,!Y+=R;:GKJ:8 -(!O;PMU/050+39
MMITH'DMWO;7VW-!/0*!0*!0*!0*!0*!0*!06F1D1X45Z=+<#42*VMZ0\K0(:
M;25+4?< *#RU@.Z7J5[MX:?W*[3X_C^-X%%=?:P6#RZ7G\IF$0UE*U%Q!2AH
MK*2E ^'7VC6@R'=3O]W!XSB.V^,B8B!P7E_/B\G(Y#ECA5B\,N+;<VXMNP*W
M+W;W>!%_<&>X'RSOWR''<KXMF6L(>1PXR)'$.XN.2J1QJ>7%"Z5I2I9#B+ZI
M'O-M 2'/./\ -?5GR#NIRCM.SRCB3>7XK%B3IDU>-D&.\W,""$M@'==._6X%
M!Z^;;=2RD.D*>VI\Q2=$E5A<@> OX4'F;D_.N_7(._G)^U';+,X'$8W XF)E
MTKS,)R05_,AL*3O:)-]SE_JZ"@S7:[OUD''N=<5[V)@<?Y=VX2V_G<I#+@QL
MK'NBZ)+84"H$W2-NI.X "^E!MO;CU"=K^ZL^7B>-9!^/EH3'SIA96.YCWG80
M_P#Q+0= "VO>-1X@4&-X_P"J+LORCF3'",5F73/EOJB8S(NQG6L9-DMD)4U&
MDJ&U:KD >!N+7H.49'U%\[B\8[K9>=F\;@W.&\M9P&(R#V->FMIAN*4"AUIE
M14I9VCX_"BNJ\R]3_:KM_P @RW$N3RY_YR81F*_+AQ(+L@OHEMATK8V7!2A)
MW.%6T)]YHC*Y[U"=JN.\(PW<*3F%2\%R,[>/LPF7)$Z:Z#M6VU' "RI!T7>P
M2>IZ4$K'J'[3R.WR^YC&94OCB9(QQ8##GVC]I*^K#$6WF>>K\%-M>M[:T5E.
MW7>+B'<J=DL9AV,IB\]AMBLGALYCY&-FLMO:(64.IL0KW*)]M$6O=/OSV[[2
M2X&-Y3(F/YK(MK?B8K%Q')LI4=%PMTI0+)0+:DF@Q60]2_9_%\,X]W">R[KG
M$>22_L^%/9CN+\F2D$K3)0!N;V6^+2@O.!^H;M;W$;Y O!Y1Z(KB[2I>:9RL
M=R"ZU"2G=\SL= /ED:WZ^T"]!R'EOK PV9S_  /$=II^\YSDL?%9A&4Q[S1?
MQ;J@@R(BEA*2C=<;@;@]10=/]3?<;DW:;M+/YEQ L)S<>;"BM+F-_,->7)?#
M:[HW)UL?;06_*O4_VMX%F)7%^529PY1CX,.?(A0X3LDO)F-!T^1Y=P=B3N7N
ML$CQH,SE/4%VFQ7;S'=SY.=#G%LTL,XGR&G')DJ5=23';CI&\N)*5!0(L/$T
M&+:]4/:"1V_G]R6<C).!Q,IG&YB)\JM.1A29#@;2'XZK*2+_ (6HZVN:*MT^
MJOLROB#_ #=.0F'#(R*L-!:^2=^;GRTI2NT-FVYU&U05OZ#QL:#-L^H?M([V
M[E=TOM[R^)P7/EII<:<$MB9>PC.1]I<2Z2=$V]][:T1:\/\ 4GVEYGCL]DHV
M4?Q*.,1Q.SD;-1G8,B/$-K/%"@2I*K@#;<W(%M:"MP7U"<![@9^/QO%L9C&9
M2?'5.P_VUBY,!G(0T#<7XSKB=BD6^(%1%Q066/\ 5!V9RG-D\#B9IU61>E'&
MQ\FJ,Z,4_D$FWRS<NVQ2[Z#\$^!H)<WZG.U7'L_.P4ES*S&,3,&-S6>@8N5,
MQ$"<5;?EWY+2" L'0A(-!V=I]IY"'&E;D.)"T&Q%TJ%P=?IH*E H% H% H%
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M6/*K7M]FQOWM _7M]1HZYK'>T_\ 9L?0?V-!+^O?ZC+$_;6/L.G_ &;&U_\
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MKVD-@ _$3K0>DZ!0*!0*!0*!0*!0*!0*!0*!00*4D@D:C2@AY:0"!H#U%S0
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M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#Y@?\ B"I![W8_S+[58.. 1[?-<_\
M+6@\F!"5)6!HDJ-R3<V'2@BM"0DWOYAL$7-OI-J"!2-MTI);1:X.E_"VE! !
M*K@).Y M>]!$-**2=MOBV)-^GC_Y&@AY8!&AW7M:][Z]: JR@2-5A1U&H(.@
M%! !*5(!W)7N/C>WOH)BCX0HK(NJRP .HH)@-RP7%$(/@=#;WT$#L4%(22E)
M(4!UN1T'NH)U,I-K+^+QOU%M;4$JFD);W;E?%\11XZ=:"58:*=[25):2 2A?
MX1.AU%!#<I7BI(41N TN.@M00<4X0!N*DIL$GK:WA002;D"^M]P-NEQ^W0%D
M;="=W0I(OK_6H)K(2"4_%I<W&I/2U!*=0+J(3NU('0VTM0+#XOQF@!!%M2!0
M1VI4$V.MOJD:6'OH)O)6FZ"E7T#4 GVD4$B5)*3M^%7L/6_C0 I05=*A>Q2"
M;:>-!!)3=(N E0/]2@BW91.WZO6W36VM!+J-="KH5$T#H-R04"]MQUU%!$WV
MZ@$JTMK?2@G0#;7:3T*5 C[EQ0-JD[OJ C374]/"@E2"=NWZZ1XGHG]N@CL4
MHE2P2D?"%=?N?300^'ZR2-W3VZ^SWT$BQK\0'OMK0?2S_P .,?\ ]+^3?QS_
M .[HH/9E H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M0[Y@!;VC<%>R@Z?PCF.,Y[Q3#\PPR'6\7FXR)D1,A(0Z&W+V"T@FQT]M!L-
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MUB(J/[:].>;&P#2Q2@J-_=0;3B?3=C8]CR'/EY_K\K 0 DD>!4KI<4'0^/\
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M^1!U>-EXZ47 KX6G58^0DGZH"%[D @^%!S+G/87*8=MV1%3,C(;2C;*6CST
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M*;^%@+:42Y^YVE0UH+&?V2YLVMR-!@JW+*-S3: IPBURI*0>H(H,&[VUYHU
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M9:4\F^T):;AM-HMI>P O:@UK-9;'%A+S/%9,V*L?BUR)JW=X'2Z4$"UZ#?\
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M%E[C]%/\VN8_CE__ )MNNSM^<_5]SW_E7L6_F>E:['LE H% H% H% H% H%
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M;=XN+@T&$Y#SO/1HR5S^)X\+=2&T%#+:E-;#;6PH,$SS>:&S($''I?!(0V&
M@V3:Q&GA07,+FN5D+CJ3Y,,BX6E+ 2 E1OH2+6-!FIV9YV"RO&92.89! =0
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M8 /2H@STYE4R0PPEY>Y4/$0?QJRL[DN.'0VHCI_HS=1([&0)+1W,/Y3+O,.
M6W-N3G5)58@'4'QH-:]6/;WE/.,EQ9_CL=I]$!N6B3YKJ6K%U2"FV[KTKS>[
MW*TGCT>%\UVKWM6:QRS^YYV_0+W,M_\ <8W\*;KA^(IZ7D^3N]/M/T"]S?\
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M+^% #Z0XKRR5G\,#0CP!)/A02KDC:2E9W]4 Z@#H-1U]]!*EU:M5.$AHDD*
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MI2E!W<CX7" DH<N+6%!TG)]Q>/8?*9K"S''A.P&(5R'([&MR1 3NN4&_Q+^
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MS'2>WG^:Y/\ QY_WHKZ'Y?[$_2]+M/9GZ6X5Z;M*!00/A]-%A@N4_P"89?\
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MM0*!0<\YIV-[3]Q,LG.<WXK#S660TF.B7(\P+#*"2E'P+2+"YH-=_5/].O\
M1]C?OO\ Y6@F_53]._\ 1]C/O._E*!^JGZ=_Z/L9]YW\I01_53]._P#1]C/O
M._E*!^JGZ=_Z/L9]YW\I00_53]._]'V,^\[^4H(_JI^G?^C[&?>=_*4#]5/T
M[_T?8S[SOY2@?JI^G?\ H^QGWG?RE _53]._]'V,^\[^4H(?JI^G?^C[&?>=
M_*4#]5/T[_T?8S[SOY2@?JI^G?\ H^QGWG?RE _52]._]'V,^\]^4H'ZJ?IW
M_H^QGWGORE!']5/T[_T?8S[SOY2@A^JGZ=_Z/L9]YW\I01_53]._]'V,^\[^
M4H(?JI^G?^C[&?>=_*4$?U4_3O\ T?8S[SOY2@?JI^G?^C[&?>=_*4#]5/T[
M_P!'V,^\[^4H'ZJ?IW_H^QGWG?RE _53]._]'V,^\[^4H'ZJ?IW_ */L7]YW
M\I01_54]/']'V,T]SOY2@A^JGZ=_Z/L9]YW\I0/U4_3O_1]C/O._E*!^JGZ=
M_P"C[%_>=_*4#]5/T[_T?8S[SOY2@?JI^G?^C[&?>=_*4#]5/T[_ -'V,^\[
M^4H'ZJGIX&H[?8R_T._E*!^JIZ>/Z/L9]YW\I0/U5/3Q_1]B]?<[^4H(?JI^
MG?\ H^QGWG?RE!O/!^W/">VT&1B^#82/@\=*=^8D1XN[:MVP3N.\DWL+4&U4
M"@4')>^?+4\)XQ&Y6_S)7#\9CI#IEN(@IGJGJ7'=2U%2E6B%%RRDJ-A<6)H/
M._:/GV*>[@\4.*[P1N4Y;DTE#>7P6,XE"@37DK94ZL39;2$J2E!'QJ2I6OMZ
MT'M]JP;2 +#P%!/0*!0*"1Q2A;;XT'GKN=ZGNR3?'^:<.<Y0E/(FX&2Q:H9B
M2[_.%AQKR]P:V_6-KWM[Z#3^QOJB['<2[0<*XYG>5)BYC&XIAB=%^4EN%MU(
M(4DJ0T4FW^Q-!T+]<;T[6_[X)TZ_XE-_(T#]<;T[:?\ U@G7_P#)3?R-!Q[D
M?K8RS.?R+7$IG#I?&&GBG&2<@YF&9CC-A8NH1&*4JZ]*#G';'U+<D[4\1;X?
MALAPN?$:D3)J),I_+I<*YKZY"DD(B@625[1[J#MF8]5'9_-8G#.Y3D\9O.IC
MI5E68L::J,W*4D%Q+2G&@5("K[2?"O+[_8M?&(</<UF\QIB987]9#LIX\J1;
MV_+2?R=>9/9[L\H<<;.Y[EO4A^LAV3_UJ;_@TC\G4^!WND>M?)W/<MZC]9#L
MG_K4W_!I'Y.GP6]TCUGD[GN6]1^LAV3_ -:F_P"#2/R=/@=[I'K/)W/<MZC]
M9#LG_K4W_!I'Y.GP6]TCUGD[GN6]1^LAV3_UJ;_@TC\G3X+>Z1ZSR=SW+>H_
M60[)_P"M2/X-(_)T^"WND>L\K<]RW_J?K(=D_P#6IO\ @TC\G3X+>Z1ZSR=S
MW+?^I^LAV3_UJ1_!I'Y.GP6]TCUGD[GN6_\ 4_60[)WO^=2?X-(_>4^#W>B>
M5N>Y;U-UX?ZL.P.(@/,S>7)2XMXJ2!$EJTL!U2T17M=GMVI68GJ]#MJS6LYB
M8X^+8OUQO3M>WYX)O_U*;^1KN=2'ZX_IVZ_G@G^!3?R-!']<;T[?ZX)T_P#R
M4W\A0/UQ?3L;?_6 /L_Q*;^1H,7G?5MZ?IV*DQ6.8)+RT@)!A3 #K?J60*T=
MQ75MSAJW:S:DQ'%SS]9#LG_K4C^#2/R=?/?!;W2/6\OR=SW+>H_60[)_ZU(_
M@TC\G3X+>Z1ZSRMSW+?^I^LAV3_UJ1_!I'Y.GP6]TCUGD[GN6]1^LAV3_P!:
MF_X-(_)T^"WND>L\G<]RW_JC^LAV3_UJ;_@TC\G3X+>Z1ZSR=SW+>I#]9#LG
M_K4W_!I'Y.GP6]TCUGD[GN6]2/ZR'9/_ %J;_@TC\G3X+>Z1ZSR=SW+>I#]9
M#LG_ *U-_P &D?DZ?!;W2/6>3N>Y;U'ZR'9/_6IO^#2/R=/@M[I'K/)W/<MZ
MC]9#LIX<J;O_ -6D?DZ?!;W2/6>3N>Y;U,WQ3U.]C<9E1+F<L;2UM4/ABRU:
MGZ&B:[>T[>]+YM#IV-C<K;-JS#?QZP/3X/\ ^6]=1_B,W\A7MO0/UP/3X1<<
MM_\ V,[\A02#UB^G?I^> /\ ^BF_D* /6-Z=C_\ S!/\"F_D:""O6-Z=['_Z
MQ2D)%R?DIO0?^QH.S8#-X[DN%@Y_#O?,XO),HE0W]JD;V71N2K:H BX]HH,C
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"'C4SQ"^MJF>(
MC604"@4"@5 H%4*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#6>
M?<?_ #FX/R/CR8[4E[)XV7%CLOV#9?>94ALDJ"@FRB#NMIUH/-_9?D'=+ 9+
MB?$L]CNW*845MG$S,MB\JPO-N-,M^6-C;:B5O*VC<!U-Z*]:-_4']:B)J"!4
M +DV%!#>GVT$W6@@0#UH-/[EPH8[><Q=^7:\W[$R9W[$[K_*.:WM0:GZ;(<-
M[L+V]6[&:6O[&C"ZFTD]#[J$<G4_LW'?]$9_P:/VJ!]FX[_HC/\ @T?M4 8W
M'_\ 1&/\&C]J@''8ZX/RC-_;Y:/VJ#B_>T8R*_AFWA&C..!_:DAM!(!3TO:]
M>=WUM,P^Y_2M=4;DS&<8<J\W$#0/Q5_2IJO,MN:N<X?=:/1]AYV)_ND3^S:K
M',>\NF.GV'G8G^Z1/[-JF8]Y-,=/L/.Q/]TB?V;5,Q[RZ?1]AYV)_ND3^S:I
MF/>-,=/L/.Q/]UB?V;5,Q[QICI]AYV)_NL3^S:IF/>-,=/L/.Q7]TB?V;5.'
MO&F.GV'G8G^Z1/[-JF8]XTQT^Q OXG=_;(G]FU6RM[^]!HCI]CNO95C%2^-S
M%M-QI"4S%I*D!MP A";BXOTKU>TFTUG,YXOS?]31CN*_RND_9N._Z(S_ (-'
M[5=KY,^S<=_T1G_!H_:H'V;C_P#HC/\ @T?M4 X['#_\(S_@T?M4&K\^@PV^
M(Y@HBLBS-PKRD:74/=6K>X;<O3^51$]U2)Y9><1&8M_:&_[%/[5?/\.LOV#3
M$(_+,?W%O^Q3^U3AUDQ"'RS']P;_ +%/[5.'63$'RS']P;_L4_M4X=9-,'RS
M']P;_L4_M4X=9,0C\LQ_<&_[%/[5.'63$'RS']P;_L4_M4X=9,0A\LQ_<6_[
M%/[5.'63$'RS']Q;_L4_M4X=9,0?+,?W!O\ L4_M4C'63$-V[3Q6%<P;;<9:
M6 RZ=6T'2P]U=W:S>=S\4OF?U#6D=KF(Q.88_GO82=@N*<IY9"[J<W$S'0,A
ME8L8Y)L1TN,M+?0WM#-]@(";7Z5[$OS%8]L>QN2YGP'BO,<CW3YPWD<OCXF1
MEQVLFWY'FNI#BDI262=IZ6OTJ+AZ;9QL$-)2N*TI20!N4VC<;:7-AU-!/]FX
M[_HC/^#1^U4#[-Q__1&/\&C]JJ+A"$MH"$)"4IT"4BP ]PH)J!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<&]7G(^1<4[-S,OQ;*RL+EDY
M"$TF= =+#X0M9"DA0UL?&NCMZQ:^):]RVF,IO23R+D7*NSD#,<FRLK,Y54^8
MVY.GNEY\MH6 E)4=2!X4[BD5OB$VK3:N7=ZYVTH)/,;)*=PW 7*?&WMM08'E
MO-N*\'P[F?Y7E6<7BFK OO$W4K]RA"05+5[D@FK$9Y),X4,_SSBO%L'%Y%G,
MB&,7/+0@+2AQQV0N0G>VAEIM*EK4H:[0FF!CAW:[?'B@YH,VV>/%_P"2#WEN
M^>9U[?+>1M\WSK_\'LOX]*8,LMQ+F_&.<8US+<9GB9$8=5&DI*%LO,2&[;FW
M6G4I6A0OT4FBMBW"U_#K>H,5R+D&-XQA96>RRW$8Z&E*WU,M./NV6L(&UMM*
ME'50Z"@R##J76DNI)*%I"P2"#90N+CPTH*A<0$[B;)]IZ:T$=P'7]B@@5I'4
MV'MH,'RKF'&^&8LYCDN0;Q\ K2PTM84M;KR_JMM-H!6XLVT2E)-(XC6AWJ[;
M#!JY O-%N$B2F 8[D>0B:9BT[DLIC%L.J64B]DHZ5EIE,K?(]]^VF*Q4/.S<
ME(3B)R''&YB8$Q3;887Y;@=LU=M25:%*[&D5F4F<-DXCS? \YAOY'CSDA<5A
MSR7528S\0E12%#:E]""00>HJ3&%B5_QWD&.Y/B8^;Q*G5X^25AM3[3C#GXM:
MFU70X$J&J?$:U%9;>G4WT'6@;TVOX$7O;PH([DVOX>V@%0%KGKTH(;T:Z].O
MNH(E21U\:!N'O^\:"!6D&Q.O2WC0-Z;E-]1U%C06N2RN-PT)W)9:6U!Q[.T/
M29"PTTCS%!";J58"ZE!(]YH+NXH(T"@4"@4"@4"@T'O%RGBG&NW/('^89Y'&
ML5/B/XU&54%K6A^8TIM!:;:!6M8)W;4"]A?WT'F'LEV(C/\ )N"]R^ 2N*2N
M$PT1IF4S.-:DKR/VG$AF'*BL"0!9I]=GE>:D.-J)M[P]LM_43_7H)CTH.:]W
MN=<KX;&P,;A&$B<BY/G\B,;$Q4V480*?*4ZXZ%[5#:V$W7?PH.<#OKW<XURA
M6%[F< QF+P\:-'GY*9B\P);[4"5)3#^:;94TGS$-.J2EU-PK4$7%!Z03?I;I
M034&K=S/YN.8?Q)DO\D<H-2],_\ ,'V]_B:/^P:$<G5J!0*"!H/&GK><;;R'
M#O,( +,_77KO:KRN]B9M'T/T/]*WK7:W-7#C'W2\J+4WN*@X"%=-37FXE]Y:
M],YS"7>W^['WS3$L==.L&]O^Z#[YIB3S*=8-[?\ =!]\TQ)KIU@WM_W0??-,
M2>93K!O;_N@^^:8D\RG6#>W^['WS3$GF4ZP;V_W8^^:8DUTZP;V_W8^^:8D\
MRG6 +;L?Q@^^:8DUTZP]R^BLH/;C,;""/M=WI_Q+5>MV43B<OS;]53$[VWCW
M9_\ U+TI7HOBR@4$%=#1&L=P/^Y>:_XC_P!9-:-_\N7J_*_[K;^F'FM/U4_0
M*\%^PSS1HA0*!0*!0*!0*#>.TO\ WU:_ZL[^P*[.T_,?-?J3^S_[0Z=W7_FI
MYQ_$.5_R-RO:?F'BQO8#^9+@/\1P?^934'1Z!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*"1Q>P VO?2PJ#S)ZSN0X'(]E,CCX65AR,
MDSDH7F0F9#3DA)0X0H%M*BH%)ZZ:5U]M$ZX<^_,:)5?1KR# P>S&,Q<S*PH^
M3<R,P-PG9#2)"BMRR0&U*W$J\--:O=1,WEELS^"'I=*KGI:N1N34'%N\@PCV
M4Q#$+'Y^9W++3IX^_P 76J.^PR5;5*DOK/RR&"L_%YP5]%;*2QEA^=HS4/L1
MFG^\4C"N\Y;QV01C9*/+;L7FK!#9< !D[19PLBU_JZ5:3^+\,,;3BO%9Y+.8
M*-R3L1RB?D8RN(Q8<['+RA6AR%&RCV-:0TEUX$H0M6Q2$[CU!Z59S,SPXKF.
M#4&\GBD=TV.>N/M)[:.\YD-MY9>F/.0.*$=,CS#\&TO H2[]7=X^-7,S&,<6
M&J,Y]+JO:B1"S/<_NOR3 K$GBTV9B8D><P+QGY\&(42RTL?"O:I20M2=+UKM
MF(B);(F)<FY4[R)OC'=#G\?E><BYOBW,'(& ;:E+^2B,+DQF5H#!^!:%)>5=
M*Q8:6K9%O###'I7W<F9R#MVWW1XY@.2Y=<5CCV+S<>3,F+?E,37\B([KC+QL
MI <0+*2FP]E(XXG'BN.?%L,K*XO*]S^71>?\RG<99XR,.>(1(T\P$NQI+"7'
M) :M_C*G'KMKNE6T?#I4QPX08X\V,:>Y7&X]W@[CXW*969R;CF:S6/P&-+KC
MT&%&3Y7F+;BC1:FTK6X-U[6%A4SRC!IGJJ8_)8[#<EPD;MSS;(\KA9KCV6G\
ML#TY>20TAF%YD6:J]_EG5O\ XO;\/6VT4G/C"Q''FL^WR\]B8797EKG)LMD\
MIS-:H'(&LA*7(BOQU17'$ ,GX4%LH&Q2=>MZSQJB>')C'#'%NW=*7$P/>3M=
MRGE3R&.$1T92 W.DBT2)FY32?EUNJ/PME:$K0A:M ?$5KI[,Q#*T?BA<\_R'
M;/G#V,>Q_<"#@.7\?R"G\'R!EUAUIJ;Y%G&7/-LR^E32K+05WMXU(F866J9?
MG>7YSZ:^?93.-Q3.QLB9B#E<;N&/R:(4AI G1@O78[?VD;@;&ME8B+QAAG-9
MR]"8E17B8"]V[_%6E)^ZTG7WUHF>+;X/,/$)6<YRUV>PN7Y+EVXF<A\G7F7(
MLQQE^:(DA8;0ZZ#N(186L;VZ5NX1$M49G"QXYD.0PN-<;YNOE>7FY6+SQKB+
M;<F4I<5>&^>5%,=UJP2XHH&KJOCOK>K;&<)$SC/I6O(^3)8QO<W-'G>1C=Q.
M+<IEQN'\?;G* "''VDL,HA__ (A+VY:5)LK:/9645XQT7/-O3"N2S.2=W>51
MLEDIF=X8/,XUQMN2LX]N8YB?,(+ T=NYJE)TN-.M83$<&7'BU_C60@2WNVZN
M)\YR7(^0\V96QS?''(*DJ$61"4J5)4T-(;D5T_BM$D'X==:<LY2)Y)^/\SYY
MG4QN*-SI3_*^U&*S<KE:6MY3-RL3S(V(8>M_;"XW:3M.BZLUK''J9E1[7YCE
M<R?@\RSG&3$R&&G/\G:D<D1EI60>^34ZTZU"VI5&<9='QA-MJ?A.HUM]+&N5
MAQ>'FIF&[.Y)[FF?5-Y\[*@\B>,]:@_$;;<<2TVDW#93L"0XGX[7UUI,QF2,
MX@R/+N6XC!R^(LY25+XWC>X,SC<K)3L@84E.*;C)?9B/9)25*;2MQ13YIUL-
MMQ2(B9^I9SCZU],E\R:XEB<<>2*@8W(\]Q>-Q;N'S(R\Z'CY+2P_$<G)%E:Z
MH"]0#K3AGZDG./K6W<O#B%Q#O#PM_*Y&?Q[BDKC>4Q:)DMU]V.<@4+DA;I.]
M36A<"5DA!^(5C6>,,IC@]0<38PL; 06>.3SDL(E),2:9)G^:DJ))^84I97J3
MKN/LK5XLV=J*4"@4"@4"@4'$N_\ P/G',4\(R_ (6.R.9XEGD9I6/S#JF8CR
M4QW&P%$!1T*P:#4>RW%?45P#-S\?F^/<88X;R3D$[D69=A3'C(AG)64MJ*UM
M"2E!2D)O0>F46VBW2@B=!0<=]00A3./8;CR^-N\ESF;RS,?C[3,U6(5#G-MK
M<3*$U():4VE)M;Z_2QH-+[<=DY[LV2GN1Q5Z,D2863^VI/(G<[-R,B I19B2
MMZ$#Y5!5YOE !*E)257(HKTM;QHB-!JW<S^;CF'\29+_ "1R@U+TS_S!=O?X
MFC?L&A')U:@4"@4%E)Q.-FKWS(K4E7X)>;2[M_VN\&WW*3Q6)F,XF>*C^;O'
M_P#14/\ @[7[VIIAGYM^LH_F[Q__ $3#_@[7[VII@\R_64/S=X__ **A_P '
M:_>U=,'F7ZRXSZ@N:+[8X?C[F Q."@C/9/[,E\FSD4KQ6+3Y2G$K?1'2%DN%
M.Q&H%^M3$'F6ZRYRCOARR5BNW.3C\'Q"'^3H#DB&(2W$Y11R28)3!< LR PH
MS@I\_4'W[B#S+]9=M[9Y*/SJ'FN3OX;%M\5>R3T;B?E16_-?QT-:HYE.DCH^
MZA:FQM%D =;TQ!YENLM__-WC_P#HJ'_!VOWM-,'F7ZR?F[Q__14/^#M?O::8
M/,OUD_-WC_\ HJ'_  =K][4TP>9?K)^;G'_]%0_X.U^]JX@\R_65W$@0H"%-
MP8[49M1W*0RA+:2KVV2 +U6$S,\Y7%$*!005T/T426L=P/\ N5F?^)_]9-<^
M_P#ER]7Y7_=;?TP\UI^J/H%>$_89YHT0HI1$**C0*(4"@4&\=I?^^K7_ %9W
M]@5V=I^8^:_4G]G_ -H=.[L?S4\X_B'*_P"1N5[3\P\6-[ ?S)<!_B.#_P R
MFH.CT"@4"@4"@E6H)25$V \3THF<(#<?B"KI/A:@C<]+Z^VF50"B%;2;GK53
M*G)D-Q6'),AU#,=I)6X\\H(;2D:E2E&P  J*QK')L!*Q;N<C9F"]A6-WGY)N
M2RN(WLMNWNA6U-KB]S05,1GL3GXRI>#R47)QDJ\M;\)YM]L+ N4E2"1?6@N'
MY[$=UIE^2TT[(66H[:UI2MQP JVH"B"H@"Y \*"A'SN*E9"1B(V2BOYB( J5
MCVGFUR64FUBXV%%21J.H\:#)(*BGXNM!-0*#$9CDF"P*FDYG+PL87]&!-D-1
M_,(Z[?,4F_7PH&5Y#AL$TT_F\K$QC#QVM.S'VHZ%JTT27%"_7PH+?(<QXMAU
M1DY?/XZ!\V@/1/FI3#/G-$7"T;U *2?!0TH+W$YK%YV+\[A<A'R4/<I'S$1U
M#[6]/5(6@D7%!DJ!0*!02+)%K'Z:"WCSXLI3R(LA#RXSA9D);4%%MT6)0NW1
M0!Z&@N_IH% H% H% H*;HN/>*@^>'K2[5M\4YU&[A8J/Y>#Y:2F;L%D-95I/
MQW'AYR1N'M5NKT^TOGGX<G#W-53T3]JD<IYQ)[B96/OPW%_Q6/*Q=#N4=38$
M ]?)1K[E6IW6YCA'B=M3A]#Z'  :UYKN1H*9;2$JMI?4TR-4Y5V_P?+WF',P
MTB0U'39EA]EM]M*CU6D. @*MI<5NVM^:<FK<V]3%H[1<<;QZ\0V$)PSMRYC!
M'9^442=Q)9MLO<7O:MWQ?'.&OR>&,JQ[78=4(XM;Y7B2@,G'*9:,3RQT3Y)&
MRP^BI\5XXA?(GJGC=M,?"CM1(,YV)#CI\N/&C(0RRVBY-DH18#4WJ3W43SB%
MC:F/%37VPQ+C3T=R2M<>2OSI3*FVRV\[<'>XDZ*5< W/LK+XS_Q3X>>H]VPQ
M,DN&5)7(+R T\7FVW"XVD[@A>Z^Y(.H!\:1W?_B?#SU2O=J\)+D1Y<MWYJ;#
M),.5(9:>>9)-SY:U@E.NNE([O_Q)[?TJ[/;>%&*S&R#[!=677O*"4>8ZKZRU
MV^LH^*CUJ3W7HA/(GK*WB=J<%CA(1C7!!3+.Z8(C#3 >)\7/+ W=?&K\7G_C
MDCM_2N(G;;%0W8;C4A?EX]:5PF V@-L[=!Y8'U-#;X:QMW.J,8PRC8QQRVV5
MC8&2B.P<E%:F0GQM?BR$)>96D&X"D+!2>GB*Y8GHWL>KAG$%XY&(7@,<K$MJ
M+C< PV#'2X18K#>S:%$#K:KE,+\8?$B ,4(,<8H(\H0 TCY8-C\'RK;=ONM4
M5=)9;0D(0G:E( 2!I8#0 ?106C.%P\8QE1L?&95##B8:FF6T%E+QNX&R -F[
M\+;U\:9$GV-AFF$L(QT5,9#_ ,VAH,MAM,G=O\T) L%[C??UO3(U;BG;/CO&
MIF4R"VF<GDLCF)>=9F2X[*GXCLW;N0RX4E24C;UOXUE-LHW%G'P8[CS\>.VT
M_)6'9+K:$H6ZM(L%+4D J( M<UBJU@\<X]BY4B=C,3#A3IA)ER8T=IEUTD[C
MO6A(*KG74U9G(N&<7CHS\F5&BM,2YI2N9(:0EMU]38VI+BT@%92- 5'2H+.+
MQ;C,&8]D86&@QLA)W?,2V8S+;S@7]8*6E(4=WC<ZU<IA<HPN':1%;;@1T-P"
M504)90!')%B6@!\%P?P;5%2NX+"/QY41['178D]9<GQULMJ;D.&UU.I*;+5\
M(U5>@I1N,\<A16H4/$0X\-AT268[,=IMI#Z>CJ4I2 %CP4-:N1<KQ.,<,LN0
MV%F>@-3RII"OF&TI* EVX^,!)*;*OI4$T''0,9$:@8V*U#@L#:Q%CH2RRVGK
M9*$ ) O[!075 H% H% H% H-/YES)KA<&-EI>(RF3Q[KWDS7\1%5.7#;VE7G
MO--_C/*3;XU(!M[*#C4?NOW'Y+W:A,\%4WFNV#LF(R#"QPDP%P76RJ7)DY7S
MDF+(85H(JV0HVM](>DF]$"VH\#[O"@BL$I('6@X)Z@,1-S_&93/*L)C7>-8O
M*Q9&+E3>2.<<:4CR5;GWGT ;7$+.U"+Z]:#7?3/C,#!Y+G7,,G%-J7!;#OV;
MS)WECA'G C>PXI0:3['/N>-%>GZ(4&K=S/YN.8_Q)DO\D<H-2],_\P?;W^)H
M_P"P:$<G5J!0*!0*!0*!0<E[S]K.0=P'>*YKC,Z!'S_$)STZ' SD=4S#S!*9
M+"T2&D'=="3N;4 =JOOT&#Q?9CF7%NQBNU6 S;#^>RCSJ<MFGDJ:CQHV4>*I
MPA-)"B@(:6MMA-Q:]]*"AP;LIRGAW=^7RAF:PGA3+#D;&MM//F2YCS%8C1,<
MXPH^4EJ&62M#@^)15K[@[X!8#_TT$:!0*!0*!0*""NA^BB2UCN!_W*S7_$?^
MLFN??_+EZORO^ZV_IAYK3]5/T"O"?L,\T:!0*"% H(T1"BHT0H-X[2_]]6O^
MK._L"NSM/S'S7ZD_L_\ M#IW=?\ FIYQ_$.5_P C<KVGYAXL;Z?_ .9+@/\
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M'@: FY/Q@E-_B6/!(]U 7NON"AIJ" 2-.@UH(%)N4VNM5B@7T^GW4$+*\L]
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M%BR%D+<63=15X  G2U!<1,2W)E!+QV("22[>[: @6\=20:#%Y_.X'AZ0O-R
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M(R[Y87:7^(<<44$JLEYT))4=EOAH8?0=-C01H% H% H% H/.W<WMCRSG'?W
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M'S>/A+/RD<14@W4$:?$?$7H*TCDS3C;J7%%1(VJ(-^O0T%2)R6*S&6A(22;
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M!MT%!>/Y)9:0DKN_:[FT?!L)MU]E!CWI:WBEJRMAL+ CIU(W>)H(.3E*3O2
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M[E.$!SX4)(N;I-[:=.M!T?TQ$*]0W;L@$6RJ ?9]16HH/LJ*"- H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MV[(O?[61H>MMBK4'V8H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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6K?U?,O\ 47TOI;V4'V4'[=!&@4'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>lc_primary-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_primary-4clr.jpg
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M_\0 Y0 !  $% 0$!              8! @4'" 0#"0$!  (# 0$
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M4=$FKPU/N*O,:F0;R".AU(_<,!4W6TFE*E$E2O@I,R(S]PC 4-Y!5K4J>@P
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M<?$IF%7C/K#<6KYCUE9EO27X!DX2U04&MQI!G0M7"E>7$<[HF)TE=ZN&J#;
M^8.U;[)O)1+$]89UD4PI<=Y],M#K$HE&A:7$H10_"=4TX=XV9L,X]&-;Q9NU
MW5X3253(QH9OSGWKMUYV(\S3&Y"8;DBR7&Y)O\)PBHA]+QTFQB6=2):3-5"Y
MT,C[1U<4QDQ]*EDCIOU.NV?,KL>_9BOWUWA,Q%M]4XSAK3,14JZ#CZ37J(^!
MD1"C."^NFBS&2NG-KG?W/+1N7Y3[SF=A;D-6>XNL%$*8DD/&EF>EK4:4F9%J
MTU+B-F&DURQ$L,MM::O'Y8S+[J&3<>S(/Z.8RS_:QYD8?80S_9[&1/YS4_\
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MEDLST]NZO6^,Y=&BHU.6RVJ0DB_)<-.HO>,3K(]P@
M                           !\)4*).97'FL-R8SI:76'DDXVM/<I*B,C
M+W0%D*VV^V,(B6V*U#B-U-$>.VEEI->=$H(BXA/$>H    !12265%<2[@'BG
M6:TW5I+-T@QY[*#JAN4TA])>X3A&)B=!](5MM]NCE$MT5F)$(ZDQ';0TV1]^
ME!$0B9U'H2A*3J7: N
M
M
M
M
M
M
M
M
M                              ,R(JGR ?-+BEE4D'I[#J7$ )VJM.D]
M7< &Y11)4FE>7$!]
M
M                                                 %B^-"YU,!^7
M^Y%ZP#-M]-QIVX.Y=UPZ(S>F[198]I9>FMK9BH]76^[H<23;9=-/P2K51\.
M);BW8D7:U8=LCY?-O,XD/6C-G28EYHP9]>7;W7"T&E2%F>D^JJJ=?'2DC[00
MRVPCN4[.^8>^^72YY),RG%7;4B[V21/.KL9PD)=41$:EZ242E)423H=".A .
MCKCO/M58[A)L][S6S0+M"7T9<&1,9;>9<(B,TK0I1&1\>1@+K3O'M;D%TC6:
MQ9I9[A=9BNG$@Q9C+KSJR*M$I2HS,Z$8"=5J J
M
M
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MNX 0
M
M                                 *&1'S 6I;TE1*C(N[W0%I,)2>HC
M/5^5V@*FT1JU&9G[H"\DDDJ$ Y,WW_>ZV#^3/_$H!UH
M
M
M                    Y+WW_>[V#^3/_$H!UH
M
M
M               Y+WW_ 'NM@_DS_P 2@'6@
M
M
M            #DO??][K8/Y,_P#$H!UH
M
M
M         Y+WW_>ZV#^3/_$H!UH
M
M
M    Y+WV_>ZV#^3/_$H!UH
M
M                                                    *&9%Q,Z$
M IU$5IJ*I\N("G5;_*(!76@SH2BKW +@')>^_P"]UL'\F?\ B4 ZT
M                       'DN-SMUHC*FW24U#B),DJ??6EM!&K@1&I1D7$
M87O6D:VG2&O)DKCCJM,1'C>&%EV+7*4W!M]YARIKI&;4=E]M;BB253,DD9F=
M!KIN,=ITK:)EIIN\-[=-;UF9[-89D;UH
M
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MR*I)IW<!SMI&+JMIT]75.G+EXG+[OVD5B]HIII>_'3QMD#K.H
M
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MZP
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M.UY6_>ER^[^5_P#DOZTT%YU
M
M                          <E[[_O=;!_)G_B4 ZT              $9
MW"_J7>?\!_[R1Q._/P.7R?&[/<OXW'Y?B2&-_FS/R$_B(=?'[$>1RLGM3Y7U
M&QK             $*VY_P WR/\ \P7'^6D4=KRM^]+E]W\LG_)?UIJ+SJ
M                          *&="J"88&ZYKC%CEG NUQ1%EI2E9MK2X?A
M7\$ZI29<?=',W'>FVP7Z,EXK;SNGM^ZMSN*=>.DVKYGNM-[ME]B>O6F04J)K
M4UU4DI):T<RHLB/@+.WW6/<5Z\<]4:Z*VYVF7;WZ,D=-M-?\:,B+2H
M                      M<<0TVIUQ1);01J6I1T(DD53,S&-K16-9Y,JUF
M9TCFPZ,NQAPT$B\PE&X>E!$^@S,SX$1<1SX[SVL_ZE?K0OSW;N8YX[?5EF2.
MHZ3G*@
M  .2]]_WNM@_DS_Q* =:              "&;EW:VPL3NL67+:9E/,$;,=:T
MDZLC6152BNH^/<0X??DQ]RR1VS'QNIW/EI3>XXM:*\>V8CL\:16FYV^XQ&W+
M?+9EH0E"5J8<2X23TD=%:3.A^@QUL5HFD:3V0Y<Y*WM/3,3QGE.K(5(;A6I
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M?N&.>JVLWOVSX(34>F><
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M%_26QP._?PW\=/YH=WN3\3_#?^64K'?<(
M  !$B*P?[0;Q_JZ'^D='!P_^2R_\=/7+N9O_ !^/]^_JA*AWW#
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M/GX,)WN?)]EAGRWGHCT<;>FL/C(QC/;[7VM>;=:6%EQ8M<),AWOJ3TJM#[_
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M?TEL<#OW\-_'3^:'=[D_$_PW_EE+!WW"
M  1(BL'^T&\?ZNA_I'1P</\ Y++_ ,=/7+N9O_'X_P!^_JA*AWW#
M                              !\WBU(IWF1=_: XORS>/=N_P!ZM6=X
M[?&\?VPB[@PL$9QUEA#DVXI)_IRI,E]5="3TFE#:.P^-*<26ZMM<NSR)NKF>
MU&X$EBZN6]I&1XK>F$$RMRS3I"FRC/H25-<==$)5S453!#=0
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MW5%A1(+1,0H[49CGTF4);3^!)$0Z=:Q7E&CU=:Q6-(C2'WH,F:H
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M,Q$\:^M*HT5B&RB-$:2Q&;*C;39$E"2[B(N0O5K%8TB."[6L5C2.3[#)D
M H::G7D8#6./8GB\7='(W8UEA,OQ8MN?C.ML(2MMUSK:EH,B\*E=IES'4RY\
MD[>NMIXS;XF$1&K9J2,JU[1S&:X0     "&;GVNVS\1GO3HC,EV.39L+=02U
M-FMULE:3/B52[A3W5(FDS,?XU>@[AW&3'NZQ2TUB===)Y\)2F#;X-L83#MT9
MN)$14T,,()MLC4=3,DI(BXF+-:Q7A$:.+ES7RVZKS-I\,\9>H9M(
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M66/O3'K%<L3AO/9?M\EH^;/IU\2:$LC(C(ZD?$C+D9&+3L+A(
M  *'0BJ I_Z<!!J%0N% -5PD*                             %"
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MR/J*=*3/<)UXB73PZB(O"78+N+'T5TUF?*[&'%[NNG5-O+S9<;F\
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M?7%=2Z2'.F1Z5&DSH?H,<_WM;VGIF)XMV?:9L&D9:6IK&L=4::PSHR50
M       %#YD UKLS_F>9_P#FV[_RVQU.\.=/W*M6+M\LMECEMH
M     "TR,SK7@"$8O>!8[>I7M13"[??2X-WBW+.),+C7BM%-1>A9&0JY-M2_
M'E/AAS\_=^'+;KTZ;_2K\VWICG'BG@Q2E[CXL1$I#69VA'-:-$&[(21?DG1E
MWWC09C7_ %L?[<?"JS.\V_9&>OFK?_TV_P K+8]GV,9"^NW1)*HMY:X/6B>@
MXDU!_P""<H:O=14ANQ[BM_%/@E:VW>.#-;HK.EX_5M\VWHGCYXX).2JG2@L.
MBJ      -/\ F5_LX9_US:OZ4D=KN?[?^&WJ4=]]EYX];< XJ\
M                   !@(+:_P"UK(O]3VW]-(%.GV]O(XF'_P AE_X\?\V1
M.A<=L  $;SC_ $,S^O0?Z2V*>[]B/+7UJFZ]CSU]<)(+BV      "$V3^T[*
M_P!1MGXGA>R?AZ>6S&.:;"BR      !%]Q?ZF73Y+7Z9L5=S]G/F];L]R_C*
M>?\ EE*.T6G&              !\GZFV9(XJJ5"+G6H#CC-,Z\M4+/,]C1L4
MO^5W*_QSL>=%CT-V7:7'T*2LU&25$DI*%)+\XBE%%7X53 2CRJ%M9"N&16W
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M2VXXALDJU:"*JB,J'JXD.=EV_N;VKT],Z^#1GEW5\_&UYOX)F=>"4C!H
M        4/F0#6FS/^9YE_YMN_\ +;'3[PYT_<JU8N4^66S!S&T
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M>^#W\>0#FW,\*\W,_+KQ,PC<"T6S$GY"EV>!(C-N.L1C(M*%&;*C,R]TQ Y
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M->7 <]L79-;L\F8"_;,6O42W;AKB,ML7R1'ZD0IJ='6<Z)I51*Z+TEI.E2X
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M\M?7"INO8\]?7"2"XM@      A-D_M.RO]1MGXGA>R?AZ>6S&.:;"BR
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MBB)OCM$3VZ:QZ8X)*3;=.1'7C7F+#F!MMGS20@.FWW"0Z+9_% .FV1D9)IW
M-9[,$7JF;$7+ZWW@O]\V.GWASI_QU:Z<O.V9T6^[@.8V'2;I33P[@ VD'S2
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MUKU5^=XN2QW=_:6]W.XC#DK.*)B9ZIKK7TQP^%J_9+>N ]DLS$CM#R7<HO\
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M^G;UZ/0C=7!C*KMQ7'5VI>BR4&7NU:H01O<,QS^"6[\SV_;;3RQ:/B>EO<O
M'"K]9(#9GV//H95SIR<-)C97=8K<K03WIM(YY:1Y;1'K9!O+L6?:4\S>X+C2
M2U+6F2R:2215,S/5P(BXC.F:EYTK:)GRKE-QBO[-HGSPUM:-R,"=W:OQHR*W
MZ'K7 CLO'):)EQUMQTU(2LU:3,B<3R,9UVF?WUIZ+::?1ER<-X_,,O\ QT^"
M;_+#<25$HJ\O=&;NJ@ "-YQ_H9G]>@_TEL4]W[$>6OK5-U[$>6OKA)!<6P
M    0FR_VG95^HVS\3PO9/P]/+9C'--A19       B^XO]3+I\EK],V*VY^S
MGS>MV>Y?QE//_+*4=HLN,              #EOS37F;C6XNQE^MMFDY#<(%X
MNRX]D@4]:DF<5LM+>KA4B\7O ,DGS*;D)K38/+>)_P!Z_P!P!/=K=V,KW ND
M^!D&W%ZPJ/#82\U-O&CI/K4O3TD:2+Q$7B]P!M)SX%>X!Q_OAFVU6WGF5LV2
M;DPU7^#)QE=N. J$J>BUN'(ZC<I+:TFVM+J=;9Z:K2?'D8"38CO]Y5+[E=EL
M>*VB*SDUQF,Q;.\C'BC*3+<51LTO=%.CC\:O #5TRU4B,CYD8#Z    H=>SF
M H2C_P!P J=:4 7 .2]]OWNM@_DS_P 2@'62DDKF USN5BUV-Z%G^%(-6;XX
MA1HAIH172W*,E/0'3_C$1J9/XJ_=J.GL\U=)Q9/8O_EGLM\OB:LE9]J.<)7B
M>5VK,[! R2QN=2VSVR6DE%1QIPO"XTXGXJVU$:5%V&0J9\%L-YI;G#.MHF-8
M9T5V0 U;O0FD#"Z&?];K/_+<'4[OCCD_X[-63L\L-HI222H7NCEMJH#Q7:Y0
M+-;95WNCZ8MM@M.29<E9T2VTTDU*4?N$0SQTF]HK6-9E$SI&LM<;9VR=D%PF
M[N9+'4S=[^V4?'X#O$[?8D*U-)(NQ<C@\Z?I(AT]Y>,=8P4GA7VI^E;]'*&G
M'$S/5/\ \(;3+B1#DMZH          MT$1U(S(Q.H@F2[2X=?9IWF/'=L63<
MV[]97#@S25QXJ-NB7*UXZTF+^'?9:1TS/57Z-N,-=L<3QY2P:G=X\&TDXTQN
M-CS956\UHM]];21?\7_,OT]!I4H;]-KF\.*WIK\L,?GU_:CX4AQ;=;#<KEG:
M8<U5OR-OPO8_=$'!N*%%S+I.TUT[VS40K9MCEQ1U3&M?I1QAG7)$^5@]ZMMY
M&=XDNW8[!AIORI3+Q27DI95TTUU_G"29\:\AY_?;7WM?FQ'5J]O_ &MWY7N_
M=]>>UO=],QI''CV<-6@-I]D<SEY5[8];1;X%DNLJW3YL1_3+:D14FE1LDI!D
M9:E%SYE4;>\-ADF^&==-,=/@>@P?W7LZ[+<XNF;VRY<EJUM7YLQ:T>UQ\#I!
M-FW6LI%[,R*#D+*:Z6;U&.*\=>]Z)PX?X,:?=[FGLVBW[T?(\K.Z[KS_ &F&
M^&?#CMU1]6_RJ(W RNTGHRS!Y["$D1KFV=;=TCD1\*Z4&APN/9H,3]ZR4]O'
M/FXIGN?:YN.WW-)_9R1..?AUK\+(VO=? +L\F(U>V(MP52L&X:H,A)F=-)H?
M)!UKV$-E-[AM^MIY>"KN/[>W^&.J<4VK]*OSZ^FNJ7MNI=0EQI25MJ*J5I,E
M)/W#(7(G5P)K,3I+Z$,F(                      **.A5$2F&E_,5?[*W
MAJ+.]<8S=U3<[4^J$IY!/DT4M"M?3,]6FA&=:#I=U9J1N>G6->FW#S,\VSS3
MAC)%+33JB.K2=-=8X:MLVN]6N]QO7;--8GPR6;9OQ7$O-ZT_"3J09E4J\1R:
M9*WC6LQ,-V?;9<%NG+6:6YZ6C2?A9 ;54                  "E0%* &D
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M1ZCC$LD$MMYQ->D9ITF?Q@'8C-"-1<N/ O00(?4!0S(N9TJ M4>HB-/(_=Y
M. ?-EO5O#).1;L<A3,/V]L>1E8W+\3RV)UXN+.I563+2KU9*4FKPU2HS*IGR
M(F6V?-!G.<-2-M-H\#O3E@N^X<IN-<+VV:DOM1RZ2")MQ/%.I2E&O3Q,BIR,
MP&*V*R#<#;;?Z_>7;-<HDYA:56XKS8;I,JJ0T>E"U)4I:E*))I-1:*FDE%4N
M9U(=,RL_P2VR7;?<LHM$2?'5HD19$^,T\VOGI6A;A*2?H,@'+V\&06'(/-KL
M._8+K#NK+7KR'7(,AJ2E"C)1D2C:4JAGZ02[%!"E"]_O :?NR5[19FO*(Y&C
M;/*Y"4Y*R1D3=KO#IDAN>DOBLO\ !#_<JBO0.S3_ -UBZ)^TI'S?VJ_1\L=C
M1:>B=?U9;=:42N1U*A&1D=2,C[??''EO?00-7[T_YCA?_FZS_P MP=7N_GD_
MX[-.3E'EAM <IN6J/@9$=#/D U'E1KW/S5O;F*>O#<>6S/S=]*O#(D\'(MM(
MRY\4DZ^7Y-$\#'8P_P#ML7O9]NW"GB\-OBAHM\^W3V=OR-MMI)*"22221<"2
M14(B+D1#D2WKQ             4(^8"AD5.0"-Y3@^+9K&*+D]H8N"4\&7EI
MT26C[VWD&EQ!U_)40M8=SDPSK2VGJ]#"U8MS:8W3:S_9/#9%WPS*I4['3<;A
ME;KTT4^3!Z_A)UB6=%:4TH27:D7?4=O9>YWF6*Y*1%N>M>$3Y8^15SVMBK-J
MRT]L3NSFU@S--JTSLFMEZ<?DW"U,I*1,5)-)K5*:-5**J7YRJB)1>F@[/>>P
MPY,75PI->4]FG@^13VV>\6TYZNHOVJW;_P#;O*/HK'^.'E?N-?\ =IZ9^1T_
M>3]&?@4/=BZI/^SG*3/T1&/\>'W&O^[3TS\A[R?HRQ]TSF/?&C9O.U603FU)
M-)HDVV,[P/G0U.F9>\-5^[,5_:OCG_'D6]OO\^"=<4WI/BG3XT17&M+#RI&/
MX-GF-R#K0[2KHM%7^\KD+;I7C0DBE/<6&/8RUIY+3\CO1_=&ZM'3FI3-'_4I
M69^M&EOA6+W"WCLCB4VVQWR_L)I6->+(B,Z9'P_SB(\I/#_!F$=V;BOLY\5O
M+P1&_P"Z\WVFWR89\..W5'U;<?A26V[V9(W&-[)MM,DA&V1&XY#CG*;KVF1'
MH53NX&+6/97F/GWQQY+?H<S/CV\VTV][7U[+4Z9]>BB?,MABY1P3LU];F$=.
M@]#2PNO=1QU/'T#",6*?];'];3UL[=U[VM.OW-YKX8CJ_EU9/]N-LU4/$<IT
MI/2MQ%K4M!=_B2LR,7([OF8UC)CF/WG'G+I.DQ,3Y)>C]MMB*O\ X>R8_P#^
M3R!'Y=?Z5/K0GWL>"?0?MML7V=R;_N=\/RZ_TJ?6A'O8\$^AYRWZQ8UZ56/)
M4\:&H[+*H5/<28S_ "O)]*GUH1[^O@GT2^W[=L2+_JK(?^Y9W^+&/Y9E\-/K
M0>_KX)]$A[[XC3_160_]RSO\6)_+,OTJ?6@]_7P3Z)6)WYPTSI[-R$O2=DG4
M_1B?RO+X:?6AC&XKX_1/R+_V\8;_ -G7_P#[EG?XL1^5Y?#7ZT,O?U\?HE16
M_.%I(U*M]_))<3,[+.H7_P"&'Y7E\-?K0CW]?'Z)?-K?_ 75&73O#94K5RTS
M2+WOS8F>Z\T?1^M"8S5\?HE]_P!O. =]T_[KF_XH8_EF;]GZT)][7Q^B5CF_
MNWC2#<<<N;;9<UJM<TB+WS:".Z\T_1^M![ZOC]$D;?\ VPD:JW.2QI_XZ!,1
MJKW?FC">Z]Q'9'IA,9JR]'[=MK_^VU_0YG^)&/Y;N/H_#'RGO:^%1>_.UB"U
M.7U2$\JG#F$5?^1#\LW'T?ACY3WM?"-[\;3.I,_K(A/'DN/*2?N\6@GNS<_1
M^&/E/?4\+GKS%;P8]E#T?&\0B0YS"#CS)^0NQ_SRG&%]1MAO6E*M!4+J&?,O
M"0[G=?=%:6G-EC2VDQV:Z3SXM.;O++2L8Z6GIYZ:STZ^37FW_L9GD'<+"476
M+;8]HG19"XMSM\-*4,^L((C-U"4D5$N$9&52KS+C0>?WNPKL\G17V9XQPT6J
M[N^YCKO,VGEQF9];9Q+3WB@E4C(^0"H                           -6
M6/\ M]R[_4%J_3/#K9/P5/WK?$T1]I/DCXVTQR6]8XZVRA3CJB0VDC4I:CHD
MDI*IF9GR(@$=QW<+!<NE2X>+Y';KS+@EJE,P9+3ZT(K371"CJBO#67AKV@,L
MW>K.]=9%C9FL.7F(TB3*@)<2I]IETS)"UH(ZI)1D=*\P'LZC9'3450#JM\?$
M7#F =5O\H@%Y'7B0   (39/[3LK_ %&V?B>%[)^'IY;,8YIL*+(      $7W
M%_J9=/DM?ID"KN?LY\WK=GN7\93S_P LI1VBTXP              .9_,^U;
M;MD^R^*Y8I);=7G)74Y"P\OI17WV&-4)E]?#PJ6I1:#.BO>!+S2K?9LX\V-A
MQVUQHKV*[3XTN>4-E"3B1[M<'"0PE+:"T$M#>A:.ZG#D"'KVN5":\V.\C&.F
MR5D]EV5R[MQ#3T?:ZT\5*)'A)TRZFOMK6O&H#H6]WBU6"VO76]S&;?:V-)R)
MDI9-,-DI1)(UK5P253(JF T]NFOS,.W^.]LPO%G,2=BMK4N]FXJ0J0HS,S2I
MLS(T&G3IH"6G,HVZ\ZN8Y%C&0WX\+DN8C+5<K1;DN2$0O7S3I1(=0DB6MQO_
M (/QZ2[@&_\ 9&];FW2WWR-NO<,>FY+;9Q1^EC#BG6X[9MD?3DZC/2[JJ>GF
M14J"&U@%JTF=*=@#GC*-@-SKWN6_FMOW:N5KQYRX,3D8TTEPV$,,Z#4P1DZ1
M45I/XO: @_\ M 8DV?MYB"(49Z4I&1MJ-$=I3AI3ZNX7$D$="KP ??S667);
M-=-I]Z;#9).00<#EMO7NW1",WDL*-IQ*R21*.AFE2353PG2H#%[$N9!O/YE,
M@\P2L?G8UAL*U(LML1<6]#LF0;:&S(C.A'I(E+5I(R35)5J(2VYE'E(V-S7(
M[EEF0V%V3>[N\<J>^4M]M*W5$1&9)2JA5IR(2AH+*=G=O]G_ #5[(V[ K8JW
M1[DN8_-)3SC_ %%MI4E!_G#.E",^0)=W@@ 8^ZVFWWBVR[5=F$2[9.:6Q,C.
ME5#C3A441^\-E+VI:+5G281,1,:2UQMS=KAB%\>V@R=]<F3"95*PZ[/&5;A9
MT&1$RH^U^+\!?Y2:*I3B.GNZ5RT]_3A$^U'@MX?)9IQZU^;/F\C:R5:DDKO'
M(;VL-Z?\QPO_ ,W6?^6X.KW?SR?\=FG)V>6&T!RFY"-RLSD8C84IM#29>77I
MXK9C, S(^M/?J25J(_\ @FB_..'RH5*\2%[9[>,M_G<*5XVGQ?+/*&O);ICA
MS>W;W#HV#XVS9D/*F7%Q2YEYN2SJY,N4D]<A]1GQ\2O@EV)(B[!ANMQ.:_5R
MCE$>".R$TKTPE0J,P                !X[I:[?>H$BUW6,W,MLM!M2HKZ2
M6VXA7,C(QG2]J3%JSI,(F->$HIA.TN![>2)4O$[4B',F'1Z2I2WG2;K4FT*<
M,S2@C^*7OBYN=]FW$1%YUB&K'AI3V8T3<4&X   !;I])@**0:BI7WP'@N=AM
M%Z9./>(,>X,F1EHE-(=(J\.&HCH-5\5+^U$3Y5K!NLV"=<5[4GQ3,(>O9W%X
MSG7QR5<L:>(O![(FNL,EW_F5&MKCV^ 4Y[OQQQI,TGQ2[U?[EW5HTSQ3/'_4
MI$S];A;X5OL7=JRJ2=LR6WW^(@B_R:\0SC2%$79UXRJ5,OC*;,1[O<TY6BW[
MT:>IG]Z[JS_:8;X;>''?JCZMO5$AYYEMH/3E&$3T-)(S7.LSK=S8HGF>A)H=
M(J<?@U"-UDK[>.?X>*/RC:YOP^YIK]')$XY]/&OPLA:]U<"NCY0T7IJ)/.M8
M=P)<%\J=Z9!(&VF^PW_6T\O!5S_V]O\ #7JG'-J_2I\^/375+VWD/(2XRLG&
MU<4K09*2?OE46XMJX5JS6=)X2O(ZG2HG5CHK17>)045W_P   9&?;0 (C[3
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M;P;&@W.!<XR)ELDLS8;GP)$5Q#S2N-#HI!F1CFVI-9TF-);7I2LE#$7"
M                    !JRQ_P!ON7?Z@M7Z9X=;)^#I^_;XFB/M)\D?&VD9
MT(S[AR6]K*^9_C-^O]RVLOE@OA0I;$B-<[J["6S93BFP:W35-)9$E!HJ6H!
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M      $7W%_J9=/DM?ID"KN?LY\WK=GN7\93S_RRE':+3C
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MD(0V@B2E*4EP(B(J$0Y4S,SK/-NA]QB
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M>/375,6GV9#:7F%I=97Q0XV9+29=Y&52%N+1,:PX%J36=)C25^HA.K'142@
M:WWP_J.C_6MJ_IS0Y^_^R\\/6_VI^-_^GE_^W9L@=!Y(     >.X6R#=8RX=
MSBLSH;GPX\EM+S2N!EQ2LC+D8SI>:SK$Z2B8U:YE;&X[%DKN&#W&XX3<5U-1
MV60:8:U'VKB.ZVC+LHDDCIU[RO,:9(C)'[4<?3S:9PQ^KK7R?)R6>M[W8IJ]
MHP;;G=K09_Y1;U>RKMI+M4RYJ86?'@2%)#IVF7E,XY\?SJ^GF:Y(\%O@E[;1
MO3A$R85JO;LG%;Y4D>S<A85 <-1T^"XO\THC/E1?$89.[\L1U5TO7PUX_I3&
M6O*>$^-L)B0R^RA]A:76'"U(=;,EH4GO)23,C(<Z8F)TEN?0EI/D(T%P@
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M>F/(N)+:F$D^YQQLG-/89G0!N(  0FR?VG97^HVS\3PO9/P]/+9C'--A19
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MS6(BOD_QS7=O,6IU>'FVV7 J#CK(
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M]3CG%UYU?%;KA]JE'_N#D;G<6SY)O;G*S2D4KI"1BLS
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M_O=;!_)G_B4 ZT
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M0      (ON+_ %,NGR6OTS8K;G[.?-ZW9[E_&4\_\LI1VBRXP
M                      Y+WW_>ZV#^3/\ Q* =:
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MEM            0BR?VGY7^HVO\ $\+V3\/3RV^)C'--Q19       B^XO\
M4RZ?):_3(%7<_9SYO6[/<OXRGG_EE*.T6G&
M !0S(N8!4N8!J+O 5  ')>^_[W6P?R9_XE .M
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M)*KQH8#DW??CYN=@S_BS_P 2@2ZT!
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MQ0EFO$      B^XO]3+I\EK],@5=S]G/F];L]R_C*>?^64H[1:<8
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M?JZ_$7;XC!#2ESMN]=M\TNR;>]-XM5WN*W9AVM=H;-M+;)(7U"<JVW4S.E.
M)=_ @
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MIS_0^BYO[&O.RIM_?1_3O>^O3]*(X<_$ZW;XH2?*I$?X1ZR)?"YC25X(
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MWNM@_DS_ ,2@'6@
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MP/<-JL                                Y+WW_>ZV#^3/\ Q* =:
M
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M]".I5                              ')6^O[W.P7R9__O .M0
M
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M ,2@'6@
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M_P#$H!UH
M
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MMDMWJVS%;C%G62IK6MF#?6#EE'JLSJEIS7HX\CIV -P).I$8"H
M                 .2]]_WNM@_DS_Q* =:
M
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MV -FD5"(B 5                           !R7OM^]UL'\F?^)0#K0
M
M                                                     !::$*XF
M1&?> $V@C(R+ER 7  "E"[@"A&5*<  TD94,N "B4)3\$J4Y +@
M            !:I1(*I@-<Y5O[L[A%[D8WEN7P+1?HJ6U28$E2R=;)Y!.(U:
M4&7%*B5SY& S1[H8 6&M[AKR"&WA#J#<:OCKG3C*22C1X361&9U29$DBJ ^^
M&[B81N';7+OA%\BWVWM+Z3SL-PEFVOC1*T'123.G#4DJ]@"3$9&52 <F;[_O
M=;!_)G_B4 ZT
M
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M!]_#"?L/E7T)/S@#[^&$_8?*OH2?G 'W\,)^P^5?0D_/ /OX83]A\J^A)^<
M^4GS\X##95)EX;DT>.CX;SL1#:$UX%52ED15 ?1/GRP=:26G"<I4A1$I*BA)
M,C(^)&1Z@%?OX83]A\J^A)^< ??PPG[#Y3]"3\X ^_AA/V'RKZ$GYP!]_#"?
ML/E7T)/SP#[^&$_8?*OH2?G 'W\,)^P^5?0D_. /OX83]A\J^A)^< ??PPG[
M#Y5]"3\X ^_AA/V'RKZ$GYP!]_#"?L/E7T)/S@#[^&$\OJ/E5?U)/S@'GC>?
MS;V:E:X6(9+(0VHT+4S%;<)*RYI/2LZ'Z 'H^_AA/V'RKZ$GYP!]_#"?L/E7
MT)/S@#[^&$_8?*OH2?G 'W\,)^P^5?0D_. /OX83]A\J^A)^< ??PPG[#Y5]
M"3\\ ^_AA/V'RKZ$GYP!]_#"?L/E7T)/S@#[^&$_8?*?H2?G 'W\,)^P^5?0
MD_. /OX83]A\I^A)^< \Y^?W;TI90#Q#)2GFGJ%%]5;ZQH_*T:]5/30!Z/OX
M83]A\J^A)^< ??PPG[#Y5]"3\X ^_AA/V'RKZ$GYP!]_#"?L/E7T)/S@#[^&
M$_8?*OH2?G 'W\,)^P^5?0D_. /OX83]A\J^A)^< ??PPG[#Y5]"3\X ^_AA
M/V'RKZ$GYX!]_#"?L/E7T)/S@#[^&$_8?*OH2?G@/C*\_>W\)KKS,.R6,Q4D
M]5Z*AM&I7(JJ61<0'V^_AA/V'RKZ$GYX!]_#"?L/E7T)/S@#[^&$_8?*OH2?
MG 'W\,)^P^5?0D_. /OX83]A\J^A)^< ??PPG[#Y5]"3\X ^_AA/V'RGZ$GY
MP!]_#"?L/E7T)/S@#[^&$_8?*OH2?G 'W\,)^P^4_0D_. /OX83]A\J^A)^>
M HKSXX21&9X1E)$1&9F<))$1%S^, ^,7S]X!-83)A8=DTF.JI)>9BH<0JAT.
MBDK,N!@/O]_#"?L/E7T)/S@#[^&$_8?*OH2?G 'W\,)^P^5?0D_. /OX83]A
M\J^A)^< ??PPG[#Y5]"3\X ^_AA/V'RKZ$GYX!]_#"?L/E7T)/S@#[^&$_8?
M*OH2?G 'W\,)^P^5?0D_. /OX83]A\J^A)^> 'Y\,)^P^4_0D_. 3C:#S2XE
MO)ELS#;-9+K:KK!AJN#WM-I#2>FA:$4H2C41GK*G !O8CJ1& J
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M96)HN/<E,0B_ (2[ $H
M                $0OFWF&Y#EEDS6]6I,O)\:-966XFMQ*HW5^%1*5$E5?X
MQ&"4N+M!"H            "-YOAF,[@6&1BF7V]-TL$S0J3#4I:"4;2B6@]3
M:DJ(R45>!@,O;(,2V0(ELM[9,0(+3<6*PFIDAEE)(0FIU/@DB(![0
M     'S<;4I25)5I,O? 1#"-ML*VU9G0<(M"+1$NDHYL]+:G'.M(45#55Q2J
M<.P@2F8(            6J*O;0@$.>VVPA6>-[H+LZ/KTS&]11>#6X2TQS2;
M>G1JT?!495TU$)3))U(A*%0            $4S[ ,1W)M",<S:UIN]E2\W+*
M*M;C9$^S70JK2DJX5/A6A@)/'0EMEMM!:4(224)+L214(@'T           !
M11Z4FKN >&?'8N$9^',;ZD*2TN/(;54DK;=+2I)F7>1T 8/"<(Q;;RP,8OA=
MM*UV",XMYJ$VIQTDK>4:EGJ=4I1U/CS 2A*S4=*4 7@           ^+JC,C
M215/\("(0-N<)M>;7#<:!:&V,VNS!1+A=B6Z:GF2T$2=!JT%\!/$DD? 0E,$
MND9D1D9'Z> E#Z@
M          \=PFM0(S\V0LT1(K3C\A9<3)MI)K5_ 0#\^'=S_,[EN$93YF<?
MS5FV8ECUT<8@X83*'(ZX+;K:%:BT47H)U-37XE>(R4G@0#NG;G+D9[A&.YFR
MDFFK[;H\\V2K1"WFR-:2KQH2JD50$J           !\WE*0BJ.=0'+>Z,;S.
M;E;N2\(V^NDG;W;JS0D/IRA4:J+C+,DF9(=(M2N*])(2HB(DJ4=>! ,MY0]U
M<]W$Q3)+?N!(1<KOB=W5:$7YI"$HFH2DZU-I*4*4@T_#3S)15X\3#I(CJ50
M           &%RO);5AU@N.47Z2F'8[3&<ESI"S(B2VT5:%4RJI1^%*>U1D1
M"$N0_+#O9N7NKY@LQ1ETB7!QUVSG<K-B[]"9AL./1CC*)))+QFRYJ-9\5:JB
M1VL"            &!S')&,0Q:]Y7,+5#L<&5<7D5TZDQ6E.::T.E=- '!&.
M[K>8S+G+'N-:=S[%]9+[,4NV;32)4*&ARVI>4S1774A!&K31!+5UE%XDF9\
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MIK21FG2:%F?PDJ+GQ#KTN1
M                  QU[@'<[5/MFOI>O1GHI.&522;S:D5,O14!^9,+<E>W
MNQ&;^5V^8Y<T[H7"ZN,6^(AK6AUN4ZRK66GB9D37ATD9*U$9'0!^A.R^+S<)
MVLP[$;E_I*T6B+'FII32^39&M/;\%1F0"?            M<,B2=>0#B;S1>
M9ZVPLN5LC:[_ "\9L[1$G.,KM["I-P;2I.HX$)!&C2M23+6]JX5H7(ZDMQ>6
M+--H,CP9VP;*PI4'&\9=;C243F2:?>D24&LWEJ)2NHM>FJU'[A$14(!O@N1
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M=\CV'W[&=HI%VR&*N!+RJZR;U&@O)-#B(KJ4-MJ,CX^/2:DU(O"9 ATR
M      !\C <C^?HR3M1CJ:$5,DB4))?WMTSY$ F'F:\PS>P^$6T[4TF5FF0M
M&S9$/$9QHY-(23DIXB(S42-9:4?&5Z",!KGRH;C[)R<K?L5AN=YR?>+*VW)N
M1Y?>(A-*E*C(ZJVFS-:C:922? @NXJGP21$NS2Y A4
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M+S##;:R(^9$I*2/B R)%0J
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M J
M
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M2'"=?0V@G7DIT)6LB+4HDU/21GR*O !Z0
M
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MTU-IU!\E)/@8#,@
M
M                              &1'S*H"A$1%0N !I+M #21\^("M "A
M%R(!B<@M'MVSS[,J2_#;N##D?UN(OI2&3=33J-*H>E:3XD?> A6TNS./[06^
MY1[1+G7>\7V24V^Y!>'BD7"8\DM*-:R)):4$9Z2IVGW@-ED 4(!325:TX@&E
M/'ASY@!D1\# -)%RX %" 4-!&>JGB[P%:%W *@
M
M
M
M
M
M
M
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MT *@
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MU<54)14X@.LFR(B45.TR 7@
M
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M]+G6;D2R;;.?(3P9C+H7AU<"K0"7>K2M1&9?!J=/P@/H
M
M                                                     4 6&TE1
MU,!0VDJ*AU-/.E0%R$$BM*\>=0%P          I0!4!2A<Z<0%0   4H7< H
M:$F5*<# 4-HC*AF9EV<0%4H)!43P 7
M
M                                   +.JW6FH!7J([^8!K3W@*U(P%0
M             !0S(BJ? @%-:>\ ZB.\!4E)5P(ZF J   "W6FNFO$^P!<
M
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M4I:FS5J(B3XN/9Q 2*)):F1FI<=Q+T=]"7676S)2%MK+4E23+F1D=2 ?8
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MZBY4Y@/I:,@M5^@M72QSHUTMK_\ -2X3J'V%4YT6@S*I=I ,J
M
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M%V^G*4IAQG61O&R:"0:5(_-].M?C .X-O246!XMKIK]CV\E4I2OJK?*@"2
M#&7FWS[E'0S;[F[:W4K):GV4-N*4FAEI,G",J"ENL&3+6(I><<^&-/C7=KFQ
MXK3-Z1DC3E,S'GX,(>+9-0__ !A,K3@?JT;YHYGY=N?^YO\ 5JZ/YAMO^WK]
M:S6-EVXSAC.'G%S7(9QU&\[D"2U==#O8@E<%*5\9*N!#R&U[EWM=Y/SIKIQZ
M_#KX/#,^#T^/V6Z[[V-ME$=,6UX1C\&GA\$1V3VMG_5?)?MA,^C1OF#V'Y=N
M?^YO]6OR/&_F&V_[>OUK?*D%KB2H4)F-,F+GR6R,G);J4H6NIF=32@B(J<N
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MI&N 5+8]D!-GZTN#H(FS22=)/=/@:J&7"@#I!/P2KSH J
M
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M<>CT/S=*U^")2SX(
5                        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lg_rezolute-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_rezolute-4clr.jpg
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M_\0 O@ !  $% 0$!              @!!08'"00" P$!  ,! 0$
M      ,$!0(!!A   0,# @,#!0@'$!(#     0(#!  %!A$'(1((,4$342+3
M%!5A<3(CI!96&(&10E*S=96AT9*R,X,D-)2T)355-A=7L?%B@L+20V-SDU1T
MU*5&=B='-R@X$0 " 0,# 04'! (#         0(1 P0A41(Q03)2$Q3P87&!
MH2(SD;'1(\$T0F(%_]H # ,!  (1 Q$ /P"?U * 4 H!0"@% * 4 H!0"@%
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IAPVH]JDQ74/LNQVDA*5I<;)2OFTU*AVFOG9MMOD;$4DE0R&N3H4!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tb_treatment-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_treatment-4clr.jpg
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M_\0 R0 !  (# 0$! 0            $' @4&" 0#"0$! 0$! 0$
M      $# @0%$   ! 4! @<&"@T7"@8# 0$! @,$ !$%!@<2(3%!$],4%1<(
M46$BTI46<8'1,I(CE%97&)&Q0E.3L\-TU"55=3>AP5)BPC-C<X,D-%2$M#5E
MA:4F-I8G*'*"LD.C9$5&=D>B1,2U9CCPI(8)X1$!  (" 00" @$$ P$
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MP2HDFJ55L-Q@J9L01 %!TRYQO#U\],>W?]?'D\VF)YKH]6]I7/%UX[&W<=V
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M 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0 (! (! (! (!
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M8LE+HI?;L_A*H?9$"P,"8L LAI"\@[M2J'V1 LZA<5[PI2_I5*H</[H@6P'
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M&7VI7D.[[95#[(A18; F+!"0TEQ+[Y5#[(@6QZ@<52_@I>7WRJ'V1 LZ@L5
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MCCMT>#I"6W;!'865VG*9=V0:98[^SZO;2-RM%']G5>K%(0E2;IE$PG%$/"2
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M/;4NRHFI-J5KCFZ72"Y%!3$01$9D 1 PDF;;(8#T\@,TBB(:1EM*.\.\/?"
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M7 0-,Q]@ 6>K?*"PX.TKXO2B9-OK$I+^6R7:"5I/JN6OJBFHYIKPJ R3%P@
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ME&TJ9>MKJ'4HU4(8Q"K !5DE4QT*)*% 1 #%$)#(8"OLU!_>G@\1WA7GP?\
MZ0P%Y0" 0'YJ)ZP$)R&0AJ#>$^$(#Q'D6V,PVEEZP<?-,U7$HQOU=\"S@Q4P
M.T*W*90@)A.0@/K>""K7JN7*CB9Q2,/TFEUO,.3V; 7]561,FW6*T.H.E5RJ
M;4 &'4!2ET[I;=L$<7E#M4U5U@U]?>+:2_I]R,JCT17>>)(JGH+E$Q!.5RF>
M8&*H!M!# 7?OD.R"K#:YNO8MAV[6R8JN&J7=7 ,7H5$$4B$*W(2;IPO,2(I+
M">:8"48)3@\F9L;93[-.3JA3J?4+7N6VS!2ZY2'9@*Y:.RK$F4JJ8AJ*(<.S
MA@/1&+E%5L;V@NNH99=2BT\RBJ@B8YA%L01$1':(C. ZZ 0" K%]^'ZE3W>:
MSO\ ?R<%[,6(A\8"KCP^:K3]_*0%GZ@]+NP0U .Z H3M48UO')UN6I3;,9)/
M'=+N%G4WQ5ER-P(U0 VHP"<0U#,0V!M@/JRW8%VW9F##]W4!HDM0+2>OW%><
MJ+%2.BDY(D4@E3-M//0;UL!P7:!P36[KRM2,I4BVDKVI*=.&D5RV#5)2BNY%
M,8R;A!P02S$NKUL]^\.$ YJMX.R"&/Z4RLZQ$[8HYZ\H_O/'E/N!07=9IN@@
M(F5J8C,% D8#) ,OFM\!M\1X$O:WRYA:U*A-[5I=], 1MQB2I#50;&.DJF"*
MJYM1Q$@B768?2V0'/EP[G6J=F]'#E3M5DQJ]MU6EJT9PE4D50?H).557*AA&
M0)<7,DMOA3[T%6T\QK>RW:BMO)Z;5,;.IUNJTMZ]%P3C"NC <!+Q0CK$)B&T
M E!)58Z[,^1*WAR\;1?MVC2Y'%[KW?0FJKDID7J "8 2.JD/M8J%4, ".X93
ME ?7;^$:RHPNHU.PVWLRN/;<?TUE5G-RJ5==1\\3XOB$2*B)2(F 3>&;= ;"
MNX/R94,48*M)O3D3UFQZK3WERH&=I 5%!JH!A$IA&2@@ ;BC =0%D94M+M-U
MG(EM4!G7;,O!HQ85%\J^*U6IZ;<2\<?BC (G$-,RE /"#OP'0..SGCR@M[MK
MEC4<[:]*[2ZHQ1<+/7"B1U:FD<!#2J<Q"ZC&WR\& K_ UKYRQNQM*T:WBF@)
MTNECS2HW<G46IZF5NL<QCJZ2%$QA #2T@;:  $!H2X"RLGV>,FX\&F(><]R7
M$K4Z0T!XEQ:C,[M)43B<!TE'241 IAVP'?U7%-]O,MX6NPC%)2AV;0U*;<BP
MN4P,BY4;@F($)/4IX6R98*IIEV8KBM-6MVZ_Q0UR(@XJ*[JA7(:Y%J2U,T7/
MK*F\:%-+4GOF ;1^3!%]XVQC=%KY_OJ]G+%%K958H],I]%427(<1,R*F44P3
M]>4I-)B@)@VR[\!X\5J-,6J61LG5BF,+FM-G=:SU]2%[BZ!.\YH< 2 U'(!A
M5,01F35+C!GOE!5KU3"=5KM\U;++;&Y[[L_(C)E5V=+/6E+>J-)=J)!K16*0
MP%43$-PR&0?BD6!:N&[OHN2\17*PM9G;%KVM1JHSK=*9/P>)LG+]58X)D.<>
M,6UZRB8P3"8CP! ?+3\%Y"6H/:$HKYLW:.,B.U5K96,X(H18@E.)14T3$D]@
M>%W8"UNS\UR)2<?TZV,C6ZWMY[;Z*%-IX-7A7P.V[=("BL?1L3$1^9F,!4M-
M[.%Y7YDB_P#(>1+AK5FJU=\5I06=MU%$IU*.V 2)\X,":FP0 LB[)#. X1KV
M9<PVW:Y:'0&[5Z;'MWA<]AF=NTP"JL'  "Z*FG8DH7BTS@)I3F8("R["Q_F.
MM=HA7,&2[=IU&HE1MY2DC3F;XKTS8 -(B*LP 3F. B8PE "A.7 ,!R^)>SED
MBT<KTU.YR-E,0V.ZK;ZS1(J15516L@*9-20&$P:"F$VTH2$(#E:-V8+AM,*A
M:M5Q*TR"D9^JO2;G-<B],:'9+*@< <LP-(#IAW F(]W>(7U;V-+HI/:6J.0R
ML4FUAK6FUH;59)<AC%<MSI^U%2]?I*!1D8>Y 5G5<092KN9*->EO60UQ_6F=
M:YY<=XTRM HPJU+(H(Z3L"E PJK$V' >$=N_8'./.S-7;9NR\B*8O;Y'H-PU
M)>IV_4"7$M1>;%=")S-W: & #%*)MHRVRW]P/5S>V%FN)5+.IM,;TIZ-"6IS
M6DH+"JV076;&(5(JQ]IB <TM8P%!8$L_.^,*=:]HU;%5OJ,*:N9)[=@5)H:I
M$;KJ"910H%*)A$H&D :MH!* T]7[->2'V;G:)$FH8'J=TM[VJ$EB%5%VW2,(
MI B ZAF<PEEHVSG. F_NSK7&^8+LO@EB$R3:EW"FY3:IUQ6@NV#X D<J@$,
M*)FEW]G?@.LM?#5W4;(^([BIUK,[8M>UZ34VU:I+*H \38N7ZAU-!#J#K6$P
MB F,&R8C!7RM\%9">TOM#4MZ@W9FR.XXZV'!W)% 5*0J@EXS1,4P&90\+NP'
MSDLG*%2PG0,?9!Q!3+D;4,X4Y6EIUM-!Z9J@W J3YJN4H@F?C!,4Q-0C+;N@
MBU.S595_V%C<M"R$\%5]SM=6F4XSD7YZ=3SB'$M3.9!Q@D -X; G 7($!,!5
MN#!*6W[A#@&YZU+W2,15HZ@G+ABH",H#A<H5"_:=2&SG']L,;M?E<%Y_2:BZ
M*S 6H (B=%0X"76!I;P@* MW!%]7S=61[ZR#2*?8I;SH"EN,*!3%2NQ+QI0
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MF*!IR$2E FKOP&PO'/V+;$J+^D7!7!2K-+,B5W2VS9=V[(FN3C"J\4B0QA2
MNTZGK0W3G =$YR=85-HU-N.J7/3&E K1 4I%1<.DT4')!+JFD8XAJ$ ':'!
M</D;M#6I;]BU2Y+%J=+NNMM5V=/9L6CLBR)7E36!!N9R*1ID2U"(F'O2@-=0
M+URS9.2K<L+*KVF5QE>S5RI1JK2VQF9VE48IE66:G()A Z(D$>+4]=LVP1K;
MYSU<K++5NV?9C5JYM%"O,+:O&KN $_VTJA#JD9M1*,M:21!.J/S(B!1@KK+3
MN2OL<XWQCJNOE7U-78L;HM85=/ZW:*F%JZ;@( $RE5* D#@#? 6^&T)P" 0%
M9/\ \/M)_P"EG?[]3@O9^; /\0=7D.SS5:3]'GRDH"T8(0" 0" 0" 0" 0"
M0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0%6X) 2VY<(#O\
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MB"B85)"4AQ^8'?W(#F[)M"Y*I6NT!36;!HV6J]R(+4D;A8F<4E< ;DU*<48
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M?M"V[6;@N%AB^@C6+H<).ZPZ5N-14YS-TP22(34EX"9"AX) W"(P'1!=W:E
M0EC6W@)W.GAG]*@B/._M42$.K6W=0CL^WQI2^A0'+9-NCM'N<>W(A6\?4%G2
M3L%BO')*X90Z:0EVF*4$@F(< 0&[HEU=IM*BTTC''-O*M2-$"MU1KQ@U) F7
M2/YUPA*"ON"[>U*8?;,:V\)>]7C3^E0'.-F?:$9WN^R"UQ?0D;CJ;)*F5!0E
MQG!%=NW-J2,HEQ4A5)ZT#_D=D!T@79VH0F(8UH$QWB-?-R4$ N[M3RVXUMV?
M!*O&E])@'G9VH^#&MOAPC*OF#ZE /.SM13 W5K;^H E/I\=WT*"M5<KWM*W7
M0:E;=5QM1"TVK-U&3T6]QG16XA8NDX$.5*91$-D$?M0ZKVD[=HU/H5)Q=;K6
MFTQNDR9H$KYA*1! H$(4!%*8R*&T1WP&P\[^U-/\&MO2^_P\E <.6Y>T3UO*
MNO,"@><1K<!,605LW%\RY[/C-?%>NU^#I[FV"NW&[^U/+P<:VZ ]^O&Y&"-?
M7:IVD[EHC^WJYBVVW=*JB"C1ZV/7C 51!8HD.68)3"8#L$-T%?G;3WM*6K;]
M.MFFXWHIZ92FZ;)F+JY#N%N(0+I)K4,E,QI!O@-IYV]J39+&MO3#8$Z\/)01
M/G=VHQ -6-;?F'\?CR4!'G;VI V]6MO^7S<E!4!=7:A*("7&EOS#=]OQY* Y
MQPS[0CN^&>0G6+Z"K<E-8J4JG*FN(XHH-ES\8H8J7$R!0X^"8_Y'9!'1A=W:
MF#8&-;= /O\ #R,!\M5NSM/J4Q\1UC>WB-S-UBJGZ>-L(*8S'\Z#@@KG,6W/
MVCFN.;9;V]C^@/*.FP1!FZ5KADSJ)RV&,44I@(\(01UOG=VIA"1L:V[WY5XW
M)0'./VG:$J%Y4B_5<74$ERT1LX8,G2=Q'(!VKR7&)+$!*2A0$-1 'UIML!TG
MG;VHM6L,:6_JW3Z>'=]"@J/.WM2E_.\:VZ$QF,Z\;DH(!=G:C#=C6WYCM'[?
MFW_0H*#=G:C-+7C2WAEM#[?CR4!^;BYNU&X;JM^K>@D!4IB:R7"<AB@<!*(E
M,"4P&0[!#= :6RTNT)CZV65HVKBRWVE%I^OFZ9[A.H<PJG,HH=0XI3,<YS&,
M8>Z,$;[SN[5 [\;6[+[_ !N1@*PR7<.?E[]Q6K6[&H;2IMZP[/16R=9,HFX7
M%F;410_%>  %\(!VS'9 6CYW=J0/68UM[;W:\/)0&/G?VJ)!+&MNSX9UXTO2
M]I@(/=_:K'\[QK;DORU>-^,C <_>#?M#7U3&U*N+%]!41:/&]2;+-[C4070>
M,S\8DJBH5*93 (2[X"(0'0^=G:D'2)L:V\)@WRKYI3[WM4!(W=VI=X8UMZ8[
M_M^;DH!YW=J/AQK;\^]7AY* @;K[4)MIL:6^(\'V_'DH*>=G:BV_W:6]X6_[
M?#M_V4!SM!:]H2W:Y<-RT_%U Z<NI=%S6GBMQ**G4YJGQ2"9=24BIIEGI*'=
M'O0'1^=W:FW=6MNR^_P\E! +O[4_P:V[Y>-R, \[^U-\&MO>7AY* ^.S*IDJ
MJYN;GR7;U/MYVG;+H*<G3'PU#CBB\2U<9,I-$N#NP5US#;V@JN$_^56FSA_9
MRD!:,$(! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (!
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M]FE>5@('M)M9>#B[(HCW!MM4 ^3QL ^,FT^"[(L^$/-M7E8!\9-G\%^19?\
M32O*P$?&4;S_  6Y$EW?-Q7E("?C*,YRZK\B_P!FE>5@(^,HUW!B[(NKN>;:
MLOD\;  [2C7YK%V1 [DK;5'ZK 3\9-M+9B[(FKN>;:LOD\; 8!VE$I[<5Y#
M.$0MU4?JD!^@=I-F/_:_(O\ 9I7E8#@\4YX9T*BUE <>WV^YS7:J[!1E;ZJY
M" LX$W%G$% DH7<<O ,%=S\91*?X+,ARX!\W59R]#C((S^,FSW]5^19?]-*\
MK 0/:3:?,XOR*(_]-*A]5@'QDVGP7Y%G_P!-*\K  [2;7AQ=D4/_ .;5'ZK
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M 4^@W@FEPP',->TWB]W7&]&2=ON8NWW1#*YSL5B4)>I3T\W([$-(B)O! TM
MC\U =#3\T6/4[X4Q\T?*#<"2KAH4YVZB;)=ZR IG+5%P8-!ED2F 3E@-BQR'
M3:Q5;JHMOHKU6H6@4"5/B2E!N9\=(5@9)*B,C+@73K#Y@3!/; ?7CZ]Z9D>S
MJ5>5'(H@TJB0G%JO+CD%DS"FJBH!1EK(<IBC <RF,^T"J74,O,\.$?NB$%=A
M<UW4*SJ2XKUSU%"ET9L$U7;DVDLQW$( 3$YQEX)"@)AX((YNE9FL6L8[4RJT
MJ1B6.D50ZC]5NL"I>)4XLP<0!14$VK8!0+. ^2P<YV5D:KN[;HQGS"Y&B!'I
MJ366:M/=*,E=A'*15 D=,>\,PX0@-YD;(3#&]N!7W[95^JL[;4RG4QK(7#MZ
M]4!--)/5LGM$WH ,!H<B9VL;%U68T*ZU7IJU46IGR#&FL5WZ@-R&$ACGXDII
M!J 2P'36M>])NZUT+RIBBS>A.DU7!%:BB=FHFF@(@<5$U0 2 &D=H\$!R=)[
M0N,:W9;_ "!2ZLHYMFGO!I9E"ME0<+OM0%(BW1$NI0R@F#0 !M]" V1,SV.I
MCYWDXC\YK79:TG!>).1Z1XFH"(LQ;GD8''&B"8$'>80X-L!]-6R8SH=?LRA5
M6GN6@7MQR+!XL!2D;O4T0<$:."SF550FJ4MDRB$!TU>,(T*J&F("5HX$ W?Z
MHT%AR6#!$V(+-$1$1Z,0W]X!@B*[F?'UNWI2,>5&M)^>-<<%:,Z6W(9P=-50
M-1 7,0!*EJ#<!QF,!\&1,]6)C"IIT:XU'[FK"WY\X:4I@N^,V9 80%=<R9=)
M"!+NZN] =I0;GI=UT1E<ENO$G]"J2(.&#U$9IJIFV .V0@(#L$!V@,!I*5D=
MA6;QNJSV;940LY!JK6*P(E%J"[PAE00( ")C'(F74?N;H#D;4[3N,;UK["V[
M=&K.'E35.W9.STITFR.=.8&-QYB 4"S*(:IP'[W'VD<96M<+NW*H^=J'IBZ3
M2N5AFR6<4FF.7(@":3MT0!*0PB.V4]/S4H#:W9G+']D5UG0+@J9R.G9$%E5V
MS=1RU9H/% 2;JNUDP$J1%CCI()O1W0&]=W_1VM[4W'H"JYN6I,UJH*3=,3HM
M6"!M''.5)R(50\R)?DC ,!^5E9"9WI4[IHB;-:GU6TJF>DU%LXEJ,&@%4'"8
MEWIK$'46 X+-!M.4<(D 1F->?;9\ ,A ?EP%W 7OCO[L!,H#271=%&LVA5*Y
MKB=D84*DH&=/GBDQ B9>\$Q$PB( 4H;QV! <8KG?'B-@4O)8U)0]MUTY4**@
MFW4-4'KI0PD*W0; &LR@B4=GR90&UQ[E*V<EM7R]N*KINZ2N+.LTFH('9U!D
MXE,"+HGVA,-H&+,HP'ZW#D5C0KUM2PB-%GU=NOG:J(("4"-&;!,#JN%Q,.PL
MQ I0#UQH#B7_ &H<74^Y'=J&/5WE38ONB7*K&E.EVI7@& IB<<0FGP1':,Y0
M&XR'GJQ,8U)*C7$=^YJQVXOUF=*8+OCMV(#(5UC$+I(0)"._5WH#.OYZQS;U
MOT2YUJJ>HTBX$5'=)-2VZKU95HW+K7<F33#41)$/ST3!,OI0&WJV4+9I7FJ4
MCA2IJWJX(VMI*G)\>=R0R7''<;PTHIIB!E#CZV80'[,,A,761JGC)PU6:UIA
M3F]9;.%)<W>,G!Q2,9(0&8&24#08H^CN@.RE_P#DX!+9* K)_MSY22SV!:SO
M\5ZG!7Q+LVE0S;<C"H[:>[LY%NZ 3:/:E7:I#^%P;!'; 5[0G=\=FES:EC5H
MS.Z<+U6J)T.V:JF'$UNEJO3&4;I.$P]K73 =0 HGX4MH\ 01SR-VW.EV4,GU
MY>O.@KM.JU:;L:H=Q)PB5)\0A$R*",PD Z2AWX#8WA;:M]9ZL&@/*Y4*,B_Q
M^X/5%Z8L#9Z]2YRD)VP+#X1 ,/AG$GA" 2W;8#GJC=MYVKB'/5HL[F?/1QN\
M;,K7N4ZPGJB35R9)3FZKD)"<Z$]$]\AD,$DR#<-X7SD=2QUZ?<]>MRW+?H[\
M&%I/TJ6X5?U%(JAGCI10P'5$@A),I?  P#."M@@\RE="V*,,9(JE2MM2X$*P
M]N%RBN1.L/V5+$09-EW*02*L=,0.OQ8S-* 9=Q4WI59PU;3B[K@J:)KI68-7
M;A^ O6S59 QRD!4A9BHB&PBAO"T[(#],CTVNV3DE*OY(J=TABJFDIB%HW707
MPBVHQTP*@X&L( &I05U1+K7,!@D,I=P+DS^VN)[B2NU2S:BXI]PT-(EP4U=D
M82BKT:(.#I" >O(HF4P:>$90%)LLYUE?+:64%*D*>&E*<%NJ,CJR;%J_10UD
M#_D0.)R"V >[L@/HL^K9"IS7 KNN5^HC4+YK=5J]?;*JFTJ-WK<R[=LH7YVF
MF)-)=P# :.T;%9,'G:5JI*M5W)J+TH@1LN],=NZ!>DJB87))>V&+\R81V! ?
MK;M%N#&MMX*R+3[QK%4J=TU"A6S6Z4\6#HI2DU)LII12:E "I"W @<68-HCM
M& ]$9IO@<<8QN>[$C3J+-H="E)3\)1\Z'B&Y2!O$^LP2*&^ \QXFKM!L/+.-
MFM(HU<HS*N4+S-NAW6Z:I3T7=9((O&ZY3F$0.JHJ94NW;ID$X#O46V377:6R
MH3&S^E4]4M-MX7YJT@NX(8>*4T@GQ(A(0#5ZZ"0^CM!TN\RU^CW!<I;@J.)J
M;3!-5R60[%H^IU:1/QIZBLCL.N@1(!TEU>!PE[I7H"SJI3ZQ;%&JM&J)JO2'
MC-NNRJBHZE'*!R )53C(OAF#:;9O@.@@$ @$ @$ @$ @$ @$ @$ @$ @$ @$
M @$ @$!56!?ZMW#WKGK7[Y&"RM00 =\$4;VK:-2U<&W[6U&2*E8:T<[=J_,F
M4RZ2*JR8G(0X@(E*/S4H#M4R76;'U "R>BRW22FL1:C7"K&: 3B" I/FX@K.
M7Y'TX"JNSN:J4Z^<IV[>Z).M<]19U6Y:DP,!J2Y;+HZ6?-2R R8$3&1B*^&(
M[1@-I151?=KRYA>S$*+9C%*D@/ F[="HM*?Y8 W0',W)3<L]G.@71D"CW!2:
MU8:577K[^VG30R#M1"I+$*H1)V4P^VEU ) W".R"K(S'DQS96*G%Q40BAKCN
M!-M3+38F#2N>J5< (@60 /A)ZA4$/RL$5_6\&DQY9]"KMOW4UMQ>T[;>4*YZ
ME5T3/&BK&HCSAZY*!3 ;CP6$YTPVZY@4>^%:V-=CW'2A[M:6J>KKV];+-R=G
M4W/-G=$LLIQ(@FBF)3:GSSPGKC<4H"5,.Y M<-W/$%.T7AJO4I0QS5FC5A!5
M,0D)V"B*:Y#'*'Y$1X=T!Z%+N#T(#@,XR'$5XSW=&K?*" Z2W! +6H@B,I,6
MH@/Z@6!*D;GH=-HO:9Q6VHU/08-EJ;<+I=)LD5(IUU2D,HH?2 :C#PB.V _;
MM%42FMBV#56C!!*JU&_*"5\]32*5PN"8+%(5126HP%EL 1D$!?3Q51!LNLD&
MI9-,YTR=TQ2B(0'D*S;]?8[[(%+N.BD66N6XG[UF%0214<\S>5)\X*H]5(D
MGTH$()@D ^$!0X8#0X3O/%=#S-7Z%37KQ:UPLEI3R.W3%RW47,R*JY?N%]1
M,4RLCJ"8_KC#(HP&K8-[OIF,;<KM:2.Y[)3:N-ZG3J1QB9;G1I8O .Q,Y,4
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M9A1Z[=VDRC^J#,#284XI>(:!X1E%9J3X #O,N7\G?F$K,R$S:GIE>9WE2=+
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ME#_** 3@CD[KIN6>SU1[QR1;]PTBKV*%8<7-4+9>M3(.%&[]1,JJ:3L##)0
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M597:>7X@0'[X/>V1CW'K2DUV\J I=#]PYK%Q*I55JHF-1J"HK+%*85-H$F!
M'O0$IWW8P9U5J(W/2.8&M0$.=\_;<5QO2 &T:]<IR"<IP5T%[5'$=_T7H"N7
MK3TF/&D<:Z?6T&:^M.<O;$U0&6W=!'"4+&/9DMVD5:WV%S,ST.M) B]IR]Q@
M9$H@J"P*I27 2*:PU:RC\N"MO8]L=GNPJTK<U+NNGO[E40YHG6*Q74:@[1:C
MM%%$RJOM91'?I"8]V"/PS54+2NZ@T6HVK=UNFO.TJRQN"AD<51HDBLHU/)5
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MVNTIP$!#\\X9P%<N[5[/[BSJ18C:\&E-H=#54<4M2GW FV=)*+G.<_MI%9F
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MO%SXI3H2Y^,&UJM5: DKOUI-')C$]("G H=X("[X! (! (! (! (! (! (!
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M.6?OWCQ91TZ<NEJB?4HJHH(B/@@4H $@  W0'IT!@)@$!JKF 1MVK@&\6+D
M^@F@0Y/!8SQ!9OWL0#Y # 6# (#$_K1@/-?;$L2WJIBROWQ4$UG59HK-!&E)
MJ+J<T;G5>):ERH (%%80$2ZS3V025PO;1M&[K:I"%WTAE6&35L@NFG442+I(
MF!$NI0-?K=F^"RIOLW6K;]8N2\\U6]1FM'MZNK] V6T9HE;IC1:8;0=T)2!+
M4Y5*)I[Y! >F"@(% !WA 3 !@*.S5+K2PAL_X\^\+]Q#\N O .& F 0" @=@
M3@///:Q105M^S'@<35JHPN-JYIEC.2'5)<2P%,7F@$(!O"*!A4*8Y13*(>%O
M" I=PUH->M_/3FNJ)XAJ[YG3$WEEJH*)I-V[8Q11=+ W  7YZ8W$"+8N[8,Q
M@.@Q6Y;U3.=E/;CLQ+#U;86ZNA2:*@WXD+C,J0 5*"R92)\6W  .5%4!5VP'
MLQ+\[+/?* S@$ @$!6+_ /#]2AX?-9W^_4X*PITQS_5SA,2>:K,!#N"+U2 M
M"<$?B\0%RU6;@.D5B'3U;].LHA.7#* JRV,&4FD813P?7GBE9HG-7#-R_*4&
MJQRN5SN"G( "8"'3,8!*,Q]; :.WL#W:6LVT[R+D)S>-!LI4KFVJ/S!"GEYT
MB3BD'#M1(PF7.D3UL_FO"'A@/NJV#']0OVZ+D;70NRL^_&9&EY6J1JD<SHR+
M0[-,Z+PP\8AX!M0@4-\!H*!V<KJ956Q'5P9"4J]&QNY*-N49*E-V2(M4D.;E
M!8R9IG5 D@XSO3E,9P%BV-C(++NB^[C"HF?>?%31JIVID@2!J**0)<6!@,.N
M<M\@@/@M_#5&97;>5YW.5O<]8NQZBX3&H,TCE8LF:7%-VJ0'U[" (B)@EJX8
M#EJ[V;4*E0<CVQ2J\:D6_?;UG5F+!%H0Z5)?MC)G7.F4#E Y5S)@(E\$"\$!
MO*+CO,S9&K(7%EI6J%>LC-Z8JWHC)DHQ>ZBF(Z 2"/& 60@*1]A@& _3'6):
MY;EZ5/(U\7,%TWI4J<E1".V[!&E-D:>@J*^DR2(CQBAU!U<8?: >"'@R@-;F
M.WZRTO\ QAD^AT]>H^;M36I-=;,TC*N.BZTF")E@ /F$3@4Y^] ;^F8FZ,K.
M2JL%6.MUB@0#)<24O,=#0S7P1U>V>NU;9=R Y\.S^4EDXOLTE?4 F-JDSJA'
MG-@$7W,@4#BS$U^USU[YC ?G<6#+K"[KANG&-_N;)3O$$S70P!@A42*.4B<5
MSIL94P"BJ)-@RV3\* S>8-N6C6E2+(Q=>Q[7MU@Q7IM19OJ<VK /N=&$ZCHY
ME](@L)C&G\R,Y2D$!^%9[.A LFPK9L6Y7-M5G'"PN+?KBJ"=0$QE2&*N"R*H
M@404$PF )^#N@.QLG&SJU+JNJZZE635IY=B5-(^*=L1 I5:8V%N<X%*)@DK,
M3:9>#N@*U[)..G%J6[<%U5)B\9.;EJC@M&:U,IRO6M 9*G(Q04 X )0D8QP+
M+AG 6I=F/?.B^+'O+GYFGF6J_6!D"0'!UTB@5&0G$P:-&B>X9P&H:XBYH_RD
M]Z6.IUF$(F<G$E & $8G93*.KVSUVO;+N0&JL[! 6E7+ K1:\HZ&Q;>7MHJ
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M<Y^%/@@.WM*V*99EM4JU**B"-(H[5)BS3"0>UHE NH9<)A\(W?@-R RV2'9
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M_P"6@6D,$6.&YQ6O+#_EH%IZB;(_;%:\L/\ EH%H' ]CCL%Q6A#A#IE_+Z=
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M.Q+S9$>,$B[AP7C#N#";21*4P]" NNDU"HKTEO4:VQ&E5#B..J-,!4KGFYR
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MRU"8'2(LG^=J#L$IC!+NP%(#C7-5>JUZY1?4RB6QD&L6Z>UZ!0Z>Z%=,164
M5'SUV!2@=0A3#Q(2'< # ?G7.QSCY+' T2UFRS:_&#% U(JRM0>&:]+M-*@*
MBB944R@HH4=7@; -L@-U7:#GNE9%I63+5MZBUNK.[3;4&OLGM1%F1N_(XYRJ
M9(Q2#K()@\& _?(=(RY?5J4>G7%C.UKG,Z17-6J*]J:B0T]^0X@@JU=:9B4Q
M):A3$IRCL 8"Q\7VI6K1QM;UF795#UJMT]CS*I50PB/&"<3>"4Q]IBI%,"91
M':(% 8"E,6V:%Y8%OKL^U5R-.KUO5&I4-PJ!1$42J.!>,' !\T0X"49EWR&
MWY+1S?D>R*WC+*3"B4"WEZ-T42L4MTH]>/*@EH!!T!) 5)(HI@<Y#3,,Y!!7
MQ(6+G'(#FS+9RHPHE(LRR:BRK#NI4ITH[=5IU2"Z6Q2)2+S<AC>&KJ$1X @C
MYG>$,@.<>W7:Z0, J]9OD+G9ZEQXGHX'B2XZC $P4TE'P8"R;AL*MUC.=M7\
M!4AM6FV_4J14"F.)7 KO5"B0"DX2Z=XS@.)QY:.=["9M<4H,:$[QQ357J;2[
MUG2G/U*8Z,JL1$690\%<#* 03ZM  &Z"M+3,,90M&Q\25>W$Z8]R3C,*FB\H
M;EP9-@^:U@QRJD(YD.@Y"B4Q1$)3GW((VE P_D2XZEE2JY1/3F"^2:0Q8($H
MJIURL#MT#I F;4!1/Q?@:C[C[92@/AQ?BF[[9KMO-J[BJS&*5'(9N_O2GK =
MTL1%+BDUVS8" 8BJN\VH?!$1@K1/<,9Z9XYN#!-O)T%:PUEW#JE70[<*$>K-
M%W)7161FP%'0J S**PCIEWX(]849N=I26+58 !9LW114 HZ@ R:8%$ 'A"8;
MX#RXV[-%SJ5#(S*H.&IK768/&>,4 /,[4S]X%4,"P2F4"N2%+,9^#. W(82O
M<_9SKECO#M'&4;J?$K=><F4TM#OE'Z+A0 5 )2*DD !LE. ZCS0R-;N=3WY;
MK"GU6T[FI]/I-PJ.7)FSJG%IPF RB*<A!8#@(" =V Y/J2OP.S0?$Y@9#=QZ
MB9V  N/->(&I\Z#VP0WZ."6^ ]$U,*LG1G'0I4C5HC<P,"NA,#<S@I)$!31M
MT".P1" \NT7L_7A<[V^%KAH=*QM1;LMY:B.J%;SLSYJ[JJZH+%J)TBE(FEQ0
METR*748!V[X#?XFQE>%M7-11K^++-HY:2B=)[>%,6!1VN=$G%IJM6^@#)'4E
M,VL=DQ@/L=X/N%7/9;P2<($Q6X?-KM?4TII.1N=@W,U2.4DO6"!^,,/=" YB
MY\%W)1KTNVL4+'ML9#H]V/35ELO7W ,WM.>*D(11 XF*;C$)E$Y=(@.T8"SJ
M!C^Y&.6Z9>RC6GL;?;V8A;J[&GG$J:#\CCCC)()B >T%#808#@\D83N V3:U
M?]!LRW\A4VZ&K=-]2+@7!HYI[UB02$406,0X&25 0U$W@(0&=]TATO3,,8B-
M1J=1ZY4Z^WK%7H="\&G-*=1=3AR*9I .R9)&'UQIP%GX.,)J!<0FWC<]:'Y+
MH1@LK0@A (! ?FL,BR$ ,0=A@'A 8#RB;$6;J1:]=P=;Q*2;%U=>.SM[R7='
M+46%+J*W.%V_,](ZU"S,F0P#+; >G;?IC:B4IC160"#&FM46;8#!X7%H$!,L
MY;)B 3@-K (! <M?%Q.K2MBHW"RIJU7<,B@8C%"8&,)C $QV".DLYFD C*,=
M^R<,9RB+I]/_ ,ST\?;]C#5GG&N,O^TN,OBNKW3@.O5YRP5I:S^C+*G8K_GB
M8R[\AD,IA,-T-.<YXQE,5;C_ -#U<?6]C/5CG&<8S7E'25B6I_5>B?>]I])+
M&SY\MQ (! :&ZW5QL:$_=6DP;U*Y4R:J<Q>+"V;K*3#P3J@ Z0E/;* I#!MO
M9OM&[;B4O*V:,RMR[JJZN"H/&-3,Y<-'"Z8%(W(EI#669=INX,!Z,GN[\!,
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M"=ULBBEMNJXP58MJJ1 NI3FIS[S 7PM)P*(A :O#=PUNKY$S13ZO45GC"C7
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MN61:6=J_76;VV[B>,35RQ2L"(HL:75EM"!FSK49454BF*8XG]>/H0'K%(!*
ME&6P1E+N0&< @$!1N:OPJ8/^_P __>0P%Y0" 0" 0&)Q  F(RVP'F/.6<KSM
MV[&E(QXX:ITBW:I1F%Z.ET2...<UY?0DQ2$P>"9-$IE5#%VA,H;(#TX0  !
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M2066W@A (#ALLW97K*L:JW#:U <7-<+8H$IU(;%$PJ+J#I*8X%V\63UQY;1
M("G>SO6B-JR[:5JU[I-D*[##4;KO2MTWF;15PBG,K=(=9N*;I![6@F'HCO@/
M3< @$ @*O3 WQA' SV#:   =S[8A!5H00@$ @/-G:5NJ[UZK3<<TZ@W$-AU1
M 7%X5^VV@NWJ[69BA36PS $N-E[<KO*49  S& M+$U<I=9L]H2BVS4;0HU*$
M*6QHE5;<S531;$*!!(29ID$!V&GM&<!8, @$!J[C*)K?JQ9RFR<A\E(T%AR6
M"PEB"S0'@IB(?B#!%@P" 0'-7];@W=9=PVP!RIFK%-=,4U3#(I5%TC$(89<
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M]O>45^2@@%:S[,9VQ;P!]\5^3@H-9S]\S;%O>G45^3@ 5G/W#:]O3[U17Y*
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MW C+Z' 9]-9^V_T7MZ7!]LE^3@)Z:S]L_HO;W?\ MDOR4 Z:S][U[>\I+\E
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MWE)?DX*CIG/_ +UK>\I+\E 8=+9\ T_-:W@,/<J;@-_ZG!&1*OGU,H%+:UO
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MG*>H40-K ._* VA!U!,-T!E (! (! (! (! (! )! (! (! (! (! (!((!
M)! )! (! (! (! (! ("JL#CKMRX3&"8A=%:D(_7(P65JP0@$ @,1'\490%
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MJR\V*)+]H-?I)(++;P0@$!0/:W252QO2:X)3&IEO7/1:Q6!* FTL&ZXE4,(
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M//@[NWR>GRT!(Y;>3_![=OI4]/EH%)+EIX/_ &]NP/1IZ?+0*3UM/O@^NOW
MGRT!CUMOP&75Y=DN[S%/EH">MIY/\'MV^3TY?3H%(ZVWOP>W;[@)RT"CK;>_
M![=H?R>GRT"@,MO)?@]NWR>GRT!F7++T3  X^NL $93Y@GL_VT!7N),CN:90
MJT0EE7(^%:X:NN)VK),Y":W CH,(JAX0;A" L#K:>RV8^NSR>F'U:!2>MI]*
M?5[=<^YS!/EH%'6T^^#VZ_<"?+0$#EIZ 3ZO;LGW 8)\M HZVG@[!Q[=GH]'
MI\M IRSBJV:[N5*\G>%:TO=J E,E6U*&U,\*8@2*;C14U:BAZTV\(#IBY9>
M(_W>7: #_N"8S_VV^ D<N/OF<=W8/=FP3#ZM ID&6GVGPL>W8 ]SF"8_5H%
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MDJ9Q#2(DXQ01+J#8,M\!M6&2"4MJBPIN,[H9T]N0$6S5O3$4D4DRA("D(14
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M"8P&WLV^;9O^WVMT6E4"5.B/-0).$P,0P'3'2HFH0X%,0Y!V&*8 $(#H]^V
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M:1[G&RG ?CV<"@6LYC%B!1H@WW418\7+B>,T)\?Q<MDIRG+9 >@(! (#5W&
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M #< 2V0+?O\ &*P7\(5"]W)>K 8_&,P5\(5"]VI>K 9?&*P6&_(5"G]?)>K
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M! 55@;^K=P!*4KGK0?\ [(P65JP0@$ @$ @$ @$ @$!7^<9CB*\9;^C5OE!
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MVU^?I^S+ZL YVU^?I^S+ZL YVU^?I^S+ZL!2>9U4E<GX3%-0A@+7WHF$#!(
M!B;O]Z NP'34-ZR>\?FR^K .=-?GZ?LR^K .=M?GZ?LR^K .=M?GZ?LR^K .
M=M1_UZ?LR^K .=M?GZ?LR^K .=M?GZ?LR^K .=M?GZ?LR^K .=M?GZ?LR^K
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M2L&@.VA.3>C4GW+01E\4O!LI!0G =\*B^Y:"L?BDX.X:(Z\I/N6@ =DG!H"
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M"X#O](ON6@,?BDX-^X;GRD^Y: D.R5@T/^!N?*3[EH /9*P:.^AN1_E)]RT
M#LDX,X:"X'T:B^Y: ?%*P7P4!>?WQ?<M ?%6.RMA!C2:@[3H;G6@U65+.HOA
MVD3,8/\ 7=Z YW%79FPW<F-[7KE2HBYW[VGHJKG+4'I"F.(;1 I5@ )]P @.
MP^*7@S[@./*+[EH"/BE8*^X"_E%]RT!(=DO!@?\  %_*+[EH /9,P8/_  !?
MRB^Y> CXI6# W4%P'H5%]RT #LEX-W#07$OOD^Y: ?%+P9ME07 3[E1?<M
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M0^:"".@[4-],Z;FRQ&=;O"NV[CFHT59V]/;BJA5CF$QS)&*1,IYZATS-I'9
M=>TS+:6'\(T>Z+-J-9OPEUUD6%"<W2Y% X.UYE'G"ZJ9010)HX0@+NQC=-ZW
M1;_/K[MQ*VZT1P*146CQ.H,G2$@,1PW63F D, [H#RE0\GY L#*V?%K*LIQ>
M1FU9+4:HX4<\2R9,6A%!.4)@(F6, B)2%X"^E 7/3.TVPJ=QXM:$H:B5IY09
M*'IM:.K-1O5$S"0S0Z>F0R.&C5/;,!" ZS&&6S9-N*^Z:TI@-K>M"JA1F=8!
M7C >K)SX^02"6@0X!'?!7E^\+D,MG6ZK?SK>=SV%-TD7&=4I"QFU%2:S-)0T
MBF*<3!HF8VSUVJ6R"/05"SVT:W'D6S+I:&9.<<TTM93J9ER'+5:41N"O.I@
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M!TUJ?U8HGU@U^DE@LMQ!" 0" 0" 0" 0%8)@'QA%QX1M )^40@JSX(0" 0"
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MBQ0,612'D,RDX8#:W#GW&EJ.*\WKU35:(VP^8TJN/11.=N@[J:1EDBB<LQ$
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M*953.SB7P00*4=IISGP0%I6]6Z7<M&8W!1'1'U&J:";M@\2&9%4%2@8A@]*
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MLR4Y=B85P1%LX22$Q9'GJ3&<Y01?\ @$ @*O2$![0RX?_$"_^XA!>RT((0"
M0%'7K<U^W=EE3$N/*XC:J-(HY:U<5QF:$J#GC7"G%MFB*2H@0H"'MIS",Q#8
M$N$-I@Z_+BO*DW#2;R!N:];+K+FW:TZ9E%-L[.VTF3=)ICZP%2FVE[H# 6[
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MNH=L^DG$I_08 %7S]()VQ;D_FOMBXEZ7M,!'2_: \+^C-N#^0^V+G?W_ &J
M#5^T!(--LVV!OFA&HN93[WM4!\56JV>!I-1!Y;5N@ES5?48E1<S O%FGO2@.
M;Q+5,UI8SM0E&MV@+4P*<CS=1:H."J"27S0 D.V [0*OGSAMFW>]]L7'(P#I
MC/GO8MWRDXY& CIC/O#;%N][[9..1@ U?/(@&NU[>&7\9..1@'3&>A_Y9M[T
M>DW')0.$#5L]@'M5L6X ]T:BX$/Q$8"!JV?]/]6;;U]WI%S+Z5 06K=H.?AV
MU;0AWJBY_'2@,AJ^?1_Y7MSRDXY&!PJC*=0RXID/$9JO0J&C4"5IX-,22?+G
M345YD:8*&%,!* !NE/; 6OTOGV8RMFW)2^Z+B>KZ# 0-7[0&D--LVYKX1&HN
M9>E[5 1TOV@_>S;7E%SR4!/2_:!'?;-M^47/)0$#5^T'[VK:\HN>2@,NEL]Z
M0UVQ;HCPRJ+@ _%1@)Z7SR(2\V+>$!_C)Q*7T& #5\^2\"V;=GWZDXE]*@,1
MJ_:!W%MFV]/?J+D?J4 Z6[0&D \V;;U3VCTBYE+O>U0 ]7[0(F\"V;; OY:H
MN1'\1* D*QG^6VV;<$>]47,OI,! U?M B RMFW)]^HN>2@-!;[F^'6<V8WQ3
MJ?3G);7=<S"F.%')3@+U/5KXPI=,N"4!O6JP)Y_K9E3 1).TFICJ&&12@#U0
M1$1'@" Y5#,^4KW.ZJN&L?(7!8K195NTN.KU,E-"K';F%-0620D$03U@8I%C
M^":6Z"+)2R+2:/9C.[\A@G8XKI@+RGU=PD"C=>8@*0'*,E#;)ET!,0VR@-G3
M[]LVJVT-Y4ZNL7%IE3%52LD<)\T(4LIZU!$ *(3"8&VP'&W)G[&U'QO5<ITN
ML(5^W:7[7*G+IBHLYG($"@<2R4$-H :4P@-U3,MX[>T1K<0W-3D:8\1463.L
MZ3*!>;)%6<$$1&6I(I@U@$!]U1R=8%)M=M>E3N-@SM9\0JK&J++E(BX(<)AQ
M4]IQE\R4)P&EN_(JB-ETZ[<=+46O-Z@_9MD7+RH)-F)D'*FA02+Z@ 50X$]\
M]DN" V]P9.Q]9QW:=T7/3J4HR.@FY2=N")*IF=;40,01GX0;0V;ML!ILGYJL
MS&%%HM;K#HCEK77S5E3^;+I>&D[,!1<E,)I&23 P&.8L]D!MJME;'-O6^QN:
MM713FE J0Z:;457!.*<CJT^U2F)I#L,(!LX8#[*]D6Q[8MY.[:_7V#&V5@*9
MO557!!;K IZWBC%$>,GO\">R Y*^\\8_LA*TW3VJ(.F-WNTFM.=MW"0H$;J
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M I;*F?VF/;MH-H4JDC7Z@]=LDKA,1;BB4EK4E>);'5\ P"HL>>A,1 =(".Z
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M[=&$J8K*E-I)L =H@ P%!=DW)%AM<))MW%P-$W%N*5%]7$S&,46C99^L)%%
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MS6M]NH@D(;A(F942E]((#ZG65&;QH9@[Q==[I@H0$E&BU%2.B9,NXHD,L)1
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MNK\CT03Y?'R@K\'&6&SO21WC*\'"9#%4("M%34 JA!F4P 989"' ,!^X9G4
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M45  Z2I!U%.0P3*8HAL$! 9A ?O (! (! 5B_EU^TF>[S6=_OU."OP;%_O\
MJZ80V#:37]^J0.SSKC"WLTO,#5:H6S>]-IEF:+C,%&<4PKEP5$B[GC""O,!$
M32';P3@C"JU^XNI/L[V/1&2SRB7>FFWJU+1?A2C5!-LVXQ)B+X9<654WK@"0
MG]:&V _.Y:)DBPL/95!W3%K&LX!H3FUZ-TUTNZICH7R)':B*Q3"9- Q?# IQ
M]=/@@.]2MNCXRS'BI;'U<>51:_DZ@2[DW#]2HA5VZ+8BY*BH!CF*!DS&$0.F
M %EL#A@*KOVLTTK=7,&,Z-6DC(72W;-<F5.N""CHYGG$.FB=..?VQKZ\A2:)
MR" M6V[#M5YVP+T=N$5@<,Z/1JZUTNUR!SY1<YC&T@< ,2<O:QF0.Y!7"-JQ
M5:\1I8]:KKYK:MUY4K-+KCPCA1,ZC5NF"B--!8# 9,C@VR11#864$>I<=6/:
MF/DJG0;-?+JTXSHCA:DN'QGY*<<Y0#BD@4,<Z13@&K28W?@*7QS1,EU*]\FO
M+/O9M;U 1O9YSND.:>D\.L) 3XX064, EXP-FP-D!]UYVBRR+VG#V?<+^H!:
M0V:1Z_HC-XLU;O3D?Z"E<<48IA*75J\$0&8!M@.<M&JVTE@"]J;E"I5!_:=D
MW*^I%($CM5.J+(LU$^9-"K)""BAS'4!(@<(2GN@/R'&%]6)V?!NT'[T<AT*K
MI7\-$,[4<)LV[<X'5I0F4,)C)IMA-QD]YP& ^*][N<9$HF<,NVS5US6A1;>;
MVQ:;E YR-E%AXMZ]<IR$ $Y#G33 V\)"$!^;[&3*EW;B.ELKCKZ2>3Z<NGD!
M8:DL=6L%09I.B\88QAXL1,<2"9'2.@9=^ T]:N:Y<;V7E^Q+->O$[>H5VTFB
M44#.AYQ3:;6BE,Y32>+B<423\$BB@B">J<!8V'+%OVT,F(NVMGGL;'SRF+HU
MVEN+A"NIO'R9@.W=()F,8Q%=HE4.'@B48(ZW+XAURX/D/_$ZK^\P@*J<X_IM
M_*9]K]PU:K'=6I5:FO;"+>H+MV]-=MV7'E<(D3. <8)B!/5,)!( @K:/ZN_R
M@\P-8]]/UT[6NZA*U>X"HK&:%K%0:,R'3;JJ)"0TIS6,0I@G\B ^B_[ H:-R
M8EQ9;USU8EIU&HW$VJ?$5,[AP#4K9$ZM-%8IM14P]9I$1,0!WP'-WO;SVH9=
M6Q%2[/<WA8]E6\P5H-K&N!2CE)SI0=;T3G4XUR8@^TE-K'1* W#L*O2,36A8
M>8V56N&\:I773*U[4I57*#A^U;")TF]2J"0E*8J*1O;3:@'8&R U%A4Z^:O:
M6;,56NY/:CNEOF*5N4-U5N?$8@Z("KBGIU HB8A5](I%\+4030$/;W;8]PKE
M&G8]M^IX_P @V^I3D[@H+I^>HDI@5,0(1XS=*F5#0JF)C<9\R;;(!" VF.K$
MR5;UWL*A;E!-CZTJG2'J-QU%Y<B=>2?NCMM3.HD2.8?;R*"!S')(ND1V0&W[
M/]/;V)?)[+O2C/:7EFI4M5VI7RU16JTFY6Z2TU'I .<W%+!,HZ#%+(!@/4Q/
M6A 90" 0" 0" 0" 0" 0" 0" 0%68( P6Y< &V"%SUK9WN<C!96G!" 0" _%
MSKXDX(B +B4W%"/Y,0&7XL!XZM*HT5KV*KT;5!5--RVZ?95A%67&=)JO3AQ9
MB#M$YS'+I"4QF$!Z?QFW>L\?VJTJ0&+4$*.P3<E//450K<H" SX0X8*ZR"$
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M6Z526"ZPNG)2+J+*K+F  XQ1583G,.S9,VR!3D+CM;L8W57W]QU\])=UZIK
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M;5N_<AE[F2\6 CS9MW[D,?<R7BP$^;5N_<AE[F2\6 >;5N[/M0RV;OULEXL
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M=_ZV2\6 CS9MW@I#&?ULCXL!2^8:52FN3<*(-V#9)->NOBJD303*4Q>9#L,
M%D.^ N@+9MS[D,?<J/BP$A;=O!M"DLICO'FR7BP#S:MZ4NB64@V@'-DI?Z,
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M4@_=#OEH"?B]X<]ZR7NAWRT! ]GK#8[[61$?KAWRT!/4!AX)%"V$_0!P[Y:
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M P%@$R2BYRJAB^ELQ?F+1AK]3K*:I>):)*J\6V3$DAU"MM,49[H"Q"^M" F
M0" 0" 0" 0" 0" 0" 0" 0" 0" JS!&VV[@E[YZU^^1@JTX(0" 0$&G+9\B
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M!@/LG )P"< G <#FL2FQ/> ",OM8O\J Z6U3 %L40/XO:_22P66X 0'=! 3
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MAO\ #:R^1Q4!GU27.?8.4KEV?D3M@'Z5!4=3]S_"G<_T1MR4!/5!<_PI7/\
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M0, E/()%'A@.@L?+UJ7\>K-:6+FG5>@:!K=&K3<].?-$U2B9-51-79Q9@ 1
MX&$-D!SM,[1F-KB?BPI1JHX;J$=*4NIDIKD6-2,Q*8RQ&:VF2ABZ1V;)\$!.
M!<T];]JH5)W35J?6BD54>%YHN@QT@X.F0$559ZS:2EU!/8,X"WBC,H",!, @
M$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$!5N"A ;>N&0SE<]:
M?=(P65I00@$ @,%1*!1UCI)(1,(\ !M& \IKY0S37;'N/.UKU)@SLN@O'71-
MDKLBJC4:535N)<++NQ,"A%5 *8R8$\$(#TQ;57;7!1*=7F.QE5&B#UN4?7 1
MPF"@ (]Z<H#;P" 0" X'-IM.);P'^+%_E0'36H$K8HG<Y@U^DE@LMQ!" 0%:
M9PR(_P :V*M6Z.V1>7(^>-:/;[9R(\0:H5!3BTQ4TR'24-1Q .Y* XRD7-E#
M'V5;4L?)5P,KKHE\-G0TVI(,2TY=C5J>F"JJ %2$2G0.4? ,?PIP%_0" 0"
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MC4]A@* E3 3^M,&J6W=* [_"5^UEM0[3Q,^QY<%%KM IY*96JBY9 WHC4[%
M4N/1=".E4%C%F0$]OA;>Z(?3V9GE7I=GCC.OV[6:/7K46=@\>5!H9*FN>/>*
MJ%%FXU""H"4X&V0%]EV% )2[T!, @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$
M @$ @$ @$ @$!5V# E;]PRV?TGK7[Y&"RM&"$ @$!^+@@*IBD<)I* )#RWZ3
M (# >-6A[]M7%-Q=FTMD5I_>3Q>H4VWZX@T$]O+4^IN!53=*O9@5,J:9QXPI
M@F A+AV!ZQLZB^;-M46VP/QH4E@V8BJ&XXMTBD$P3VR$0&4!OX! (! <'FL
M-B:\ $)AT8O\J Z2U!_HQ1 _W!I])+!9;B"$ @*:[2-GW!=^/D5+69C4;@MJ
ML4^Y&-,(;2JZ-3%!.=)/5L$YB&,)0X1V0'*,*E5\WYAL:Z&=I5JV[1L!*H/'
M[RY&9J:NXJ-11*BFV;I&$PG!.6M0_K>" ](0" 0" K!*1NT"L8/FK0#_ -Q"
M"K/@A (! >=KP=UC$N=ZEDQ6VJQ<5F790F]-=K6ZT&HNFM3IR@"F"J!! P$.
MD/@F#9JV0&_[/MLW#3*==UXW13%*)5+]N%U<*5$7$!<LV2P%*W2< &P%M)1,
M8O!.4!=4 @$!K;A*!J#50$)AS-P$O12-!8<A@S\$-G?>Q'Y0P18, @$!^3C8
M01&<BS$9!,=@3D$!Y.H^1'@]I!_?IL?WHC;E4H36U6KE2AJET/D7QCG55F:1
M6X%$!XR?I0'K-(3"3PY".Z8;MD!G ("!W# 4AFH ZT,(CW*^] /<1H"\(! (
M! (#!0)@'H[X#RGEF^WI<XV576EA7C4:/C]6JH5A[3Z*JX17,^1(FD9F8IO;
MB"8!U&V2" ]24QUSY@V>\6HD5RF18J2Y.+6(50H& JA/F3A.1@X!@/K@$ @$
M @*Q?@ 9^I1MPC:SL!'T'J8P5QUW*903SN[ZL4*$NY&V&O2'G$=TF0"<\5T<
M3S0!$=OKM4!MN<]K']H6#]'J_BP1 N>UAO%A8'IKU?Q8">==J_\ :%@3_3ZO
MN]C 1SKM7C_Y"P/H]7\6 GG/:P_:%@?1ZOXL! N>U@(@/,+ &6[V^K^)!3C^
MU?.?1]@3[O'U>?\ H01/.>U@.]A8'T>K^) .==J_A86!+]/J_B0#G7:O'_R%
M@=[V^K^) .<]K']HV!]'J_BP$<Y[6/[1L  X?;ZOXL!/.NUA^T+ ^CU?Q8!S
MKM8<#&P!_5ZOXL%0#GM8\#"P/H]7\2 GG7:Q_:%@?1ZOXL$.<]K+]HV!]'K'
MBP$<Y[6/"QL#Z/6/%@)YSVL-OZPL#O>WU?Q8"!==K'@8V '=FO5_%@H#KM82
M_8-@"/>7J_BP1/.NUC^T+ ^CU?Q(!SKM8_M"P/H]7\2 <Z[6 _\ D+!^CU?Q
M(*<Y[6/[1L /17J_BP1'.NUC^TL?_1ZQXL!/.>UC^T+ E^GU?Q8".<]K#]H6
M!/\ 3ZOXL!/.>U@/_D+ ^CU?Q8!SGM8R_8%@_1ZOXL!'.>UC^T;  /TZK^+
M.==K']I8_P#H]7\6 <Y[6/[1L ?U>K^+  <]K#]H6!Z/'U?Q8*<Y[6'[0L#Z
M/5_%@'.>UD([6./Y?IU8\6" N>UEP,L?@'?6K _F8<ASGM8R_8./Y]WCZQ+_
M $8!SGM8_M+'_P!'K'BP4YSVLOVEC_Z/6/%@ASCM8\+''X^@M6/%@)!SVL-D
MV%@?1ZON]C <%BA?M(%HU9Z 8V2* UZJBYYZO4]?.^<#QNCBRB&B?K>&4%=Z
M+GM9<#"P/H]7\6"(YSVLOVEC_P"C5CQ8*<Y[67[2Q_\ 1JQXL$2#GM9;Q96
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M_P"S&;1RFLJ0.$=)3"(@&X1"8 .S? =( @(3 9A 3 (! (! (! (! (! (!
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ME&0>F,$?9@6HU',5_P!.OVXFZG'XRMQ*U' N2&*);L7,(5)0A33G),A GO\
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M5H _(XV" YZOG@PG=\_\EKRL!CU]7[\"-V_(:\I 2&>K[^:PE=P>@#4?JD!
MYWO@X2/A*[N]X+4?JL!K%,K5A:J)UQ7L^W&K742Z$:HHU8&=D* 2 "K"83@$
MMF^ V),ZWLF(B7"5W (_E6O*P'Z=?5\_ G=WL6O*P&/7U?G!A*[?D->4@'7U
M?OP(W;\AKRD Z^K]^!&[?D->4@.6R9FF\:OCZY::ZP_=5.;N6"R9WJY6O%)
M(>N/[;N#A@-[0\XWDSHM,:)X9NY8B#1!,JQ"-1(<")% # /&[AE!7V]?5]_
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MU2*=EH2[XP1^2AQ+("!J,.P"SVP#C#@.D2#/\2 P*N;2)I; VB,Y@$!EQIP
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MK+:8F:OU'EWNA734(V2,HV;K-B<8=%9:8%!27S)9RX90%E$'468P&6GOC\F
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MH:8>$H9^5<@"4@;1XP!*>?<D,![&++PI=V R@$ '<,!1N:A'K3P?]_GW[R&
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MP#KKQ/P7A3/HX0#KIQ-[[Z8/ZN$ '->)_??3?HX0 N:L42_K?3/HX0 <U8G
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M[J8=51JN5,A5P$3"9,P  0(<QA[+F,Z1BZTZ?4KKIK=XA3D2K(G7 #%';L&
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MNB&XU3UXD B@ 2?"!0" M6G9>Q!3F#>GM;OIA&C1,B#8G.-6A)(H$(69MHR
M-X[X#[.NG% !MO"F=V?'E@,>NW$VP?/"F=Z:X! 3UVXEX+QI?N@L!'7=B0-]
MXTR?Z>$!/7=B4=@7C3/HX0')TN[K7N[.[)Q;%6;U9%M:SDK@6I^,XL3/4Y:I
M=V"MBBS9O\^59!\U2<IA:S,X%73*J "#U0-FL!E 6*-NVZ 3&DL@#ZV2\6"
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MI3*6[]CI>+ :5POCUG7VEL/0I"%PU AU6-).1N#M9)()F.5.6K2 <,H%MX%
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M1%8HD.0=NX0$0@*-HW9HI5-=T>G52\*M6\<VR[+4;:L=X9N#)JX2,)D.,6*
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M)_@__0_YZ@<G^#_]#_GJ!R?X/_T/^>H')_@__0_YZ@<G^#_]#_GJ(<G^#_\
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MA\3[YGB92"6GIG3IELE+9*7<@<@?$^_0?3Z9_'@<I#XG_P"@>GTQ Y"_$_\
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8G-S(.>:>=\YYAQ@3T\[VZ-<IZ.&"2__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2420753d1_ex23-2img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2420753d1_ex23-2img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !L U(# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %-W#!/IG)[<8_GGBG4@'7.#DDTG>ZMW5_2^OX"=^G9_?;3\3G/%
M>L2:'X:\0:S!&DLND:/J>II%(2J2O86,]TD;D<A7:)0Q!!"D^AS_ #U^ /\
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MWVJ"[N%;="V'CC (!)'R7XX_X*D?M"?!J\^(OPT^+GP9^'EC\8/AA\5/V?\
MPEJ#^%_%.JZIX,USPA\==5OK&UUK39;K3;&^M]1TC^S;I)K=A- \OEXD S7T
M-^W7^Q3X^_:G_:9_8Q\6Z5J^N^&_AU\)M0^*,OQ&\3>#?&5]X+\<:3#XDT32
MK;17\-ZII,D&I+)/=V+179M9X\6Y9) 4=EKQ']K#_@E_-IOP,O;+]F+2]=^)
M'QFUSXU_"/XD^,_$OQA^)>LZQXF\9:9\,-5:]T[2;_QAX@?4Y[6RT^!WM]/@
MB@,5O]HEE$+R$[NCA^'!4\-PWA\TIY?+$XW#3IYC.I2Q="IA<9_;&;J%?,,V
M6(6'PN"_LNEE]-X)X:<Y>THXE5(R<SBS=\7QKY[B,!/&TZ.%KMX**J4:M/$8
M-Y=EK^KX'*_8NM6Q*QU3%3CC77C%*%:BX-<J/M[_ (*#_M8^(_V._P!E;7?C
MWX7\,Z5XKUG2=9\#Z;'HNKW4]GI\L?BKQ/HVB7,DD]L#*'MH=2DEA 4AY(E#
M<$U)^VO^V?#^Q]^S?;?&W_A!KSXC>*==U#PAX<\'?#_2+S['>>)/%GC!X([+
M2K:[^S7LJ*/,EE/D6<\S(A"QDMN7X3_;,^''[??[:_[)_P 0O@9K7[,O@#X8
MZY-=> ]9\,7L/QKM_%-OK-]X7\:>'-6NM.NE_P"$7TG^SHWTZPN[A;D23?O(
MEA\HF3(ZOXU? []M#]LCX+Z%X:\5?"GX<?L[?%'X!_$'X8_%?X*:I?\ Q(F^
M)/A'QIXJ\'+?V=WI?C&STSP]HU]I&D_8Y 1+:M=S-/<HRJ!;$/C@,KX=I83A
MFIF=7*7*AQ'FZXG]GG,'6J90Z6"EE$?]FE5G+"3Q"J4:^*P$*E:CAZN*J5DW
M0A%[XW,N()XW/X9?0S+V57(,!+(7/*Y^RAFW/B?[2Y5B%"$<3&C&%6E1Q<H4
MJE>GAZ46E59UOPF_;Q_:?M/B7\#O#O[4'[-VA?#;P=^T=H7B'5_!.N^#_%>L
M^(]1\"ZGX?T>/7&\/?$FRU+P[I$&GW>HV/FBTN(;A2+N+[/]G8-Y@_8>.421
MK( =KHKJ<=58 CT[$&OR[^&.F?\ !2/XA_$;P!'\<+'X*_!?X?\ @33=7;Q_
MJ/PSUJ7Q_J?Q=\17E@MIHP\/6?B?PK9-X%T'3I7FO[LR7-YJ%S-%%9+FW=I:
M_45%VHBL=Q5%4L0,DA0"2   3C)  '8#%?/<0QP$<52^IX7)L).5.JZU'(LS
MQ&98/E>,Q3PDG5JPA2C6>$>&C4C1<N91C5Q"IXBK6I0]SAWZ_P"PK?7,5FN+
MC?#^QJ9QE^'R_%J7U6A]:BHT)RG4I?6?;.#K1@J;<J=#GH0IU)+AO[WZ"BCY
MNVW]:*\/7O'\/\CZ37^:/W1_R/XS_P#@I3\-_'GQ3_X..?V7O W@R_\ L'AO
M6/V5/AY<?%W3EA>6'Q9\-;?XM^+H?$/AK58UG@2YT[4XI($NH;A)XI!#&&B8
M 8_LDM+2"TLX+6VBC@@MH8X+>*%5CCBAA1(XXXU4;56-$"*!P H' XK^-?\
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MT_6]2\$2Q1Z=JGBS0M$.I(/L5RDEO933/;QW4AFC03J6_6?_ (.>M0N/'/\
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M[>]U$36HMKJX1;>262)E^W* "BBB@ HHHH **.W].U% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4F0>G;'Z]*6B@!" P(.".A'4?C3=BY
M'R@<;1QU'H,=!Q]3[4^BI<4^BWN[Q3O;;?MW#Y_G^G?^M"(1H. @X!( &!R>
M@.>">_'\J!&H.=B XQZG\>" "!Z=A^$M%/ECV5^]E?\ +05K;:;ZKL]UO9I]
M>_H1&-,8\L'.1SCL#WYQG)P.*=L7(.%R.G'\AGT)'X_A3Z*3BFK65O1-+T3V
MZ_??>]RWF_D[?UKY$91, ; >#C(X'4X/3U(I/+4\;5Z@XQR".^03C//7/7WJ
M6BDXW=[]M/3I?>W51V3]Y:C^_P#X/?U?5[VTV(_+3/" ?_JQQSZ<'../U0QJ
M,+M&#T&,\Y)QR0.I.W(_E4M%7L[_ -+T[>?</^!KZ?U\B/RH^?D7\!^'^/\
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M>/9[;7]77Q9K?PZ\/2^&=#&D:8D%LUK8:LES-J^HI<W#36=W'#:0M/&KSO\
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MZ5T6J***\H]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^FM_):??/NWZ_<1;3Z'\C1M''R#WR#D_Y^AJ? '0 4@4 D\\T^7^ZE_V^_\
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M9:)I=NUW+XOGTRXUG4;Z2.U%Q-J4KZ9$HNA,KLD]RLF]9"%]\    P !@ =
M!QC\.E "T444 %- &2<Y!'?GOG\O:G4C' /(!YQ[G!X'(YH#^OO/Y<-0\':1
MXE_X.E/"VKZE;P37?@K]@O4?$6BO)"LC6VHS^++K0GFB=^8938ZO=Q&5,L8Y
M'3[KM7]1KC<.@.#G!&?\_3OZBOY:? 'C?2O%G_!T#XD6RNK9FT/]@_6?#<ZI
M<1R,;ZP^(MF\T) /RS*A+-#]Y%4DC%?U+.P49) '/)XQ[]OQ/;T-'KKZZ_F!
M_)Y_P;\>'H+7_@HE_P %VM>C*J]]^UK%IODB-0L26/BGXDW+,A&,>>]Z=X
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MPF2"&$RR/%'%'&TCR,RK&B(-SL6.%5% R2<#:,D]Z_C_ /\ @EY\2;WXB_\
M!QE_P4Y\8ZOILVCQ>,?AA#;^#3+'Y<.O>%_AIXDT#X:KK^GNW%U87MSH!DAN
MK<O#(K[@XX% 'SU_P3H\!^'?%G_!U?\ MX:]K=A;7NH_#_X9^.O$OAJ6>WCF
MDT[5KG7_  EX>EO+:1PQ@F.EZS?VQDCPYBG>,D*S9_N-_P _Y_S_ $K^'W_@
ME7XLTC6?^#H[_@I/-#<QQN_PK^)&AV\<DL9:XOM'^(7@6"[AAP?GE4VDTAC
M+K'&Y8#:U?W A@>A!STY]L__ %Z /Y8/^">5C;Z-_P '%O\ P5YTG2XH[33[
MKP%\&]6N+6(>7#+J%WX:\-W<]RZ( K227%Y<R.Q!9GE<DY8D_P!4%?RM_P#!
M/?5M-U'_ (.//^"N+V5[;W _X5O\'[?$<J,3-I_AKPI:7J *>3;7*F&4=4D&
MU\-FOZI <@$=QG\Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KX:_;Q^'>K>*/@AXG\2Z+\3_B
M5\-M4\&Z'?7UC<?#GQ*_AV6]GD,2J=1D2WE:=8>L(!4KDC(S7W(2 ,D@#U)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2420753d1_ex23-2img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2420753d1_ex23-2img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B (L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_*XN([:,
MRRY$:Y+L!PBA69G8G 5%"DLQ("CDD5^9_P =?BA^V1\4+C5_#W[,/PFU'1?
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2**  =3]?Z"EHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
